Curriculum Vitae

Personal Details

GLENDA MARGARET HALLIDAY

Qualifications

PhD(hc)	2021	Lund University
PhD	1986	University of NSW
BScHons class I	1981	University of NSW

Appointments

Senior Leadership Fellow	NHMRC (2015-25)
Professor of Neuroscience	Faculty of Medicine and Health, University of Sydney (2016-25)

Level of Appointment Professorial level E
Classification of Appointment Research Focussed
Date of last promotion 2010

Previous Appointments

Professor of Medicine	School of Medical Science, University of NSW (2003-16)
Conjoint Senior Principal Research Fellow,	Neuroscience Research Australia (NeuRA) (2003-16)
Director, Sydney Brain Bank	University of NSW & NeuRA (2008-16)
Principal Research Fellow	NHMRC (2000-10)
Conjoint Associate Professor	School of Anatomy, University of NSW (1999-2002)
Senior Research Fellow	NHMRC & Prince of Wales Medical Research Institute (1996-9)
Conjoint Senior Lecturer	School of Anatomy, University of NSW (1996-9)
Research Fellow	NHMRC (1993-5), Prince of Wales Medical Research Institute (1994-5)
Conjoint Lecturer	School of Anatomy, University of NSW (1994-5)
Research Fellow	Department of Pathology, University of Sydney (1993)
R. Douglas Wright Fellow	Department of Pathology, University of Sydney (1991-2)
Queen Elizabeth II Research Fellow	Department of Pathology, University of Sydney (1989-90)
Queen Elizabeth II Research Fellow	School of Physiology and Pharmacology, UNSW (1988)
Research Officer	Centre for Neuroscience, Flinders University of SA (1986-7)
Tutor	School of Anatomy, University of NSW (1981-5)

Theme Association Neuroscience, Brain and Mind Centre

Research (last 5 years, except publications)

Summary of research

My research concentrates on understanding neurodegenerative diseases at the cellular and molecular level along their disease course. I collaborate with geneticists, cell biologists and clinicians and use quantitative molecular pathology to discover novel changes differentiating different disease processes. I have published on the more extensive neurodegeneration in Parkinson's disease and related syndromes with recent work highlighting previously unknown compensatory changes. In frontotemporal dementias, I developed a disease staging scheme now used internationally with recent work changing the concept of *MAPT* mutations as a separate disease. My research is used to develop diagnostic protocols and new therapeutics.

Description of Research Team (*Postdocs, Research Assistants, HDR students, Honours students)*

I have a small administrative and clinical team (9 with different skills) and run a large, shared laboratory group at the Brain and Mind Centre split into different teams working on different laboratory aspects of non-Alzheimer neurodegenerative diseases. Assoc Prof Scott Kim has students working on biomarker development. Dr Nicolas Dzamko has a team of 3 postdocs, 2 RAs and 6 students working on biomarkers and stem cell models for Parkinson's disease. Dr Yuhong Fu and I run a histology group targeting Parkinson's disease with 1 postdoc, 4 RAs and 5 students. I work with 4 postdocs and an RA working on molecular aspects and biomarkers of dementia and motor neuron disease syndromes.

Collaborators (*Names and locations of collaborators - National, International)*

My research is highly collaborative – see the academics I work with above.

My NHMRC Dementia Team program included the following collaborators – Prof John Hodges (USyd), Prof Simon Lewis (USyd), Prof Olivier Piguet (USyd) Prof Jillian Kril (USyd) Assoc Prof John Kwok (USyd), Prof Matthew Kiernan (USyd) Prof Dominic Rowe (Macquarie Uni Sydney), Prof Ian McKeith (Newcastle Uni, UK), Prof Amy Brodtmann (Florey, Melbourne), Prof Ian Blair (Macquarie Uni Sydney), Assoc Prof James Burrell (USyd), Prof Jonathon Rohrer (UCL, London UK), Prof Michael Fulham (USyd), Prof Rosa Rademakers (VIB, Antwerp, Belgium), Prof Sharon Naismith (USyd), Prof Stanley Prusnier (UCSF, San Francisco USA).

My NHMRC-European Union Joint Program on Neurodegenerative Disease program includes the following collaborators – Prof Yolande Pijnenburg (Amsterdam University, Netherlands), Prof Janine Diehl-Schmid (Technical University, Munich Germany), Prof Daniela Galimberti (University of Milan, Italy), Prof Simon Ducharme (McGill Uni, Montreal, Canada), Prof Olivier Piguet (USyd).

I am co-chair of the MRFF Australian Parkinson's Mission research committee which includes the following collaborators – Prof Antony Cooper (Garvan Sydney), Prof Joseph Powells (Garvan Sydney), Prof Daniel MacArthur (Garvan Sydney), Prof Sarah Kummerfield (Garvan Sydney), Jacqui Everett (Garvan Sydney), Prof Simon Lewis (USyd), Dr Nicolas Dzamko (USyd), Prof Deniz Kirik (USyd), Prof Justin O'Sullivan (Auckland Uni, New Zealand).

I am a co-investigator on three Aligning Science Across Parkinson's international grants which includes the following collaborators – Prof Deniz Kirik (USyd), Assoc Prof Lachlan Thompson (Florey, Melbourne), Prof Claire Parish (Florey, Melbourne), Prof Carolyn Sue (USyd), Prof Jennifer Johnson (NysnoBio, Mill Valley California USA), Prof Robert Edwards (UCSF, San Francisco USA), Prof Alexandra Nelson (UCSF, San Francisco USA), Dr Kira Poskanzer (UCSF, San Francisco USA), Prof Ken Nakamura (UCSF, San Francisco USA), Prof Chris Ford (Colorado Uni, USA), Dr Zayd Khaliq (NIH, Washington USA), Prof Miquel Vila (Vall d'Hebron Research Institute, Barcelona Spain), Prof Jose Obeso (CIBERNED, Madrid Spain), Dr Matthias Prigge (Leibniz Institute for Neurobiology, Magdeburg Germany), Prof Nicola Mercuri (Vergata Univeristy, Rome Italy), Prof Ernest Arenas (Karolinska Institute, Sweden), Dr Jan Tonnesen (Achucarro Basque Centre for Neuroscience, Bizkaia Spain), Dr Federico Soria (Achucarro Basque Centre for Neuroscience, Bizkaia Spain), Dr Jose Lanciego (CIBERNED, Madrid Spain).

I am a co-investigator on a NIH grant which includes the following collaborators - Prof Vikram Khurana (Brigham and Women's Hospital, Massachusetts, USA), Assoc Prof Tim Bartels (UCL, London UK), Assoc Prof Ulf Dettmer (Brigham and Women's Hospital, Massachusetts, USA)

I am the research neuropathologist for the Sydney Brain Bank with Dr Claire Shepherd director and am CIA for Frontier Brain Donor Program with Prof Olivier Piguet (~100 participants), CIA for Motor Neuron Disease Brain Donor Program with Prof Matthew Kiernan and Prof Dominic Rowe (~50 participants) & CIB for NSW Movement Disorder Brain Donor Program with Prof Simon Lewis (~200 participants) with Honorary Visiting Scientist appointment in Anatomical Pathology at Westmead Hospital for brain retrievals. The brain collection for research has grown by ~600 cases over the last 10 years.

I am part of a number of international collaborations including – International Frontotemporal Dementia Genomics Consortia, International Parkinson's Disease Genetic Consortia, Global Parkinson's Genetics Program GP2, International Dementia with Lewy Bodies Consortia, International Movement Disorder Society task forces defining Parkinson's disease subtypes (& previously on defining Parkinson's disease), multiple system atrophy & progressive supranuclear palsy, NINDS and MDS Integrative Criteria for Parkinson's disease, and a number of neuropathology consortia for dementia with Lewy bodies, frontotemporal dementia, limbic-predominant age-related TDP encephalopathy, and age-related astrogliopathy.

Research Grants (*Credit share*)

<u>International</u>

Aligning Science Across Parkinson's (ASAP) Initiative, The dual role of neural activity in Parkinson's disease. US$ 9,700,972, 2021-2024 CIs: Edwards, Nelson, Poskanzer, Nakamura, Ford, **Halliday** (17%) & Khaliq

Aligning Science Across Parkinson's (ASAP) Initiative, Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease. US$10,975,372, 2021-2024 CIs: Vila, **Halliday** (19%), Obeso, Prigge, Mercuri, Arenas, Tonnesen, Soria, Lanciego

Aligning Science Across Parkinson's (ASAP) Initiative, An *in vivo* approach to elucidate the pathobiology of PD-associated genes using human diseased neurons. US$8,897,885, 2020-2023 CIs: Kirik, Parish, Sue, Thompson, **Halliday** (9%) & Johnston

NIH RO1 Award, Elucidating the biological differences between distinct fibrillar and non-fibrillar α-synuclein inclusions in human stem-cell models. US$3,866,129, 2020-2025 Cis: Khurana, Dettmer, Bartels & **Halliday** (6%)

Michael J. Fox Foundation Astrocyte Biology in PD Award, Astroglial proteins associated with astroglial α-synuclein in different stages of Parkinson's disease. $217,217, 2020-2021 CIs: **Halliday** (100%) & Fu

Michael J. Fox Foundation Target Advancement Award, Using digital spatial profile to screen targetable molecules to halt α-synucleinopathy. $221,225, 2019-2020 CIs: **Halliday** (100%) & Fu

Michael J. Fox Foundation Research Grant, Inflammatory markers in GBA carriers with and without PD. $259,736, 2018-2020 CIs: Dzamko, Lewis, Pope & **Halliday** (0%)

Michael J. Fox Foundation Research Grant, Using MJF-14 antibody to uncover novel α-synuclein pathology in Parkinson's disease and MSA. $285,683, 2018-2020 CIs: Jensen & **Halliday** (67%)

Michael J. Fox Foundation Research Grant, Are there peripheral changes in GBA protein/activity in idiopathic PD patients? $209,709, 2016-2018, $224,449, 2018-2019 CIs: **Halliday** (100%), Lewis, Dzamko & Kwok

Michael J. Fox Foundation Target Engagement Award, Fluorescence tagging of endogenous LRRK2 to enable *in vivo* imaging in mice and differentiated human IPS cells. $143,628, 2016-2018 CIs: Dzamko, Fu & **Halliday** (0%)

Michael J. Fox Foundation Biomarkers and Clinical Outcomes Award, Peripheral inflammatory cytokine profiling in Parkinson's disease. $560,000, 2017-2018 CIs: Dzamko & **Halliday** (0%)

Australian (category 1)

MRFF Australian Parkinson's Mission, Biomarkers for clinical trial APM002, $2,430,572, 2022-2026 CIs: Dzamko, **Halliday**, Cooper

NHMRC Investigator Grant, Leadership Fellowship Salary Package, $2,101,595, 2020-2024 CI: **Halliday** (100%)

NHMRC-EU Joint Program on Neurodegenerative Disease Research, Diagnostic and prognostic precision medicine for behavioural variant frontotemporal dementia, $498,850, 2020-2023 CIs: **Halliday** (98%), Piguet

NHMRC-NIHR Collaborative Research Program, COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT), $1,218,120, 2020-2023 Cis: Watson, Lewis, Yassi, Churilov, Ford, Bhat, **Halliday** (0%) & Brodaty

NHMRC Equipment Grant, Nikon Ni-E C2 Confocal System, $277,166, 2020-2021 CIs: **Halliday** (100%), Dobson-Stone, Absalom

MRFF Australian Parkinson's Mission, Biomarkers for clinical trial APM001, $3,164,662, 2019-2024 CIs: **Halliday** (100%), Dzamko

NHMRC Equipment Grant, A set-up for multi-analyte spatial profiling platform in 3D neuroscience, $60,000, 2019 CIs: **Halliday** (50%), Double, Fu

NHMRC Equipment Grant, Meso QuickPlex SQ 120 system for shared use in the open access, multi-used, Bosch Moleclar Biology Facility, $180,000, 2019 CIs: Richardson, Scolyer, **Halliday** (10%)

NHMRC Centre of Research Excellence Grant, To optimise sleep in brain ageing and neurodegeneration, $2,499,557, 2018-2023 CIs: Naismith, Grunstein, Lewis, Phillips, D'Rozario, Hoyos, Rajaratnam, **Halliday** (0%)

NHMRC Program Grant, Frontotemporal dementia and motor neurodegenerative syndromes, $17,069,580, 2018-2022 CIs: **Halliday** (50%)**,** Mattick, Hodges, Kiernan, Piguet, Kril, Ittner & Kassiou

NHMRC Equipment Grant, A complete mouse neuroscience research set-up, $63,000, 2018 CIs: **Halliday** (50%), Collins-Chibib, van Nieuwenhuijzen

NHMRC Dementia Team Grant, Non-Alzheimer's disease degenerative dementias: identifying prodromal genetic/familial phenotypes, modifying factors, and protein variants involved in progression, $6,449,246, 2015-2022 CIs: **Halliday** (100%)**,** Hodges, Lewis, Piguet, Kril, Kwok, Villemagne, Kiernan, Rowe & McKeith

NHMRC Project Grant, Neuronal toll-like 2 receptors contribute to the spread of Parkinson's disease, $910,010, 2016-2019 CIs: **Halliday** (100%), Dzamko & Sue

NHMRC Research Fellowship Grant, Senior Principal Research Fellowship Salary Package, $911,915, 2015-2019 CI: **Halliday** (100%)

NHMRC Program Grant, Frontotemporal dementia and motor neurodegenerative syndromes, $11,011,390, 2013-2017 CIs: **Halliday** (30%)**,** Götz, Ittner, Kril, Hodges & Kiernan

Research Awards/Recognition

Fellowships of Learned Academies

2021 Member, Australian Academy of Science
2014 Member, Australian Academy of Health and Medical Sciences

Scientific Awards and Distinctions

2023 Companion of the Order of Australia, *Governor General of Australia*
2022 NSW Scientist of the Year, *NSW Premier's Prizes for Science and Engineering*
2021 Robert A. Pritzker Prize for Leadership in Parkinson's Research, *Michael J Fox Foundation*
2020 NHMRC Elizabeth Blackburn Investigator Award – for leadership in Clinical Medicine and Science
2018 Highly Cited Researcher, *Clarivate Analytics*
2017 C. David Marsden Lecture Award, *International Parkinson and Movement Disorder Society*
2016 Cozzarelli Prize for outstanding 2015 paper, *National Academy of Sciences, USA*
2014 NHMRC Elizabeth Blackburn Fellowship – Clinical Award
2013 NHMRC high achiever (http://www.nhmrc.gov.au/high-achievers/biographies)
2011 Nina Kondelos Prize, *Australian Neuroscience Society* (outstanding female contribution to basic or clinical neuroscience)

Keynote Presentations at International Conferences (travel and accommodation funded)

- 'Does the prion-like property of alpha -synuclein drive Parkinson's Disease?', plenary debate, Aligning Science Across Parkinson's Disease, SanDiego, USA, 7/23, ~500 attendees
- 'What's Special About Parkinson's Disease - Are Common Molecular Mechanisms Important?', plenary lecture, Gordon Research Conference, Switzerland, 5/23, ~300 attendees
- 'Alpha-synuclein is involved in adaptive neural changes', plenary lecture, Latsis/Sinergia Symposium on Imaging Neurodegenerative Diseases, Zurich, Switzerland, 9/22, ~300 attendees
- 'Neuropathology', plenary lecture, International Lewy Body Disease Conference 2022, Newcastle on Tyne, UK, 6/22, ~600 attendees
- 'Is alpha-synuclein necessary for the development of Parkinson's disease?', plenary lecture, Synuclein meeting 2022, Leuvan, Belgium, 4/22, ~350 attendees
- 'The involvement of glia and astrocytes in Parkinson's disease', plenary lecture, Parkinson's UK Online Research Conference, 9/20, ~2,000 attendees
- 'Role of α-synuclein and lessons learned from the brain', plenary lecture, 14th International Conference on Alzheimer's and Parkinson's Diseases, Lisbon, Portugal, 3/19, ~4000 attendees
- 'Neuronal cell vulnerability in Parkinson's disease', plenary lecture, International Parkinson and Movement Disorders Society Movement Disorders Journal Symposium, Aspen, USA, 7/18, ~20 paid attendees
- 'Pathology of Parkinson's disease' & 'Pathology of multiple system atrophy', plenary speaker, International Parkinson and Movement Disorders Society Asian & Oceanian Neuropathology and Neuroimaging in Movement Disorders meeting, Seoul, Korea, 6/18. ~250 attendees
- 'Pathology of cognitive dysfunction in Parkinson's disease and dementia with Lewy bodies' & 'Pathology of non-Alzheimer dementias', plenary speaker, annual meeting of the Korean Movement Disorders Society, Seoul, Korea, 4/18, ~500 attendees
- 'Clues to Parkinson's disease from the types and patterns of cellular pathologies in the brain', Presidential plenary lecture, 21st International Congress of the International Parkinson and Movement Disorders Society, Vancouver, Canada 6/17. ~2500 attendees

Invited Presentations at International Conferences

- 'Contemporary issues in non-Alzheimer dementia and other motor syndromes', invited symposium speaker, XXXIV International Congress of the International Academy of Pathology (IAP 2022), 10/22, ~2,000 attendees

- ‘Astrocyte pathology in Parkinson’s disease’, invited symposium speaker, Aligning Science Across Parkinson’s disease 2022 symposium, 4/22, ~200 invited attendees
- ‘Types of human brain tissue collections – what can they tell us?’, invited workshop speaker, Aligning Science Across Parkinson’s disease 2022 symposium, 4/22, ~200 invited attendees
- ‘Diversity of TDP-43 pathologies in ALS/FTD’, invited online symposium speaker, 2021 Pan-Asian Consortium for Treatment and Research in ALS, 9/21, ~1,000 attendees
- ‘Neuropathology of FTLD”, invited online symposium speaker, 2021 Alzheimer’s Association International Conference, 7/21, ~1,500 attendees
- ‘New aspects of neurodegenerative diseases – for the future’, invited online symposium speaker, Annual meeting of the Japanese Neuroscience Society, 7/21, ~2,000 attendees
- ‘Synucleinopathies’, invited online symposium speaker, 2021 virtual International Parkinson and Movement Disorders Society Movement Disorders Australasia and Oceana conference, 6/21, ~500 attendees
- ‘Copathologies in FTD syndromes’, invited online speaker, International Society for Frontotemporal Dementias Congress, 3/21, ~150 attendees
- ‘Is MSA prion-like or a prion disease?’, invited online speaker, 7th International Conference on Multiple System Atrophy, online, 3/21, ~100 attendees
- ‘The role of glia in progressing α-synuclein pathologies’, invited online symposium lecture, 15th International Conference on Alzheimer’s and Parkinson’s Diseases, 3/21, ~4000 attendees
- ‘What I have learnt from assessing neurodegenerative diseases through research on the human brain’, invited international speaker, Brain Research New Zealand workshop, Dunedin, New Zealand, 2/2020. ~50 attendees (expenses paid)
- ‘Is synucleinopathy a single entity?’ invited symposium speaker, 2019 International Congress of the International Parkinson and Movement Disorders Society, Nice, France, 9/19, ~5000 attendees (expenses paid)
- ‘Spreading of α-synuclein – driver or epiphenomenon?’, invited speaker, International Synuclein Meeting, Porto, Portugal, 9/19 ~200 attendees (expenses paid)
- ‘Lysosomal dysfunction in Parkinson’s disease and what postmortem brain tells us’, invited speaker, 60th Annual Meeting of the Japanese Society of Neurology, Osaka, Japan 5/19, ~6000 attendees (expenses paid)
- ‘Fatal attraction between tau and α-synuclein in Parkinson’s disease: Neuropathological findings’, invited speaker, 2018 International Congress of the International Parkinson and Movement Disorders Society, Hong Kong, China, 9/18, ~4000 attendees (expenses paid)
- ‘Pathology of Parkinson’s disease update’, invited speaker, 19th International Congress of Neuropathology, Tokyo, Japan, 9/18, ~3000 attendees (expenses paid)
- ‘ALS/FTD: experimental models versus reality’, invited speaker, Society for Neuroscience annual meeting, Washington, USA, 12/17 ~5000 attendees (expenses paid)
- ‘Neuropathological basis of central autonomic failure’, invited speaker, XXIII World Congress of Neurology, Kyoto, Japan, 9/17, ~2000 attendees (expenses paid)
- ‘Neuropathological studies in longitudinally followed cohorts of sporadic Parkinson’s disease’, ‘Dementia with Lewy bodies Neuropathology’ & ‘mulitple system atrophy neuropathology’, invited speaker, Hellenic Society for Neuroscience & Attica Institute of Neurological Sciences Scientific Meeting, Athens, Greece, 9/17, ~200 attendees (expenses paid)
- ‘Mixed pathology in Alzheimer’s disease’, invited speaker, Alzheimer’s Association International 2017 Congress London, UK, 7/17, ~2500 attendees (expenses paid)
- ‘α-Synuclein propagation and multiple system atrophy’, invited speaker, Catalan Institute for Research and Advanced Studies, Barcelona, Spain, 5/17 ~150 attendees (expenses paid)

Invited Presentations at National Conferences

- ‘How the brain works”, 2022 annual meeting of the National Judicial College of Australia, Adelaide, 10/22, ~50 attendees
- ‘Vascular dementia and LATE TDP-43 mechanisms in dementia’, invited online symposium speaker, 2021 annual meeting of Australian Dementia Trials, 10/21, ~200 attendees

- ‘What’s new in the pathology of dementia’, invited online keynote speaker, Australian Dementia Forum 2021, 6/21, ~200 attendees
- ‘The role of α-synuclein in dopamine neuron degeneration in Parkinson’s disease’, symposium speaker, Annual Meeting of the Australian Neuroscience Society, Melbourne, 12/19. ~1,000 attendees
- ‘The gut microbiome in Parkinson’s disease’, invited speaker, 2019 annual meeting of the Movement Disorders Society of Australia and New Zealand, Adelaide, 11/19, ~100 attendees (expenses paid)
- ‘The impact of Neurobiological Research on Understanding Behaviour’, 2019 annual meeting of the National Judicial College of Australia, Adelaide, 10/19, ~50 attendees
- ‘Ageing and neurodegeneration’, 2019 Australian Biology of Ageing Conference, plenary lecture, Sydney, 8/19. ~50 attendees
- ‘Diagnosing non-Alzheimer’s dementia’, invited speaker, Hobart, 6/19, ~150 attendees
- ‘Neuropathology in frontotemporal dementia (FTD)’, invited workshop speaker, International Conference of the Society for Frontotemporal Dementias, Sydney, 10/18, ~1000 attendees
- ‘Mixed pathology in Alzheimer’s disease’, invited speaker, NHMRC National Institute for Dementia Research annual forum, Sydney, 6/18, ~250 attendees
- ‘Catching Parkinson’s disease – does the evidence stack up?’, invited speaker, Australian and New Zealand Association of Neurologist’s annual meeting, Darwin, 5/18, ~150 attendees (expenses paid)
- ‘Does neuropathology support the existence of dementia with Lewy bodies (DLB) as a unique entity?’, invited speaker, RANZCP Section of Neuropsychiatry Conference 2017, Sydney, 10/17, ~100 attendees (expenses paid)
- ‘Identifying prodromal genetic/familial phenotypes and modifying factors, and protein factors involved in progression’, invited speaker, NHMRC National Institute for Dementia Research annual forum, Melbourne, 10/17, ~250 attendees
- ‘Prion hypothesis – true or false’, invited speaker, Aust. NZ Association of Neurologists registrars training weekend, Melbourne, 3/17, ~70 attendees (travel and accommodation funded)

HDR Supervision

Currently enrolled HDR students

Anastasia Filimontseva, F/T PhD student, Medicine, USyd, 2023-2027
Topic: Neuromelanin attributed mechanisms to catecholaminergic neuron loss in Parkinson’s disease
Lead supervisor, Supervisor B Dr Yuhong Fu

Jennifer Oraha, F/T PhD student, Medicine, USyd, 2023-2027
Topic: The contribution of leptin signalling on NPY neurons to the development of the metabolic features evident in neurodegenerative disease (NDDs) such as Huntington’s Disease (HD) Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS)
Lead supervisor, Supervisor B Dr Nikki Lee & Dr Rebekah Ahmed

Cormac Peat, F/T PhD student, Medicine, USyd, 2022-2026
Topic: Astrocyte dysfunction in genetic models of Parkinson’s disease
Lead supervisor, Supervisor B Dr Asheeta Prasad

Yuan Tang, F/T PhD student, Medicine, USyd, 2022-2026
Topic: The role of Rab and ESCRT proteins in autophagy dysfunction in Parkinson’s disease
Supervisor B, Lead supervisor Dr Nicolas Dzamko

Giselle Sagredo, F/T PhD student, Medicine, USyd, 2021-2025
Topic: Biology of Parkinson’s disease associated genes and neuro immune Interactions
Lead supervisor, Supervisor B Dr Yuhong Fu

Laura Hughes, F/T PhD student, Medicine, USyd, 2021-2025
Topic: LRRK2 and GCase as peripheral biomarkers for Parkinson’s disease
Supervisor B, Lead supervisor Dr Nicolas Dzamko, 3 publications

Fatima Afaar, F/T PhD student, Medicine, USyd, 2020-2024
Topic: Investigating blood immune biomarkers in prodromal Parkinson's disease patients
Supervisor B, Lead supervisor Dr Nicolas Dzamko

Jessica Chedid, F/T PhD student, Medicine, USyd, 2019-2024
Topic: The role of autophagy in TLR2-mediated α-synuclein accumulation in neurons
Supervisor B, Lead supervisor Dr Nicolas Dzamko 1 publication

Fiona Weiss, F/T PhD student, Medicine, USyd, 2020-2024
Topic: Monocyte contributions to neuronal α-synuclein pathology in Parkinson's disease
Supervisor B, Lead supervisor Dr Nicolas Dzamko, 1 publication

Research degrees awarded in the last 5 years

Kosar Hooshmand, F/T PhD student, Medicine, USyd, 2020-2023
Topic: Transcriptomics in neurodegenerative disease
Supervisor B, Lead supervisor Dr Boris Guennewig, 1 publication

Benjamin Huynh, F/T PhD student, Medicine, USyd, 2019-2023
Topic: The Staging of Neurotransmitter System Deterioration in the Non-Motor Symptoms of Parkinson's Disease
Lead supervisor, Supervisor B Dr Yuhong Fu, 1 publication

Finula Isik, F/T PhD student, Medicine, USyd, 2019-2023
Topic: Functional Study of the CDH4 Gene in multiple system Atrophy
Supervisor B, Lead supervisor A/Prof Scott Kim

Andrew Affleck, P/T PhD student, Medicine, UNSW, 2015-2023
Topic: Effects of anti-hypertensive medication on Alzheimer's disease and cerebrovascular disease brain pathology
Primary supervisor, co-supervisor Prof Perminder Sachdev, 8 publications

Jared Katzeff, F/T PhD student, Medicine, USyd, 2018-2022
Topic: Understanding immune pathways altered in frontotemporal dementia and amyotrophic lateral sclerosis
Supervisor B, Lead supervisor A/Prof Scott Kim, 5 publications

Elie Matar, P/T PhD student, Medicine, USyd, 2017-2022
Topic: Utilizing neuroimaging methods to understand and delineate the continuum of cognitive impairment in Lewy Body Disorders
Supervisor B, Lead supervisor Prof Simon Lewis, 16 publications

Jieyao Feng, F/T Masters student, Medicine, USyd, 2019-2021
Topic: Rab29 expression modulates glucocerebrosidase (GBA) protein levels
Supervisor B, Lead supervisor Dr Nicolas Dzamko, 1 publication

Jasmin Galper, F/T PhD student, Medicine, USyd, 2018-2021
Topic: Biofluid markers in clinical and pre-clinical Parkinson's disease
Supervisor B, Lead supervisor Dr Nicolas Dzamko

Diba Rastegar, F/T PhD student, Medicine, USyd, 2018-2021
Topic: LRRK2-mediated inflammation and Parkinson's disease
Supervisor B, Lead supervisor Dr Nicolas Dzamko, 2 publications

Jianqun Gao, F/T PhD student, Medicine, USyd, 2017-2019
Topic: TLR2 and α-synuclein mediated pathology in human neuronal cell models
Primary supervisor, co-supervisor Dr Nicolas Dzamko, 5 publications

Ye Zhao, F/T PhD student, Medicine, USyd, 2015-2018
Topic: Potential role of LRRK2 Ser910 and Ser935 phosphorylation in the pathogenesis of Parkinson's disease
Primary supervisor, co-supervisor Dr Nicolas Dzamko, 6 publications

Tony (JH) Hsiao, F/T PhD student, Medicine, UNSW, 2015-2018
Topic: Understanding the role of lipids in α-synuclein aggregation process in parkinsonian syndromes
Co-supervisor, primary supervisor A/Prof Scott Kim, 7 publications

Guinevere Fernandes Lourenco De Souza Lima, F/T PhD student, Medicine, UNSW, 2013-2017
Topic: Non-coding RNAs in frontotemporal dementia
Primary supervisor, co-supervisor Dr Michael Janitz, 3 publications

Student placements after PhD

- Elie Matar, specialist training in neurology, 2022 NHMRC Early Investigator Fellow USyd
- Andrew Affleck, RPAH hospital scientist
- Jasmin Galper, research academic level A USyd
- Jared Katzeff, enrolled in medicine, Wollongong

- Diba Rastegar, research assistant USyd
- Jianqun Gao, neurologist China
- Ye Zhao, senior management Pfizer China
- Tony (JH) Hsiao, research academic level A USyd
- Guinevere Fernandes Lourenco De Souza Lima, research academic level A USyd

Top 10 Research Outputs for Levels D and E.

1. Murphy KE, Gysbers AM, Abbott S, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, **Halliday GM** (2014) Reduced glucocerebrosidase is related to increased α-synuclein in sporadic Parkinson's disease. Brain 137:834-848. 347 citations **Highly Cited** Web of Science

First identification of deficits in glucocerebrosidase activity in sporadic Parkinson's disease. As therapy for glucocerebrosidase deficits are successful for the most common lysosomal storage disorder, Gaucher's disease, with homozygous mutations in the gene, this therapy was then successfully trialled for idiopathic Parkinson's disease (JAMA Neurology 2020) (35% contribution).

2. Prusiner SB, Woerman AL, Rampersaud R, Watts JC, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz S, Geschwind DH, Glidden DV, **Halliday G**, Middleton LT, Gentleman SM, Mordes DA, DeArmond SJ, Giles K (2015) Evidence for α-synuclein prions causing multiple system atrophy in humans with Parkinsonism. Proc. Natl. Acad. Sci. USA 112:E5308-17. 489 citations **Highly Cited** Web of Science

First study to identify prion-like transmission of a non-prion neurodegenerative protein. The study was awarded the 2016 Cozzarelli Prize for papers of outstanding scientific excellence and originality (30% contribution; human data analysis)

3. Burrell JR, **Halliday GM,** Kril JJ, Ittner LM, Götz J, Kiernan MC, Hodges JR (2016) The frontotemporal dementia–motor neuron disease continuum. Lancet 388:919-31. 222 citations **Highly Cited** Web of Science

Synthesis of the work of the NHMRC program grant I was CIA for; study led by postdoc Burrell (30% contribution; genetics and molecular and histopathology sections)

4. Surmeier DJ, Obeso JA, **Halliday GM** (2017) Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci.18:101-113. 548 citations **Highly Cited** Web of Science

Summarises all quantitative studies from Halliday laboratory of neuronal populations affected by Parkinson's disease, showing highly selective involvement within any region. Vulnerability shown to correlate with cell properties - a long, highly branched axon, autonomous discharge, elevated calcium entry and basal mitochondrial oxidant stress (45% contribution; human data analysis).

5. Poewe W, Seppi K, Tanner C, **Halliday GM**, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson's disease. Nature Rev. Dis. Primers 3:17013. 2,470 citations **Highly Cited** Web of Science

Invited author for global overview of Parkinson's disease; responsible for the mechanisms/pathophysiology section and figures

6. McKeith I, Boeve B, Dickson D, **Halliday GM**, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Ferman TJ, Kantarci K, Postuma R, Tiraboschi P, Attems J, Ballard C, Bayston A, Babcock D, Beach T, Blanc F, Bras J, Bundin P, Burn D, Bohnen N, ChenPlotkin A, Duda J, El-Agnaf O, Fujishiro H, Ffytche D, Galasko D, Goldman JG, Hoing L, Hsiao J, Iranzo A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine T, Mori E, Murray M, O'Brien J, Petersen RC, Phelps T, Salmon D, Sieber B-A, Silvereberg N, Sutherland M, Taylor A, Thomas A, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K, for the Consortium on DLB (2017) Diagnosis and management of dementia with Lewy bodies: Forth consensus report of the DLB consortium. Neurology 89:88-100. 2,024 citations **Highly Cited** Web of Science

Revision of the criteria for dementia with Lewy bodies; one of the four in the writing group; lead for genetics, biomarkers, pathology, animal models

7. Dzamko N, Gysbers A, Perrera G, Bahar A, Shankar A, Gao J, Fu Y, **Halliday GM** (2017) Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to α-synuclein pathology. Acta Neuropathol. 133:303-319. 151 citations, Web of Science

First study to identify functional immune related changes in human neurons that occurred in patients with Parkinson's disease and seemed to propagate the pathology within the brain. This has led to the development of drugs targeting these toll receptors.

8. Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, Huang Y, McGinley CV, Werka H, Kiernan MC, Götz J, Spillantini MG, Hodges JR, Ittner LM, **Halliday GM** (2018) Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 141:521-534. 101 citations Web of Science

Changed the paradigm for discussing the genetic forms of frontotemporal dementia (see commentaries), showing the artificial distinction between sporadic and genetic forms. Abnormalities map either to a single disease pathology or to the deposition of the same protein isoform. Modelling can now better identify the underlying cellular mechanisms (30% contribution).

9. Aarsland D, Batzu L, **Halliday** GM, Geurtsen GJ, Ballard C, Chaudhuri RK, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Primers 7:47; correction 7:53. 234 citations **Highly Cited Hot paper** Web of Science

Invited author for global overview of cognitive impairment in Parkinson's disease; responsible for the mechanisms/pathophysiology section and figures

10. Poewe W, Stankovic I, **Halliday G**, Meissner WG, Wenning GK, Pellecchia MT, Seppi K, Palma JA, Kaufmann H (2022) Multiple system atrophy. Nat. Rev. Dis. Primers 2022;8:56. 27 citations **Highly Cited** Web of Science

Invited author for global overview of multiple system atrophy; responsible for the mechanisms/pathophysiology section and figures

List of career publications

Refereed journal articles

1. Affleck AJ, Sachdev PS, **Halliday GM** (2023) Past antihypertensive medication use is associated with lower levels of small vessel disease and lower Aβ plaque stage in the brains of older individuals. Neuropathol Appl Neurobiol. 49:e12922
2. Chatterton Z, Lamichhane P, Ahmadi Rastegar D, Fitzpatrick L, Lebhar H, Marquis C, **Halliday G**, Kwok JB (2023) Single-cell DNA methylation sequencing by combinatorial indexing and enzymatic DNA methylation conversion. Cell Biosci. 13:2.
3. Forrest SL, Kim JH, Crockford DR, Huynh K, Cheong R, Knott S, Kane MA, Ittner LM, **Halliday GM**, Kril JJ (2023) Distribution patterns of astrocyte populations in the human cortex. Neurochem. Res. 48:1222-1232
4. Ge YJ, Ou YN, Deng YT, Wu BS, Yang L, Zhang YR, Chen SD, Huang YY, Dong Q, Tan L, Yu JT; **International FTD-Genomics Consortium** (2023) Prioritization of drug targets for neurodegenerative diseases by integrating genetic and proteomic data from brain and blood. Biol. Psychiatry 93:770-779
5. Henden L, Fearnley LG, Grima N, McCann EP, Dobson-Stone C, Fitzpatrick L, Friend K, Hobson L, Chan Moi Fat S, Rowe DB, D'Silva S, Kwok JB, **Halliday GM**, Kiernan MC, Mazumder S, Timmins HC, Zoing M, Pamphlett R, Adams L, Bahlo M, Blair IP, Williams KL (2023) Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia. Sci Adv. 9:eade2044
6. Hsiao JT, Tanglay O, Li AA, Strobbe AYG, Kim WS, **Halliday GM**, Fu Y (2023) Role of Oligodendrocyte Lineage Cells in Multiple System Atrophy. Cells. 12:739
7. Lok HC, Katzeff JS, Hodges JR, Piguet O, Fu Y, **Halliday GM**, Kim WS (2023) Elevated GRO-α and IL-18 in serum and brain implicate the NLRP3 inflammasome in frontotemporal dementia. Sci Rep. 13:8942
8. Marian OC, Teo JD, Lee JY, Song H, Kwok JB, Landin-Romero R, **Halliday G**, Don AS (2023) Disrupted myelin lipid metabolism differentiates frontotemporal dementia caused by GRN and C9orf72 gene mutations. Acta Neuropathol Commun. 11:52

9. Mazumder S, McCann H, D'Silva S, Furlong S, Shepherd CE, Kril JJ, **Halliday GM**, Rowe DB, Kiernan MC, Tan RH (2023) Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis. Brain 146:e17-e19.
10. Nelson PT, Lee EB, Cykowski MD, Alafuzoff I, Arfanakis K, Attems J, Brayne C, Corrada MM, Dugger BN, Flanagan ME, Ghetti B, Grinberg LT, Grossman M, Grothe MJ, **Halliday GM**, Hasegawa M, Hokkanen SRK, Hunter S, Jellinger K, Kawas CH, Keene CD, Kouri N, Kovacs GG, Leverenz JB, Latimer CS, Mackenzie IR, Mao Q, McAleese KE, Merrick R, Montine TJ, Murray ME, Myllykangas L, Nag S, Neltner JH, Newell KL, Rissman RA, Saito Y, Sajjadi SA, Schwetye KE, Teich AF, Thal DR, Tomé SO, Troncoso JC, Wang SJ, White CL 3rd, Wisniewski T, Yang HS, Schneider JA, Dickson DW, Neumann M (2023) LATE_NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 145:159-173.
11. Pinkerton M, Lourenco G, Pacheco MT, **Halliday GM**, Kiernan MC, Tan RH (2023) Survival in sporadic ALS is associated with lower p62 burden in the spinal cord. J Neuropathol Exp Neurol. 2023 Aug 21;82(9):769-773
12. Qi R, Sammler E, Gonzalez-Hunt CP, Barraza I, Pena N, Rouanet JP, Naaldijk Y, Goodson S, Fuzzati M, Blandini F, Erickson KI, Weinstein AM, Lutz MW, Kwok JB, **Halliday GM**, Dzamko N, Padmanabhan S, Alcalay RN, Waters C, Hogarth P, Simuni T, Smith D, Marras C, Tonelli F, Alessi DR, West AB, Shiva S, Hilfiker S, Sanders LH (2023) A blood-based marker of mitochondrial DNA damage in Parkinson's disease. Sci Transl Med. 15:eabo1557
13. Shepherd CE, Lewis SJG, Tisch S, McCann H, Jonker B, **Halliday GM** (2023) Effects of STN/SNr deep brain stimulation in a case of progressive supranuclear palsy with a Parkinson disease phenotype. J Neuropathol Exp Neurol. 82:821-823
14. Tse NY, Bocchetta M, Todd EG, Devenney EM, Tu S, Caga J, Hodges JR, **Halliday GM**, Irish M, Kiernan MC, Piguet O, Rohrer JD, Ahmed RM (2023) Distinct hypothalamic involvement in the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. Neuroimage Clin. 37:103281.
15. Valentino RR, Scotton WJ, Roemer SF, Lashley T, Heckman MG, Shoai M, Martinez-Carrasco A, Tamvaka N, Walton RL, Baker MC, Macpherson HL, Real R, Soto-Beasley AI, Mok K, Revesz T, Warner TT, Jaunmuktane Z, Boeve BF, Christopher EA, DeTure M, Duara R, Graff-Radford NR, Josephs KA, Knopman DS, Koga S, Murray ME, Lyons KE, Pahwa R, Parisi JE, Petersen RC, Whitwell J, Grinberg LT, Miller B, Schlereth A, Seeley WW, Spina S, Grossman M, Irwin DJ, Lee EB, Suh E, Trojanowski JQ, Van Deerlin VM, Wolk DA, Connors TR, Dooley PM, Frosch MP, Oakley DH, Aldecoa I, Balasa M, Gelpi E, Borrego-Écija S, de Eugenio Huélamo RM, Gascon-Bayarri J, Sánchez-Valle R, Sanz-Cartagena P, Piñol-Ripoll G, Molina-Porcel L, Bigio EH, Flanagan ME, Gefen T, Rogalski EJ, Weintraub S, Redding-Ochoa J, Chang K, Troncoso JC, Prokop S, Newell KL, Ghetti B, Jones M, Richardson A, Robinson AC, Roncaroli F, Snowden J, Allinson K, Green O, Rowe JB, Singh P, Beach TG, Serrano GE, Flowers XE, Goldman JE, Heaps AC, Leskinen SP, Teich AF, Black SE, Keith JL, Masellis M, Bodi I, King A, Sarraj SA, Troakes C, **Halliday GM**, Hodges JR, Kril JJ, Kwok JB, Piguet O, Gearing M, Arzberger T, Roeber S, Attems J, Morris CM, Thomas A… (2023) Creating the Pick's disease International Consortium: Association study of *MAPT*H2 haplotype with risk of Pick's disease. medRxiv. 2023 Apr 24:2023.04.17.23288471
16. Yang Y, Rowe D, McCann H, Shepherd CE, Kril JJ, Kiernan MC, **Halliday GM**, Tan RH (2023) Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. Neuropathol Appl Neurobiol. 49:e12919
17. Youssef P, Hughes L, Kim WS, **Halliday GM**, Lewis SJG, Cooper A, Dzamko N (2023) Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting. Sci Rep. 13:5217
18. Ahmadi Rastegar D, Hughes LP, Perera G, Keshiya S, Zhong S, Gao J, **Halliday GM**, Schüle B, Dzamko N (2022) Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis. 8:34
19. Bitar M, Weissleder C, North HF, Clearwater MS, Zalucki O, **Halliday GM**, Webster MJ, Piper M, Weickert CS, Barry G (2022) Identifying gene expression profiles associated with neurogenesis and inflammation in the human subependymal zone from development through aging. Sci. Rep. 12:40.
20. Bocchetta M, Todd EG, Tse NY, Devenney EM, Tu S, Caga J, Hodges JR, **Halliday GM**, Irish M, Piguet O, Kiernan MC, Rohrer JD, Ahmed RM (2022) Thalamic and cerebellar regional involvement across the ALS-FTD spectrum and the effect of *C9orf72*. Brain Sci. 12:336.

21. Boel JA, de Bie RMA, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; **MDS Study Group Mild Cognitive Impairment in Parkinson's Disease** (2022) Level I PD-MCI using global cognitive tests and the risk for Parkinson's disease dementia. Mov. Disord. Clin. Pract. 9:479-483.
22. Chedid J, Labrador-Garrido A, Zhong S, Gao J, Zhao Y, Perera G, Kim WS, **Halliday GM**, Dzamko N (2022) A small molecule Toll-like receptor antagonist rescues α-synuclein fibril pathology. J. Biol. Chem. 298:102260.
23. Chen Y, Landin-Romero R, Kumfor F, Irish M, Dobson-Stone C, Kwok JB, **Halliday GM**, Hodges JR, Piguet O (2022) Cerebellar integrity and contributions to cognition in C9ORF72-mediated frontotemporal dementia. Cortex 149:73-84.
24. Ehgoetz Martens KA, Matar E, Phillips JR, Shine JM, Grunstein RR, **Halliday GM**, Lewis SJG (2022) Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. Neuroimage Clin. 33:102958.
25. Foxe D, Hu A, Cheung SC, Ahmed RM, Cordato NJ, Devenney E, Hwang YT, **Halliday GM**, Mueller N, Leyton CE, Hodges JR, Burrell JR, Irish M, Piguet O (2022) Utility of the Addenbrooke's Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. Brain Commun. 4:fcac161.
26. Fu Y, He Y, Phan K, Bhatia S, Pickford R, Wu P, Dzamko N, **Halliday GM,** Kim WS (2022) Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain. Acta Neuropathol. Commun. 10:165.
27. Fu Y, He Y, Phan K, Pickford R, Kim YB, Dzamko N, **Halliday GM**, Kim WS (2022) Sex-specific lipid dysregulation in the *Abca7* knockout mouse brain. Brain Commun. 4:fcac120.
28. Fu Y, Zhou L, Li H, Hsiao JT, Li B, Tanglay O, Auwyang AD, Wang E, Feng J, Kim WS, Liu J, **Halliday GM** (2022) Adaptive structural changes in the motor cortex and white matter in Parkinson's disease. Acta Neuropathol. 144:861-879 & correction 2023;145:157.
29. Galper J, Dean NJ, Pickford R, Lewis SJG, **Halliday GM**, Kim WS, Dzamko N (2022) Lipid pathway dysfunction is prevalent in patients with Parkinson's disease. Brain 145:3472-3487.
30. Ge P, Yang M, Bouchard JL, Dzamko N, Lewis SJG, **Halliday GM**, Doran TM (2022) Chemoselective bioconjugation of amyloidogenic protein antigens to PEGylated microspheres enables detection of α-synuclein autoantibodies in human plasma. Bioconjug. Chem. 33:301-310.
31. Hatton C, Ghanem SS, Koss DJ, Abdi IY, Gibbons E, Guerreiro R, Bras J; **International DLB Genetics Consortium**, Walker L, Gelpi E, Heywood W, Outeiro TF, Attems J, McFarland R, Forsyth R, El-Agnaf OM, Erskine D (2022) Prion-like α-synuclein pathology in the brain of infants with Krabbe disease. Brain 145:1257-1263.
32. Hooshmand K, **Halliday GM**, Pineda SS, Sutherland GT, Guennewig B (2022) Overlap between central and peripheral transcriptomes in Parkinson's disease but not Alzheimer's disease. Int. J. Mol. Sci. 23:5200.
33. Hopfner F, Tietz AK, Ruf VC, Ross OA, Koga S, Dickson D, Aguzzi A, Attems J, Beach T, Beller A, Cheshire WP, van Deerlin V, Desplats P, Deuschl G, Duyckaerts C, Ellinghaus D, Evsyukov V, Flanagan ME, Franke A, Frosch MP, Gearing M, Gelpi E, van Gerpen JA, Ghetti B, Glass JD, Grinberg LT, **Halliday G**, Helbig I, Höllerhage M, Huitinga I, Irwin DJ, Keene DC, Kovacs GG, Lee EB, Levin J, Martí MJ, Mackenzie I, McKeith I, Mclean C, Mollenhauer B, Neumann M, Newell KL, Pantelyat A, Pendziwiat M, Peters A, Molina Porcel L, Rabano A, Matěj R, Rajput A, Rajput A, Reimann R, Scott WK, Seeley W, Selvackadunco S, Simuni T, Stadelmann C, Svenningsson P, Thomas A, Trenkwalder C, Troakes C, Trojanowski JQ, Uitti RJ, White CL, Wszolek ZK, Xie T, Ximelis T, Yebenes J; Alzheimer's Disease Genetics Consortium, Müller U, Schellenberg GD, Herms J, Kuhlenbäumer G, Höglinger G (2022) Common variants near ZIC1 and ZIC4 in autopsy-confirmed multiple system atrophy. Mov Disord. 37:2110-2121.
34. Johnson EG, Kuiper W, Ahmed RM, **Halliday GM**, Burrell JR, Hodges JR, Guastella AJ, Piguet O, Kumfor F (2022) Plasma oxytocin is not associated with social cognition or behavior in frontotemporal dementia and Alzheimer's disease syndromes. Dement. Geriatr. Cogn. Disord. 51:241-248.
35. Katzeff JS, Lok HC, Bhatia S, Fu Y, **Halliday GM**, Kim WS (2022) ATP-binding cassette transporter expression is widely dysregulated in frontotemporal dementia with TDP-43 inclusions. Front. Mol. Neurosci. 15:1043127.

36. Katzeff JS, Bright F, Phan K, Kril JJ, Ittner LM, Kassiou M, Hodges JR, Piguet O, Kiernan MC, **Halliday GM**, Kim WS (2022) Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain 145:1598-1609.
37. Koutsouleris N, Pantelis C, Velakoulis D, McGuire P, Dwyer DB, Urquijo-Castro MF, Paul R, Dong S, Popovic D, Oeztuerk O, Kambeitz J, Salokangas RKR, Hietala J, Bertolino A, Brambilla P, Upthegrove R, Wood SJ, Lencer R, Borgwardt S, Maj C, Nöthen M, Degenhardt F, Polyakova M, Mueller K, Villringer A, Danek A, Fassbender K, Fliessbach K, Jahn H, Kornhuber J, Landwehrmeyer B, Anderl-Straub S, Prudlo J, Synofzik M, Wiltfang J, Riedl L, Diehl-Schmid J, Otto M, Meisenzahl E, Falkai P, Schroeter ML; **International FTD-Genetics Consortium (IFGC),** the German Frontotemporal Lobar Degeneration (FTLD) Consortium, and the PRONIA Consortium (2022) Exploring links between psychosis and frontotemporal dementia using multimodal machine learning: dementia praecox revisited. JAMA Psychiatry 79:907-919.
38. Kumfor F, Liang CT, Hazelton JL, Leyton CE, Kaizik C, Devenney E, Connaughton E, Langdon R, Mioshi E, Kwok JB, Dobson-Stone C, **Halliday GM**, Piguet O, Hodges JR, Landin-Romero R (2022) Examining the presence and nature of delusions in Alzheimer's disease and frontotemporal dementia syndromes. Int. J. Geriatr. Psychiatry 37:10.1002/gps.5692.
39. Matar E, Brooks D, Lewis SJG, **Halliday GM** (2022) Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders. Neurobiol. Aging 112:122-128.
40. Matar E, Ehgoetz Martens KA, Phillips JR, Wainstein G, **Halliday GM**, Lewis SJG, Shine JM (2022) Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. NPJ. Parkinsons Dis. 8:16.
41. Mazumder S, Kiernan MC, **Halliday GM**, Timmins HC, Mahoney CJ (2022) The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: a systematic review. Neuropathol Appl Neurobiol. 48:e12845.
42. McCann H, Bahar AY, Burkhardt K, Gardner AJ, **Halliday GM**, Iverson GL, Shepherd CE (2022) Prevalence of chronic traumatic encephalopathy in the Sydney Brain Bank. Brain Commun. 2022;4:fcac189.
43. Narasimhan M, Schwartz R, **Halliday G** (2022) Parkinsonism and cerebrovascular disease. J. Neurol. Sci. 433:120011.
44. Phan K, He Y, Bhatia S, Pickford R, McDonald G, Mazumder S, Timmins HC, Hodges JR, Piguet O, Dzamko N, **Halliday GM**, Kiernan MC, Kim WS (2022) Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis. Brain Commun. 5:fcac340.
45. Phillips JR, Matar E, Ehgoetz Martens KA, Moustafa AA, **Halliday GM**, Lewis SJG (2022) Exploring the sensitivity of prodromal dementia with Lewy bodies research criteria. Brain Sci. 12:1594.
46. Phillips JR, Matar E, Ehgoetz Martens KA, Moustafa AA, **Halliday GM**, Lewis SJG (2022) An adaptive measure of visuospatial impairment in dementia with Lewy bodies. Mov. Disord. Clin. Pract. 9:619-627.
47. Poewe W, Stankovic I, **Halliday G**, Meissner WG, Wenning GK, Pellecchia MT, Seppi K, Palma JA, Kaufmann H (2022) Multiple system atrophy. Nat. Rev. Dis. Primers 2022;8:56.
48. Stevanovski I, Chintalaphani SR, Gamaarachchi H, Ferguson JM, Pineda SS, Scriba CK, Tchan M, Fung V, Ng K, Cortese A, Houlden H, Dobson-Stone C, Fitzpatrick L, **Halliday G**, Ravenscroft G, Davis MR, Laing NG, Fellner A, Kennerson M, Kumar KR, Deveson IW (2022) Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. Sci Adv. 8:eabm5386.
49. Trist BG, Genoud S, Roudeau S, Rookyard A, Abdeen A, Cottam V, Hare DJ, White M, Altvater J, Fifita JA, Hogan A, Grima N, Blair IP, Kysenius K, Crouch PJ, Carmona A, Rufin Y, Claverol S, Van Malderen S, Falkenberg G, Paterson DJ, Smith B, Troakes C, Vance C, Shaw CE, Al-Sarraj S, Cordwell S, **Halliday G**, Ortega R, Double KL (2022) Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain 145:3108-3130.
50. Tse NY, Tu S, Chen Y, Caga J, Dobson-Stone C, Kwok JB, **Halliday GM**, Ahmed RM, Hodges JR, Piguet O, Kiernan MC, Devenney EM (2022) Schizotypal traits across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: pathomechanistic insights. J. Neurol. 269:4241-4252.
51. Weiss F, Labrador-Garrido A, Dzamko N, **Halliday G** (2022) Immune responses in the Parkinson's disease brain. Neurobiol. Dis. 168:105700.
52. Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma JA, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, **Halliday G**, Höglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H (2022) The Movement Disorder Society Criteria for the diagnosis of multiple system atrophy. Mov. Disord. 37:1131-1148.

53. Aarsland D, Batzu L, **Halliday** GM, Geurtsen GJ, Ballard C, Chaudhuri RK, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat. Rev. Primers 7:47; correction 7:53.
54. Ahmed RM, Bocchetta M, Todd EG, Tse NY, Devenney EM, Tu S, Caga J, Hodges JR, **Halliday GM**, Irish M, Kiernan MC, Piguet O, Rohrer JD (2021) Tackling clinical heterogeneity across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum using a transdiagnostic approach. Brain Commun. 3:fcab257.
55. Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, **Halliday G**, Hortobagyi T, Jellinger K, Kovacs GG, Lee EB, Love S, McAleese KE, Nelson PT, Neumann M, Parkkinen L, Polvikoski T, Sikorska B, Smith C, Grinberg LT, Thal DR, Trojanowski JQ, McKeith IG (2021) Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 141:159-172.
56. Bright F, Katzeff JS, Hodges JR, Piguet O, Kril JJ, **Halliday GM**, Kim WS (2021) Glycoprotein pathways altered in frontotemporal dementia with autoimmune disease. Front. Immunol. 12:736260.
57. Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S, Viollet C, Ding J, Makarious MB, Diez-Fairen M, Portley MK, Shah Z, Abramzon Y, Hernandez DG, Blauwendraat C, Stone DJ, Eicher J, Parkkinen L, Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, St George-Hyslop P, Londos E, Morgan K, Lashley T, Warner TT, Jaunmuktane Z, Galasko D, Santana I, Tienari PJ, Myllykangas L, Oinas M, Cairns NJ, Morris JC, **Halliday GM**, Van Deerlin VM, Trojanowski JQ, Grassano M, Calvo A, Mora G, Canosa A, Floris G, Bohannan RC, Brett F, Gan-Or Z, Geiger JT, Moore A, May P, Krüger R, Goldstein DS, Lopez G, Tayebi N, Sidransky E; American Genome Center, Norcliffe-Kaufmann L, Palma JA, Kaufmann H, Shakkottai VG, Perkins M, Newell KL, Gasser T, Schulte C, Landi F, Salvi E, Cusi D, Masliah E, Kim RC, Caraway CA, Monuki ES, Brunetti M, Dawson TM, Rosenthal LS, Albert MS, Pletnikova O, Troncoso JC, Flanagan ME, Mao Q, Bigio EH, Rodríguez-Rodríguez E, Infante J, Lage C, González-Aramburu I, Sanchez-Juan P, Ghetti B, Keith J, Black SE, Masellis M, Rogaeva E, Duyckaerts C, Brice A, Lesage S, Xiromerisiou G, Barrett MJ, Tilley BS, Gentleman S, Logroscino G, Serrano GE, Beach TG, McKeith IG, Thomas AJ, Attems J, Morris CM, Palmer L, Love S, Troakes C, Al-Sarraj S, Hodges AK, Aarsland D, Klein G, Kaiser SM, Woltjer R, Pastor P, Bekris LM, Leverenz JB, Besser LM, Kuzma A, Renton AE, Goate A, Bennett DA, Scherzer CR, Morris HR, Ferrari R, Albani D, Pickering-Brown S, Faber K, Kukull WA, Morenas-Rodriguez E, Lleó A, Fortea J, Alcolea D, Clarimon J, Nalls MA, Ferrucci L, Resnick SM, Tanaka T, Foroud TM, Graff-Radford NR, Wszolek ZK, Ferman T, Boeve BF, Hardy JA, Topol EJ, Torkamani A, Singleton AB, Ryten M, Dickson DW, Chiò A, Ross OA, Gibbs JR, Dalgard CL, Traynor BJ, Scholz SW (2021) Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat. Genet. 53:294-303.
58. de Boer SCM, Riedl L, van der Lee SJ, Otto M, Anderl-Straub S, Landin-Romero R, Sorrentino F, Fieldhouse JLP, Reus LM, Vacaflor B, **Halliday G**, Galimberti D, Diehl-Schmid J, Ducharme S, Piguet O, Pijnenburg YAL (2021) Differences in sex distribution between genetic and sporadic frontotemporal dementia. J. Alzheimers Dis. 84:1153-1161.
59. de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P, van den Bos M, **Halliday GM**, van den Berg LH, Van Den Bosch L, van Damme P, Kiernan MC, van Es MA, Vucic S (2021) TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 92:86-95
60. Devenney EM, McErlean K, Tse NY, Caga J, Dharmadasa T, Huynh W, Mahoney CJ, Zoing M, Mazumder S, Dobson-Stone C, Kwok JB, **Halliday GM**, Hodges JR, Piguet O, Ahmed RM, Kiernan MC (2021) Factors that influence non-motor impairment across the ALS-FTD spectrum: Impact of phenotype, sex, age, onset and disease stage. Front. Neurol. 12:743688.
61. Devenney EM, Tu S, Caga J, Ahmed RM, Ramsey E, Zoing M, Kwok J, **Halliday GM**, Piguet O, Hodges JR, Kiernan Mc (2021) Neural mechanisms of psychosis vulnerability and perceptual abnormalities in ALS-FTD spectrum. Ann. Clin. Transl. Neurol. 8:1576-1591.
62. Drouyer M, Bolliger MF, Lobbestael E, Van den Haute C, Emanuele M, Lefebvre R, Sibran W, De Wit T, Leghay C, Mutez E, Dzamko N, **Halliday GM**, Murayama S, Martoriati A, Cailliau K, Bodart JF, Chartier-Harlin MC, Baekelandt V, Nichols RJ, Taymans JM (2021) Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. Neurobiol. Dis. 157:105426.
63. Ferreira N, Richner M, van der Laan A, Bergholdt Jul Christiansen I, Vægter CB, Nyengaard JR, **Halliday GM**, Weiss J, Giasson BI, Mackenzie IR, Jensen PH, Jan A (2021) Prodromal neuroinvasion of pathological

α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy. Brain Commun. 3:fcab104; correction 2022;4:fcac067 & Brain Commun. 2022;4:fcac067.
64. Forrest SL, Kim JH, De Sousa C, Cheong R, Crockford DR, Sheedy D, Stevens J, McCrossin T, Tan RH, McCann H, Shepherd CE, Rowe DB, Kiernan MC, **Halliday GM**, Kril JJ (2021) Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. Eur. J. Neurol. 28:2192-2199.
65. Forrest SL, Shepherd CE, McCann H, Kwok JB, **Halliday GM**, Kril JJ (2021) Globular glial tauopathy with a mutation in *MAPT* and unusual TDP-43 proteinopathy in a patient with behavioural-variant frontotemporal dementia. Acta Neuropathol. 141:791-794.
66. Gabery S, Kwa JE, Cheong RY, Baldo B, Ferrari Bardile C, Tan B, McLean C, Georgiou-Karistianis N, Poudel GR, **Halliday G**, Pouladi MA, Petersén Å (2021) Early white matter pathology in the fornix of the limbic system in Huntington disease. Acta Neuropathol. 142:791-806.
67. Gabery S, Ahmed RM, Caga J, Kiernan MC, **Halliday GM**, Petersén Å (2021) Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 47:979-989.
68. Gregersen E, Betzer C, Kim WS, Kovacs G, Reimer L, **Halliday GM**, Thiel S, Jensen PH (2021) α-Synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. J. Neuroinflammation 18:177.
69. Guennewig B, Lim J, Marshall L, McCorkindale AN, Paasila PJ, Patrick E, Kril JJ, **Halliday GM**, Cooper AA, Sutherland GT (2021) Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. Sci. Rep. 11:4865; correction 11:17494.
70. He Y, Phan K, Bhatia S, Pickford R, Fu Y, Yang Y, Hodges JR, Piguet O, **Halliday GM**, Kim WS (2021) Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. Sci Rep. 11:21348.
71. Hughes LP, Pereira MMM, Hammond DA, Kwok JB, **Halliday GM**, Lewis SJG, Dzamko N (2021) Glucocerebrosidase activity is reduced in cryopreserved Parkinson's disease patient monocytes and inversely correlates with motor severity. J. Parkinsons Dis. 11:395-404.
72. Huynh B, Fu Y, Kirik D, Shine JM, **Halliday GM** (2021) Comparison of locus coeruleus pathology with nigral and forebrain pathology in Parkinson's disease. Mov. Disord. 36:2085-2093.
73. Huynh K, Piguet O, Kwok J, Dobson-Stone C, **Halliday GM**, Hodges JR, Landin-Romero R (2021) Clinical and biological correlates of white matter hyperintensities in patients with behavioral-variant frontotemporal dementia and Alzheimer disease. Neurology 96:e1743-e1754.
74. Li W, Fu Y, **Halliday GM**, Sue CM (2021) *PARK* genes link mitochondrial dysfunction and α-synuclein pathology in sporadic Parkinson's disease. Front. Cell Dev. Biol. 9:612476.
75. Long Z, Irish M, Hodges JR, **Halliday G**, Piguet O, Burrell JR (2021) Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. Neurobiol. Aging 107:11-20.
76. Matar E, White SR, Taylor JP, Thomas A, McKeith IG, Kane JPM, Surendranathan A, **Halliday GM**, Lewis SJG, O'Brien JT (2021) Progression of clinical features in Lewy body dementia can be detected over 6 months. Neurology 97:e1031-e1040.
77. Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, **Halliday G**, van Hilten AJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodríguez-Violante M, Simuni T, James Surmeier D, Weintraub D, McDermott MP, Lawton M, Marras C (2021) Parkinson's disease subtypes: Critical appraisal and recommendations. J. Parkinsons Dis. 11:395-404.
78. Nabais MF, Laws SM, Lin T, Vallerga CL, Armstrong NJ, Blair IP, Kwok JB, Mather KA, Mellick GD, Sachdev PS, Wallace L, Henders AK, Zwamborn RAJ, Hop PJ, Lunnon K, Pishva E, Roubroeks JAY, Soininen H, Tsolaki M, Mecocci P, Lovestone S, Kłoszewska I, Vellas B; Australian Imaging Biomarkers and Lifestyle study; Alzheimer's Disease Neuroimaging Initiative, Furlong S, Garton FC, Henderson RD, Mathers S, McCombe PA, Needham M, Ngo ST, Nicholson G, Pamphlett R, Rowe DB, Steyn FJ, Williams KL, Anderson TJ, Bentley SR, Dalrymple-Alford J, Fowder J, Gratten J, **Halliday G**, Hickie IB, Kennedy M, Lewis SJG, Montgomery GW, Pearson J, Pitcher TL, Silburn P, Zhang F, Visscher PM, Yang J, Stevenson AJ, Hillary RF, Marioni RE, Harris SE, Deary IJ, Jones AR, Shatunov A, Iacoangeli A, van Rheenen W, van den Berg LH, Shaw PJ, Shaw CE, Morrison KE, Al-Chalabi A, Veldink JH, Hannon E, Mill J, Wray NR, McRae AF (2021) Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biol. 22:90.

79. Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, **Halliday GM**, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF (2021) α-Synuclein research: defining strategic moves in the battle against Parkinson's disease. N.P.J. Parkinsons Dis. 7:65.
80. Phan K, He Y, Fu Y, Dzamko N, Bhatia S, Gold J, Rowe D, Ke YD, Ittner LM, Hodges JR, Piguet O, Kiernan MC, **Halliday GM**, Kim WS (2021) Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Commun. Med. (Lond.) 1:60.
81. Reus LM, Pasaniuc B, Posthuma D, Boltz T; **International FTD-Genomics Consortium**, Pijnenburg YAL, Ophoff RA (2021) Gene expression imputation across multiple tissue types provides insight into the genetic architecture of frontotemporal dementia and its clinical subtypes. Biol. Psychiatry. 89:825-835.
82. Roudeau S, Trist BG, Carmona A, Davies KM, **Halliday GM**, Rufin Y, Claverol S, Van Malderen SJM, Falkenberg G, Double KL, Ortega R (2021) Native separation and metalation analysis of SOD1 protein from the human central nervous system: a methodological workflow. Ann. Chem. 93:11108-11115.
83. Weissleder C, North HF, Bitar M, Fullerton JM, Sager R, Barry G, Piper M, **Halliday GM**, Webster MJ, Shannon Weickert C (2021) Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia. Mol. Psychiatry 26:6800-6895.
84. Youssef P, Kim WS, **Halliday GM**, Lewis SJG, Dzamko N (2021) Comparison of different platform immunoassays for the measurement of plasma α-synuclein in Parkinson's disease patients. J. Parkinsons Dis. 11:1761-1772.
85. Affleck AJ, Sachdev PS, Stevens J, **Halliday GM** (2020) Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. Alzheimers Dement. (NY) 6:e12060.
86. Amadoru S, Dore V, McLean C, Hinton F, Shepherd C, **Halliday G**, Leyton C, Yates PA, Hodges J, Masters CL, Villemagne VL, Rowe C (2020) Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. Alzheimer Dement. Alzheimers Res. Ther. 12:22.
87. Australian Brain Alliance (2020) A neuroethics framework for the Australian Brain Initiative. [published correction appears in Neuron. 2020 Jan 8;105(1):201]. Neuron. 2019;101(3):365-369
88. Chen Z, Yan Yau W, Jaunmuktane Z, Tucci A, Sivakumar P, Gagliano Taliun SA, Turner C, Efthymiou S, Ibáñez K, Sullivan R, Bibi F, Athanasiou-Fragkouli A, Bourinaris T, Zhang D, Revesz T, Lashley T, DeTure M, Dickson DW, Josephs KA, Gelpi E, Kovacs GG, **Halliday G**, Rowe DB, Blair I, Tienari PJ, Suomalainen A, Fox NC, Wood NW, Lees AJ, Haltia MJ; Genomics England Research Consortium, Hardy J, Ryten M, Vandrovcova J, Houlden H (2020) Neuronal intranuclear inclusion disease is genetically heterogeneous. Ann Clin Transl Neurol. 7:1716-1725.
89. Dobson-Stone C, Hallup M, Shahheydari H, Ragagnin AMG, Chatterton Z, Carew-Jones F, Shepherd C, Stefen H, Paric E, Fath T, Thompson EM, Blumbergs P, Short CL, Field CD, Panegyres P, Hecker J, Nicholson G, Shaw AD, Fullerton JM, Luty AA, Schofield PR, Brooks WS, Rajan N, Bennett MF, Bahlo M, Landers JE, Piguet O, Hodges JR, **Halliday GM**, Topp S, Smith BN, Shaw C, McCann E, Fifita JA, Williams KL, Atkin JD, Blair IP, Kwok JBJ (2020) *CYLD* is a causative gene for frontotemporal dementia – amyotrophic lateral sclerosis. Brain 143:783-799.
90. Ehgoetz Martens KA, Matar E, Hall JM, Phillips JR, Georgiades MJ, Grunstein RR, **Halliday GM**, Lewis SJG (2020) The neural signature of impaired dual tasking in idiopathic REM sleep behaviour disorder patients. Mov. Disord. 35:1596-1606.
91. Ehgoetz Martens KA, Matar E, Hall JM, Phillips J, Szeto JYY, Gouelle A, Grunstein RR, **Halliday GM**, Lewis SJG (2020) Invited Reply to: "Instrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder". Mov. Disord. 35:195-196.
92. Forrest SL, **Halliday GM**, Shepherd CE, Kwok JB, Hallup M, Kril JJ (2020) Are mutation in *MAPT* associated with GGT type III? Neuropathol. Appl. Neurobiol. 46:406-409.
93. Forrest SL, **Halliday GM**, Sizemova A, van Roijen M, McGinley CV, Bright F, Kapur M, McGeachie AB, McCann H, Shepherd CE, Tan RH, Affleck AJ, Huang Y, Kril JJ (2020) A practical approach to differentiate the frontotemporal tauopathy subtypes. J. Neuropathol. Exp. Neurol. 79:1122-1126.
94. Gao Y, Wang T, Yu X; **International FTD-Genomics Consortium (IFGC),** Zhao H, Zeng P (2020) Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Sci. Rep. 10:12184.
95. Gokool A, Loy CT, **Halliday GM**, Voineagu I (2020) Circular RNAs: The brain transcriptome comes full circle. Trends Neurosci. 43:752-766.

96. **Halliday G** (2020) Neglected cytotoxic T cell invasion of the brain: how specific for Parkinson's disease? Brain 143:3518-3521.
97. Hughes LP, **Halliday GM**, Dzamko N (2020) Flow cytometry measure of glucocerebrosidase activity in human monocytes. Bio-Protocols 10:e3572.
98. Katzeff JS, Bright F, Lo K, Kril JJ, Connolly A, Crossett B, Ittner LM, Kassiou M, Loy CT, Hodges JR, Piguet O, Kiernan MC, **Halliday GM**, Kim WS (2020) Altered serum proteins in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Sci. Rep. 10:13741
99. Kwok JB, Loy CT, Dobson-Stone C, **Halliday GM** (2020) The complex relationship between genotype, pathology and phenotype in familial dementia. Neurobiol Dis. 45:105082
100. Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Day-Williams AG, Stone DJ, Singleton AB, Nalls MA, Gan-Or Z; **International Parkinson's Disease Genomic Consortium (IPDGC)** (2020) Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. J. Med. Genet. 57:331-338.
101. Ling H, Gelpi E, Davey K, Jaunmuktane Z, Mok KY, Simone R, Bibo LR, Brandner S, Attems J, Mann D, **Halliday G**, Al-Sarraj S, Hedreen J, Ironside J, Kovacs GG, Kovari E, Love S, Vonsattel JPG, Xuereb J, Jabbari E, Bradshaw T, Seto-Salvia N, Wray S, de Silva R, Morris HR, Warner TT, Hardy J, Holton JL, Revesz T (2020) Fulminant corticobasal degeneration: A distinct aggressive clinicopathological variant features predominant neuronal tau lesion. Acta Neuropathol. 139:717-734.
102. Matar E, Ehgoetz Martens KA, **Halliday GM**, Lewis SJG (2020) Clinical features of Lewy body dementia: Insights into diagnosis and pathophysiology. J. Neurol. 267:380-389.
103. Matar E, Shine JM, **Halliday GM**, Lewis SJG (2020) Cognitive fluctuations in Lewy body dementia: Towards a pathophysiological framework. Brain 143:31-46.
104. McCann EP, Fifita JA, Grima N, Galper J, Mehta P, Freckleton S, Zhang KY, Henden L, Hogan A, Chan Moi Fat S, Wu SS, Jagaraj CJ, Berning BA, Williams KL, Twine N, Bauer D, Piguet O, Hodges J, Kwok JBJ, **Halliday GM**, Kiernan MC, Atkin J, Rowe DB, Nicholson GA, Walker AK, Blair IP, Yang S (2020) Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. J. Neurol. Neurosurg. Psychiatry. 91:162-171.
105. Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van Deerlin VM, Warren JD, Fox NC, Rossor MN, Mead S, Bocchetta M, Boeve BF, Knopman DS, Graff-Radford NR, Forsberg LK, Rademakers R, Wszolek ZK, van Swieten JC, Jiskoot LC, Meeter LH, Dopper EGP, Papma JM, Snowden JS, Saxon J, Jones M, Pickering Brown S, Le Ber I, Camuzat A, Brice A, Caroppo P, Ghidoni R, Pievani M, Benussi L, Binetti G, Dickerson BC, Lucente D, Krivensky S, Graff C, Öijerstedt L, Fallström M, Thonberg H, Ghoshal N, Morris JC, Borroni B, Benussi A, Padovani A, Galimberti D, Scarpini E, Fumagalli GG, Mackenzie IR, Hsiung R, Sengdy P, Boxer AL, Rosen H, Taylor JB, Synofzik M, Wilke C, Sulzer P, Hodges JR, **Halliday G**, Kwok J, Sanchez-Valle R, Lladó A, Borrego-Ecija S, Santana I, Rosário Almeida M, Tábuas-Pereira M, Moreno F, Barandiaran M, Indakoetxea B, Levin J, Danek A, Rowe JB, Cope TE, Otto M, Anderl-Straub S, de Mendonça A, Maruta C, Masellis M, Black SE, Couratier P, Lautrette G, Huey ED, Sorbi S, Nacmias B, Laforce Jr R, Tremblay M-PL, Vandenberghe R, Van Damme P, Rogalski EJ, Weintraub S, Gerhard A, Onyike CU, Ducharme S, Papageorgiou SG, Su Lyn Ng A, Brodtmann A, Finger E, Guerreiro R, Bras J, FTD Prevention Initiative*, Rohrer JD (2020) Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 19:145-156.
106. Newman M, Nik HM, Sutherland GT, Hin N, Kim WS, **Halliday GM**, Jayadev S, Smith C, Laird AS, Lucas CW, Kittipassorn T, Peet DJ, Lardelli M (2020) Accelerated loss of hypoxia response in zebrafish with familial Alzheimer's disease-like mutation in presenilin-1. Hum. Mol. Genet. 29:2379-2394
107. Orme T, Hernandez D, Ross OA, Kun-Rodrigues C, Darwent L, Shepherd C, Parkkinen L, , Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St. George-Hyslop P, Londos E, Zetterberg H, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns N, Morris JC, Pickering-Brown S, Mann D, **Halliday GM**, Stone DJ, Dickson DW, Hardy J, Singleton A, Guerreiro R, Bras J (2020) Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathol. Comm. 8:5.

108. Pellecchia MT, Stankovic I, Fanciulli A, Krismer F, Meissner WG, Palma JA, Panicker JN, Seppi K, Wenning GK; **Members of the Movement Disorder Society Multiple System Atrophy Study Group** (2020) Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. Mov Disord Clin Pract 7:750-762.
109. Phan K, He Y, Pickford R, Bhatia S, Katzeff JS, Hodges JR, Piguet O, **Halliday GM**, Kim WS (2020) Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Sci. Rep. 10:3640.
110. Phillips JR, Matar E, Ehgoetz Martens KA, **Halliday GM**, Moustafa AA, Lewis SJG (2020) Evaluating the sustained attention response task to quantify cognitive fluctuations in dementia with Lewy bodies. J. Geriatr. Psychiatry Neurol. 33:333-339.
111. Piras IS, Bleul C, Talboom JS, De Booth MD, Schrauwen I, **Halliday G**, Myers AJ, Serrano GE, Beach TG, Huentelman MJ (2020) ESHRD: Deconvolution of brain homogenate RNA expression data to identify cell-type specific alterations in Alzheimer's disease. Aging 12: 4124-4162.
112. Piras IS, Bleul C, Schrauwen I, Talboom JS, Llaci L, De Booth MD, Naymik M, **Halliday G**, Bettencourt C, Holton J, Serrano GE, Sue L, Beach TG, Stefanova N, Huentelman MJ (2020) Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. Acta Neuropathol. Comm. 8:76.
113. Raupach AK, Ehgoetz Martens KA, Memarian N, Zhong G, Matar E, **Halliday G**, Grunstein R, Lewis SJG (2020) Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. J. Sleep Res. 29:e12939
114. Shepherd CE, Affleck AJ, Bahar AY, Carew-Jones F, **Halliday GM** (2020) Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both Aβ and tau pathology. Neurobiol. Aging 89:129-131
115. Shepherd CE, Bahar A, Affleck A, Carew-Jones F, Gregory G, Small DH, **Halliday GM** (2020) Alzheimer's amyloid-β and tau protein accumulation is associated with decreased expression of the LDL receptor associated protein in human brain tissue. Brain Behav. 10:e01672
116. Szeto JYY, Walton CC, Rizos A, Martinez-Martin P, **Halliday GM**, Naismith SL, Chaudhuri KR, Lewis SJG (2020) Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. NPJ Parkinson's Disease 6:2.
117. Tan RH, **Halliday GM** (2020) Author response: The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. Neurology 94:283.
118. Vallerga CL, Zhang F, Fowdar J, McRae AF, Qi T, Nabais M, Zhang Q, Kassam I, Henders AK, Wallace L, Montgomery GW, Chung Y-H, Horvath S, Ritz B, **Halliday G**, Hickie I, Kwok JB, Pearson J, Pitcher T, Kennedy M, Bentley S, Silburn PA, Yang J, Wray NR, Lewis S, Anderson T, Dalrymple-Alford J, Mellick GD, Visscher PM, Grattan J (2020) Analysis of DNA methylation associates the cystine-glutamate antiporter *SLC7A11* with risk of Parkinson's disease. Nature Comm. 11:1238.
119. van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); **IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium);** RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer's Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der

Flier WM, Holstege H (2020) A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity [published correction appears in Acta Neuropathol. 2020 Jan 18;:]. Acta Neuropathol. 2019;138:237-25

120. Zhao Y, Keshiya S, Perera G, Schramko L, **Halliday GM**, Dzamko N (2020) LRRK2 kinase inhibitors reduce α-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiol Dis. 144:105049.
121. Ahmadi Rastegar D, Ho N, **Halliday GM**, Dzamko N (2019) Prediction of Parkinson's disease progression with machine learning and cytokines. NPJ Parkinsons Dis. 5:14.
122. Ahmed RM, Phan K, Highton-Williamson E, Stickweda-Brown C, Caga J, Ramsey E, Zoing M, Devebbey E, Kim W, Hodges JR, Piguet O, **Halliday G**, Kiernan MC (2019) Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Ann. Clin.Transl. Neurol. 6:486-95.
123. Agarwal S, Ahmed RM, D'Mello M, Foxe D, Kaizik C, Kiernan MC, **Halliday GM**, Piguet O, Hodges JR (2019) Predictors of survival and progression in behavioural variant frontotemporal dementia. Eur. J. Neurol. 26:774-9.
124. Aoyagi A, Condello C, Stöhr J, Lee JC, Rivera BM, Woerman AL, **Halliday G**, van Duinen S, Ingelsson M, Lannfelt L, Graff C, Bird TD, Keene CD, Seeley WW, DeGrado WF, Prusiner SB (2019) Aβ and tau prion-like activities decline with longevity in Alzheimer's disease human brain. Sci. Transl. Med. 11:eaat8462.
125. Atashrazm F, Hammond D, Perera G, Bolliger MF, Mater E, **Halliday GM**, Schule B, Lewis SJG, Nickols RJ, Dzamko N (2019) LRRK2-mediated RAB10 phosphorylation in immune cells from Parkinson's disease patients. Mov. Disord. 34:406-415.
126. Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henninsen JB, Englund E, McLean C, Kirik D, **Halliday G**, Petersen A (2019) SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington's disease. Neuropath. Appl. Neurobiol. 45:361-379.
127. Bhatia S, Kim WS, Shepherd CE, **Halliday G** (2019) Apolipoprotein D upregulation in Alzheimer's disease but not frontotemporal dementia. J. Mol. Neurosci. 67:125-132.
128. Bonham LW, Steele NZR, Karch CM, Broce I, Geier EG, Wen NL, Momeni P, Hardy J, Miller ZA, Gorno-Tempini ML, Hess CP, Lewis P, Miller BL, Seeley WW, Manzoni C, Desikan RS, Baranzini SE, Ferrari R, Yokoyama JS; **International FTD-Genomics Consortium (IFGC)** (2019) Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Sci. Rep. 9:10854.
129. Breen DP, **Halliday GM**, Lang AE (2019) Gut-brain axis and the spread of α-synuclein pathology: vagal highway or dead end? Mov. Disord. 34:307-316.
130. Bright F, Werry E, Dobson-Stone C, Kassiou M, Piguet O, Ittner L, **Halliday G**, Hodges J, Kiernan M, Kril J (2019) Neuroinflammation in frontotemporal dementia. Nature Rev. Neurol. 15:540-555.
131. Buckland ME, Sy J, Szentmariay I, Kullen A, Lee M, Harding T, **Halliday G**, Suter CM (2019) Chronic traumatic encephalopathy in two former Australian National Rugby League players. Letter. Acta Neuropathol. Comm. 7:97.
132. Crook A, McEwen A, Fifita J, Zhang K, Kwok J, **Halliday G**, Blair I, Rowe D (2019) The C9orf72 hexanucleotide repeat expansion presents a challenge for genetic counselling. Amyotroph. Lateral Scler. Frontotemporal Degener. 20:310-316.
133. Ehgoetz Martens KA, Matar E, Shine JM, Hall JM, Phillips J, Szeto JYY, Grunstein RR, **Halliday GM**, Lewis SJG (2019) Subtle gait and balance impairments occur in idiopathic REM sleep behaviour disorder. Mov. Disord. 34:1374-1380.
134. Forrest SL, Crockford DR, Sizemova A, McCann H, Shepherd CE, McGeachie AB, Affleck AJ, Carew-Jones F, Bartley L, Kwok JB, Kim WS, Jary E, Tan RH, McGinley CV, Piguet O, Hodges JR, Kril JJ, **Halliday GM** (2019) Co-existing Lewy body disease and clinical parkinsonism in frontotemporal dementia. Neurology 92:e2472-e2482.
135. Forrest SL, **Halliday GM**, McCann H, McGeachie AB, McGinley CV, Hodges JR, Piguet O, Kwok JB, Spillantini MG, Kril JJ (2019) Heritability in non-Alzheimer's disease tauopathies. Alzheimer Dement. (Amst.) 11:115-124.
136. Forrest SL, Kril JJ, **Halliday GM** (2019) Cellular and regional vulnerability in frontotemporal tauopathies. Acta Neuropathol. 138:705-727.

137. Götz J, **Halliday G**, Nisbet R (2019) Molecular pathogenesis of the tauopathies. Annu. Rev. Pathol. 14:239-261.
138. Gao J, Perera G, Bhadebade M, **Halliday GM**, Dzamko N (2019) Autophagy activation promotes clearance of α-synuclein inclusions in fibril-seeded human neural cells. J. Biol. Chem. 294:14241-14256.
139. Guerreiro R, Escott-Price V, Hernandez D, Kun-Rodrigues C, Ross OA, Neto J, Orme T, Carmona S, Dehghani N, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz S, Troncoso JC, Pletnikova O, Daxson T, Rosenthal L, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St. George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Graff-Radford N, Cairns N, Morris JC, Pickering-Brown S, Mann D, **Halliday GM**, Hardy J, Trojanowski JQ, Dickson DW, Singleton A, Interational Parkinson's Disease Genoimcs Consortium, Stone DJ, Bras J (2019) Heritability and genetic variance of dementia with Lewy bodies. Neurobiol. Dis. 127:492-501.
140. Hardwick SA, Bassett SD, Kaczorowski D, Blackburn J, Barton K, Bartonicek N, Carswell SL, Tilgner HU, Loy C, **Halliday G**, Mercer TR, Smith MA, Mattick JS (2019) Targeted, long-read RNA sequencing of non-coding genomic regions associated with neurological functions. Front. Genet. 10:309.
141. Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, **MDS Task Force on the Definition of Parkinson's Disease** (2019) Update of the MDS research criteria for Parkinson's disease. Mov. Disord. 34(10):1464-1470.
142. Hsiao JHT, Purushothuman S, **Halliday GM**, Kim WS (2019) Reductions in COQ2 expression relate to reduced ATP levels in multiple system atrophy brain. Frontiers Neurosci. 13:1187.
143. Katzeff JS, Phan K, Purushothuman S, **Halliday GM**, Kim WS (2019) Cross-examining candidate genes implicated in multiple system atrophy. Acta Neuropathol. Comm. 7:117.
144. Ke Y, Chan G, Stefanoska K, Au C, Bi M, Müller J, Przybyla M, Feiten A, Prikas E, **Halliday GM**, Piguet O, Kiernan MC, Kassiou M, Hodegs JR, Loy CT, Mattick JS, Ittner A, Kril JJ, Sutherland G, Ittner LM (2019) CNS cell-type specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. J. Biol. Chem. 294:14149-14162.
145. Kun-Rodrigues C, Orme T, Carmona S, Hernandez D, Ross OA, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz S, Troncoso JC, Pletnikova O, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St. George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns N, Morris JC, Pickering-Brown S, Mann D, **Halliday GM**, Hardy J, Trojanowski JQ, Dickson DW, Singleton A, Stone DJ, Guerreiro R, Bras J (2019) A comprehensive screening of copy-number variability in dementia with Lewy bodies. Neurobiol. Aging 75:223.e1-223.e10.
146. Leak RK, Frosch MP, Beach TG, **Halliday GM** (2019) α-Synuclein: Prion or Prion-like? Acta Neuropathol. 138:509-514
147. Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu YH, Kim D-K, Jung BC, Choi M, Oh KW, Li Y, Nakatani M, Nakazato T, Sekimoto S, Funayama M, Yoshino H, Kubo S, Nisjioka K, Sakai R, Ueyama M, Mochizuki H, Lee H-J, Sardi SP, **Halliday GM,** Nagai Y, Lee PH, Hattori N, Lee S-J (2019) Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Brain 142:2845-2859.
148. Matar E, Phillips J, Ehgoetz Martens KA, **Halliday GM** Lewis SJG (2019) Impaired colour discrimination - a specific marker of hallucinations in Lewy body disorders. J. Geriat. Psychiatr. Neurol. 32:257-264.
149. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol JC, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB; 23andMe Research Team; **System Genomics of Parkinson's Disease Consortium**; International Parkinson's Disease Genomics Consortium (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18:1091-1102.

150. Nelson PT, Dickson DW, Trojanoxski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, **Halliday G**, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GC, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White CL, Yu L, Schneider JA (2019) Limbic - predominant Age-related TDP-43 Encephalopahty (LATE): Concensus Working Group Report. Brain 142:1503-1527.
151. Nelson PT, Dickson DW, Trojanoxski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, **Halliday G**, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GC, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White CL, Yu L, Schneider JA (2019) Reply: LATE to the PART-y. Letter. Brain 142:e48.
152. Olanow CW, Savolainen M, Chu Y, **Halliday GM**, Kordower JH (2019) Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease. Brain 142:1690-1700.
153. Pires G, McElligott S, Drusinsky S, **Halliday G**, Potier M-C, Wisniewski T, Drummond E (2019) Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies. Acta Neuropathol. Commun. 7:195.
154. Pottier C, Ren Y, Perkerson RB, Baker M, Jenkins GD, van Blitterswijk M, DeJesus-Hemandez M, van Rooij JGJ, Murray ME, Christopher E, McDonnell SK, Fogarty Z, Batzler A, Tian S, Vicente C, Matchett B, Karydas AM, Hsiung G-YR, Seelaar H, Mol MO, Finger EC, Graff C, Oijerstedt L, Neurmann M, Heutink P, Synofzik M, Wilke C, Prudlo J, Rizzu P, Simon-Sanchez J, Edbauer D, Roeber S, Diehl-Schmid J, Evers BM, King A, Mesulam M-M, Weintraub S, Geula C, Bieniek KF, Petrucelli L, Ahern GL, Reiman EM, Woodruff BK, Caselli RJ, Huey ED, Farlow MR, Grafman J, Mead S, Grinberg LT, Spina S, Grossman M, Irwin DJ, Lee EB, Suh ER, Snowden J, Mann D, Ertekin-Taner N, Uitti RJ, Wszolek ZK, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Hodges JR, Piguet O, Geier EG, Yokoyama JS, Rissman RA, Rogaeva E, Keith J, Zinman L, Tartaglia MC, Cairns NJ, Cruchaga C, Ghetti Bm Kofler J, Lopez OL, Beach TG, Arzberger T, Herms J, Honig LS, Vonsattel JP, **Halliday GM**, Kwok JB, White CL, Gearing M, Glass J, Rollinson S, Pickering-Brown S, Rohrer JD, Trojanowski JQ, Van Deerlin V, Biglio EH, Troakes C, Al-Sarraj S, Asmann Y, Miller BL, Graff-Radford NR, Boeve BF, Seeley WW, Mackenzie IRA, van Swieten JC, Dickson DW, Biernacka JM, Rademakers R (2019) Genome-wide analyses as part of the International FTLD-TDP whole genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 137:879-899.
155. Reynolds RH, Botía J, Nalls MA, **International Parkinson's Disease Genomics Consortium (IPDGC)**, System Genomics of Parkinson's Disease (SGPD), Hardy J, Gagliano Taliun SA, Ryten M (2019) Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability. NPJ Parkinsons Dis. 5:6.
156. Shehadeh J, Double KL, Murphy K, Bobrovskaya L, Reyes S, Haycock JW, Dunkley PR, **Halliday GM**, Dickson PW (2019) Expression of tyrosine hydroylase isoforms and phosphorylation at Ser^{40} in the human nigrostriatal system in Parkinson's disease. Neurobiol. Dis. 130:104524.
157. Shepherd C, Alvendia H, **Halliday GM** (2019) Brain banking for research into neurodegenerative disorders and ageing. Neurosci. Bull. 35:283-288.
158. Shepherd C, McGeachie A, Affleck A, **Halliday G** (2019) Condensing the Aβ protocol to reduce the effort and cost of NIA-AA guidelines for neuropathologic assessment of Alzheimer's disease. Letter. J Neuropathol. Exp. Neurol. 78:975-977.
159. Stankovic I, Quinn N, Vignatelli L, Antonini A, Coon E, Cortelli P, Fanciulli A, Ferreira J, Fowler C, Freeman R, **Halliday G**, Höglinger G, Iodice V, Kaufmann H, Klockgether T, Kostic V, Krismer F, Levin J, Low P, Mathias C, Meissner W, Norcliffe Kaufmann L, Palma J-A, Panicker J, Sakakibara R, Schmahmann J, Scholz SW, Singer W, Stamelou M, Tolosa E, Tsuji S, Seppi K, Poewe W, Wenning GK, Movement Disorder Society MSA Study Group (2019) A critique of the second consensus criteria for multiple system atrophy. Mov. Disord. 34:975-984.
160. Shine JM, Bell PT, Matar E, Poldrack RA, Lewis SJG, **Halliday GM**, O'Callahagan C (2019) Dopamine depletion alters macroscopic network dynamics in Parkinson's disease. Brain 142:1024-1034.
161. Stevens CH, Guthrie NJ, **Halliday GM**, Ooi L (2019) Increased tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol. 78:605-614.

162. Strohäker T, Jung BC, Liou S-H, Fernandez CO, Riedel D, Becker S, **Halliday GM**, Bennati M, Kim WS, Lee S-J, Zweckstetter M (2019) Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nature Comm. 10:5535.
163. Swarup V, Hinz FI, Rexach JE, Noguchi K, Toyoshiba H, Oda A, Hirai K, Sarar A, Seyfried NT, Cheng C, Haggarty SJ, **International Frontotemporal Genomics Consortium**, Grossman M, Van Deerlin VM, Trojanowski JQ, Lah JJ, Levey AI, Kondou S, Geschwind DH (2019) Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Med. 25:152-164.
164. Tan RH, Guennewig B, Dobson-Stone C, Kwok JBJ, Kril JJ, Kiernan MC, Hodges JR, Piguet O, **Halliday GM** (2019) The under-acknowledged PPA-ALS – a unique clinicopathological subtype with strong heritability. Neurology 92:e1354-e1366.
165. Tan R, Yang Y, McCain H, Shepherd C, **Halliday G** (2019) Von Economo neurons in behavioural-variant frontotemporal dementia with underlying Alzheimer's disease. J. Alzheimer Dis. 69:963-967.
166. Virachit S, Mathews KJ, Cottam V, Werry E, Galli E, Rappou E, Lindholm P, Saarma M, **Halliday GM**, Shannon-Weickert C, Double KL (2019) Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. Brain Pathol. 29:813-825
167. Werry EL, Bright FM, Piguet O, Ittner LM, **Halliday GM**, Hodges JR, Kiernan MC, Loy CT, Kril JJ, Kassiou M (2019) Recent developments in the use of TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int. J. Mol. Sci. 20:pii-E3161.
168. Woerman AL, Oehler A, Kazmi SA, Lee J, **Halliday GM**, Middleton LT, Gentleman SM, Mordes DA, Spina S, Grinberg LT, Olson SH, Prusiner SB (2019) Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(*SNCA*^{A53T}) mouse lines. Acta Neuropathol. 137:437-454.
169. Yang Y, **Halliday GM**, Kiernan MC, Tan RH (2019) TDP-43 levels in the brain tissue of ALS cases with and without *C9ORF72* or *ATXN2* expansion. Ann. Neurol. 93:e1748-e1755.
170. Zhang Q, Vallerga CL, Walker RM, Lin T, Henders AK, Montgomery GW, He J, Fan D, Fowdar J, Kennedy M, Pitcher T, Pearson J, **Halliday G**, Kwok JB, Hickie I, Lewis S, Anderson T, Silburn PA, Mellick GD, Harris SE, Redmond P, Murray AD, Porteous DJ, Haley CS, Evans KL, McIntosh AM, Yang J, Grattan J, Marioni RE, Wray NR, Deary IJ, McRae AF, Visscher PM (2019) Improved prediction of epigenetic clock estimates across tissues and its implications for biological ageing. Genome Med. 11:54.
171. Ahmed R, Highton-Williamson E, Caga J, Ramsey E, Zoing M, Kim WS, **Halliday GM**, Piguet O, Hodges JR, Farooqi SI, Kiernan MC (2018) Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behaviour and cognition. J. Alzheimer Dis. 61:773-783.
172. Ahmed RM, Ke YD, Vucic S, Ittner LM, Seeley W, Hodges JR, Piguet O, **Halliday G**, Kiernan MC (2018) Physiological changes in neurodegeneration – mechanistic insights. Nature Rev. Neurol. 14:259-271.
173. Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, Kim WS, Kwok JB, Lewis SJG, **Halliday GM**, Dzamko N (2018) Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. Sci. Rep. 8:15446.
174. Baldo B, Sajjad MU, Cheong RY, Bigarreau J, Vijayvargia R, McLean C, Perrier AL, Seong IS, **Halliday G**, Petersen A, Kirik D (2018) Quantification of total and mutant huntingtin protein levels in biospecimens using a novel alphaLISA assay. eNeuro 5(4). pii: ENEURO.0234-18.2018.
175. Berg D, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, **Halliday G**, Joseph L, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schaffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB (2018) MDS clinical criteria for clinically established early Parkinson's disease. Mov. Disord. 33:1643-1646.
176. Betzer C, Lassen LB, Olsen A, Kofoed RH, Reimer L, Gregersen E, Zheng J, Cali T, Gai WP, Chen T, Moeller A, Brini M, Fu Y, **Halliday G**, Brudek T, Aznat S, Pakkenberg B, Andersen JP, Jensen PH (2018) α-Synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep. 19:e44617.
177. Bonham LW, Karch CM, Fan CC, Tan C, Geier EG, Wang Y, Wen N, Broce IJ, Li Y, Barkovich MJ, Ferrari R, Hardy J, Momeni P, Höglinger G, Müller U, Hess CP, Sugrue LP, Dillon WP, Schellenberg GD, Miller BL, Andreassen OA, Dale AM, Barkovich AJ, Yokoyama JS, Desikan RS; International FTD-Genomics Consortium (IFGC); International Parkinson's Disease Genetics Consortium (IPDGC); International Genomics of Alzheimer's Project (IGAP) (2018) CXCR4 involvement in neurodegenerative diseases. Transl. Psychiatry. 8:73.

178. Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, Kouri N, Ross OA, Höglinger GU, Muller U, Hardy J; **International FTD-Genomics Consortium**, Momeni P, Hess CP, Dillon WP, Miller ZA, Bonham LW, Rabinovici GD, Rosen HJ, Schellenberg GD, Franke A, Karlsen TH, Veldink JH, Ferrari R, Yokoyama JS, Miller BL, Andreassen OA, Dale AM, Desikan RS, Sugrue LP (2018) Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med. 15:e1002487.
179. Burrell JR, Ballard KJ, Bartley L, **Halliday GM**, Hodges JR (2018) Aphasia in progressive supranuclear palsy: as severe as progressive non-fluent aphasia. J. Alzheimers Dis. 61:705-715.
180. Devenney E, Ahmed R, **Halliday G,** Piguet O, Kiernan MC, Hodges JR (2018) Psychiatric disorders in *C9orf72* kindreds: study of 1,414 family members. Neurology 91:e1498-e1507.
181. Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, Huang Y, McGinley CV, Werka H, Kiernan MC, Götz J, Spillantini MG, Hodges JR, Ittner LM, **Halliday GM** (2018) Retiring the term FTDP-17 as *MAPT* mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 141:521-534.
182. Forrest SL, Kril JJ, **Halliday GM** (2018) Reply: Will FTLD-tau work for all when FTDP-17 retires? Brain 141:1-2.
183. Foxe D, Elan E, Burrell JR, Leslie FVC, Devenney E, Kwok JBJ, **Halliday GM**, Hodges JR, Piguet O (2018) Intrafamilial phenotype variability in the *C9orf72* gene expansion: 2 cases. Front Psychol. 9:1615.
184. Guerreiro R, Ross OA, Kun-Rodrigues C, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Scholz S, Ansorge O, Clark L, Honig LS, Marder K, Clarimon J, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St. George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns N, Morris JC, Stone D, Pickering-Brown S, Mann D, **Halliday GM**, Singleton A, Trojanowski JQ, Hardy J, Dickson DW, Bras J (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 17:64-74.
185. Guerreiro R, Orme T, Neto J, Bras J, **International DLB Genetics Consortium** (2018) *LRP10* in α-synucleinopathies. Lancet Neurol. 17:1032-1033.
186. Kim WS, He Y, Phan K, Ahmed RM, Rye K-A, Piguet O, Hodges J, **Halliday GM** (2018) Altered high density lipoprotein composition in behavioral variant frontotemporal dementia. Frontiers Neurosci. 12:847.
187. Kim WS, Jary E, Pickford R, He Y, Ahmed RM, Piguet O, Hodges J, **Halliday GM** (2018) Lipidomics analysis of behavioural variant frontotemporal dementia: a scope for biomarker development. Frontiers Neurol. 9:104.
188. Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, **Halliday G**, Goetz CG, Chan P, Slow E, Schaffer E, Rios-Romenets S, Maetzler C, Bledsoe IO, Berg D (2018) Validation of the MDS clinical diagnositc criteria for Parkinson's disease. Mov. Disord. 33:1601-1608.
189. Pottier C, Zhou X, Perkersen RB, Baker M, Jenkins GD, Serie DJ, Ghidoni R, Benussi L, Binetti G, Lopez de Munain A, Zulaica M, La Ber I, Pasquier F, Hannequin D, Sanchez-Valle, Antonell A, Llado A, Parsons TM, Finch NA, Finger EC, Lippa CF, Huey ED, Meumann M, Riessman RA, Slawek J, Sitek E, Johannsen P, Nielsen JE, Ren Y, van Blitterswijk M, DeJesus-Hernandez M, Christopher E, Murray ME, Bieniek KF, Evers BM, Ferrari C, Rollinson S, Richardson A, Scarpini E, Fumagalli, GG, Padovani A, Frangipane F, Maletta R, Anfossi M, Gallo M, Petrucelli L, Suh E, Lopez OL, Wong TH, can Tooij JGJ, Mead S, Caselli RJ, Reiman EM, Sabbagh MN, Nykjaer A, Karydas AM, Boxer A, Grinberg L, Grafman J, Spina S, Oblak A, Mesulam MM, Weintraub S, Geula C, Hodges JR, Piguet O, Brooks WS, Irwin DJ, Trowjanowski JQ, Lee EB, Josephs KA, Parisi JE, Ertekin-Taner N, Knopman DS, Nacmias B, Sorbi S, Gearing M, Glass J, Beach TG, Black SE, Masellis M, Rogaeva E, Vonsattel J-P, Honig LS, Kofler J, Bruni AC, Snowden J, Mann D, Pickering-Brown S, Diehl-Schmid J, Winkelmann J, Galimberti D, Graff C, Oijerstedt L, Troakes C, Al-Sarraj S, Cruchaga C, Cairns NJ, Rohrer JD, **Halliday GM**, Kwok JB, va Swieten JC, White CL, Ghetti B, Murell JR, Mackenzie IRA, Hsiung G-YR, Borroni B, Rossi G, Tagliavini, Wszolek ZK, Petersen RC, Biglio EH, Grossman M, van Deerlin VM, Seeley WW, Miller BL, Graff-Radford NR, Boeve BF, Dickson DW, Biernacka JM, Rademakers R (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and *GRN* mutations: a genome-wide association study. Lancet Neurol. 17:548-558.
190. Schwartz RS, **Halliday GM**, Soh D, Cordato DJ, Kril JJ (2018) Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson's disease. J. Clin. Neurosci. 58:70-74.

191. Shepherd C, Yang Y, **Halliday GM** (2018) Region- and cell-specific aneuploidy in brain ageing and neurodegeneration. Neuroscience 374:326-334.
192. Tan R, Yang Y, **Halliday G** (2018) Multiple neuronal pathologies are common in young patients with pathologically proven frontotemporal lobar degeneration. Neuropathol. Appl. Neurobiol. 44:522-532.
193. Trist BG, Fifita JA, Freckleton SE, Hare DJ, Lewis SJG, **Halliday GM**, Blair IP, Double KD (2018) Accumulation of dysfunctional SOD1 protein in Parkinson's disease is not associated with mutations to the *SOD1* gene. Acta Neuropathol. 135:155-156.
194. van Hummel A, Chan G, van der Hoven J, Morsch M, Ippati S, Suh L, Bi M, Asih PR, Lee WS, Butler TA, Przbyla M, **Halliday G**, Piguet O, Kiernan M, Chung R, Ittner L, Ke YD (2018) Selective spatiotemporal vulnerability of central nervous system neurons to pathologic TAR DNA-binding protein-43 in aged transgenic mice. Am. J. Path. 188:1447-1456.
195. Walsh RR, Krismer F, Wenning GK, Low PA, **Halliday GM**, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Galpern WR, Global MSA Research Roadmap Meeting (2018) Recommendations of the global multiple system atrophy research roadmap meeting. Neurology 90:74-82.
196. Woerman AL, Kazmi SA, Patel S, Freyman Y, Oehler A, Aoyagi A, Mordes DA, **Halliday GM**, Middleton LT, Gentleman SM, Olson SH, Prusiner SB (2018) MSA prions exhibit remarkable stability and reistance to inactivation. Acta Neuropathol. 135:4963.
197. Zhang M, Ferrari R, Tartaglia MC, Keith J, Surace EI, Wolf U, Sato C, Grinberg M, Liang Y, McGoldrick P, Weichert A, McKeever PM, Schneider R, McCorkindale MD, Manzoni C, Rademakers R, Graff-Radford NR, Dickson DW, Parisi JE, Boeve BF, Petersen RC, Miller BL, Seeley WW, van Swieten JC, van Rooij J, Pijnenburg Y, van der Zee J, Van Broeckhoven C, Le Ber I, Van Deerlin V, Suh ER, Rohrer JD, Mead S, Graff C , Öijerstedt L, Pickering-Brown S, Rollinson S, Rossi G, Tagliavini F, Brooks WS, DobsonStone C, **Halliday GM**, Hodges JR, Piguet O, Binetti G, Benussi L, Ghidoni R, Nacmias B, Sorbi S, Bruni AC, Galimberti D, Scarpini E, Rainero I, Rubino E, Clarimon J, Lleó A, Ruiz A, Hernández I, Pastor P, Diez-Fairen M, Borroni B, Pasquier F, Deramecourt V, Lebouvier T, Perneczky R, Diehl-Schmid J, Grafman J, Huey ED, Mayeux R, Nalls MA, Hernandez D, Singleton A, Momeni P, Zeng Z, Hardy J, Robertson J, Zinman L, Rogaeva E (2018) A *C6orf10/LOC101929163* locus is associated with age of onset in *C9orf72* carriers. Brain 141:2895-2907.
198. Zhao Y, Perera G, Takahashi-Fujigasaki J, Nichols RJ, Holton J, Hasegawa K, Murayama, Mash DC, Vonsattel JPG, Dzamko N, **Halliday GM** (2018) Reduced LRRK2 in association with retromer dysfunction in postmortem brain from LRRK2 mutation carriers. Brain 141:486-495.
199. Zhao Y, Keshiya S, Atashrazm F, Ittner LM, Alessi DR, **Halliday GM**, Fu Y, Dzamko N (2018) Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Neurobiol. Dis. 120:76-87.
200. Ahmed RM, Irish M, van Eersel J, Ke YD Voelkerling A, van der Hoven J, Tanaka K, Karl T, Kril J, Piguet O, Götz J, Kiernan MC, **Halliday GM**, Hodges JR, Ittner LM (2017) Mouse models of frontotemporal dementia: a comparison of phenotypes with clinical symptomology. Neurosci. Biobehaviour. Rev. 74:126-138
201. Bodea L-G, Evans HT, Van der Jeugd A, Ittner L, Delerue F, Kril JJ, **Halliday GM**, Hodges JR, Kiernan MC, Götz J (2017) Accelerated aging exacerbates the pre-existing pathology in a tau transgenic mouse model. Aging Cell 16:377-386.
202. Dzamko N, Gysbers A, Bandopadhyay R, Bolliger MF, Uchino A, Zhao Y, Takao M, Wauters S, van de Berg W, Takahashi-Fujigasaki J, Nicols RJ, Holton JL, Murayama S, **Halliday GM** (2017) LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Mov. Disord. 32:423-432.
203. Dzamko N, Gysbers A, Perrera G, Bahar A, Shankar A, Gao J, Fu Y, **Halliday GM** (2017) Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to α-synuclein pathology. Acta Neuropathol. 133:303-319.
204. Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch CM, Schork AJ,Fan CC, Brewer JB; International FTD-Genomics Consortium (IFGC); International Parkinson's Disease Genomics Consortium (IPDGC); International Genomics of Alzheimer's Project (IGAP), Momeni P, Schellenberg GD, Dillon WP, Sugrue LP, Hess CP, Yokoyama JS, Bonham LW, Rabinovici GD, Miller BL, Andreassen OA, Dale AM, Hardy J, Desikan RS (2017) Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. J. Neurol. Neurosurg. Psychiatry 88:152-164.

205. Genoud S, Roberts BR, Gunn AP, **Halliday GM**, Lewis SJG, Ball HJ, Hare DJ, Double KL (2017) Subcellular compartmentalization of copper, iron, manganese, and zinc in the Parkinson's disease brain. Metallomics 9:1447-1455.
206. **Halliday G** (2017) Pathology and hippocampal atrophy in Alzheimer's disease. Lancet Neurol. 16:862-864.
207. Hsiao J-HT, **Halliday GM**, Kim WS (2017) α-Synuclein regulates neuronal cholesterol efflux. Molecules 22:E1769.
208. Kim WS, Bhatia S, Fu Y, Hsiao J-HT, **Halliday GM** (2017) Deletion of *Abca7* alters white adipose tissue development and leptin levels. J. Alzheimer Dis. Rep. 1:237-247.
209. Kirik D, Cederfjäll E, **Halliday G**, Petersén Å (2017) Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiol. Dis. 97:179-188.
210. Kordower JH, Goetz CG, Chu Y, **Halliday GM**, Nicholson DA, Musial T, Marmion DJ, Stoessl AJ, Sossi V, Freeman TB, Olanow CW (2017) Robust graft survival and normalized dopaminergic innervation does not obligate recovery in a PD patient. Ann. Neurol. 81:46-57.
211. Kovacs GG, Xie SX, Lee EB, Robinson JL, Irwin DJ, Toledo JB, Johnson VE, Smith DH, Caswell C, Alafuzoff I, Attems J, Bencze J, Bieniek KF, Bigio EH, Bodi I, Budka H, Dickson DW, Dugger BN, Duyckaerts C, Ferrer I, Forrest SL, Gelpi E, Gentleman SM, Giaccone G, Grinberg LT, **Halliday GM**, Hatanpaa KJ, Hof PR, Hofer M, Hortobágyi T, Ironside JW, King A, Kofler J, Kövari E, Kril J, Love S, Mackenzie IR, Mao Q, Matej R, McLean C, Munoz DG, Murray ME, Neltner J, Nelson PT, Ritchie D, Rodriguez RD, Rohan Z, Rozemüleer A, Sakai K, Schultz C, Seilhean D, Smith V, Tacik P, Takahashi H, Takao M, Thal DR, Weis S, Wharton SB, White CL, Woulfe JM, Yamada M, Trajanowski JQ (2017) Multisite assessment of aging-related tau astrogliopathy (ARTAG). J. Neuropathol. Exp. Neurol. 76:605-619.
212. Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, trojanowski JQ, Serrano GE, Beach TG, Clarimon J, Lesage S, Galasko D, Masliah E, Santana I, Ortega-Cubero S, Pator P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, ferman TJ, Escott-Price V, Graff-Radford N, Cairns N, Morris JC, Stone D, PickeringBrown S, Mann D, Dickson DW, **Halliday GM**, Singleton A, Hardy J, Guerreiro R, Bras J (2017) Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiol. Aging 49:214.e13–214.e15.
213. McKeith I, Boeve B, Dickson D, **Halliday GM**, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Ferman TJ, Kantarci K, Postuma R, Tiraboschi P, Attems J, Ballard C, Bayston A, Babcock D, Beach T, Blanc F, Bras J, Bundin P, Burn D, Bohnen N, ChenPlotkin A, Duda J, El-Agnaf O, Fujishiro H, Ffytche D, Galasko D, Goldman JG, Hoing L, Hsiao J, Iranzo A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine T, Mori E, Murray M, O'Brien J, Petersen RC, Phelps T, Salmon D, Sieber B-A, Silvereberg N, Sutherland M, Taylor A, Thomas A, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K, for the Consortium on DLB (2017) Diagnosis and management of dementia with Lewy bodies: Forth consensus report of the DLB consortium. Neurology 89:88-100.
214. Obeso JA,Stamelou M, Goetz CG, Powew W, Lang AE, Weintraub D, Burn D, **Halliday GM**, Bezard E, Pszedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Webster Ross G, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ (2017) Past, present and future of Parkinson's disease: A special essay on the 200th anniversary of the shaking palsy. Mov. Disord. 32:1264-1310.
215. Poewe W, Seppi K, Tanner C, **Halliday GM**, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson's disease. Nature Rev. Dis. Primers 3:17013.
216. Purves-Tyson T, Owens S, Rothmond D, **Halliday G**, Double K, Stevens J, McCrossin T, Shannon Weickert C (2017) Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from postmortem human midbrain. Translational Psychiatry 7:e1003.
217. Silsby M, Tweedie-Cullen RY, Murray C, **Halliday G**, Hodges JR, Burrell JR (2017) The midbrain to pons ratio distinguishes progressive supranuclear palsy from other non-fluent primary progressive aphasias. Eur. J. Neurol. 24:956-965.

218. Surmeier DJ, Obeso JA, **Halliday GM** (2017) Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci.18:101-113.
219. Surmeier DJ, Obeso JA, **Halliday GM** (2017) Parkinson's disease is not simply a prion disorder. J. Neurosci. 37:9799-9807.
220. Surmeier DJ, **Halliday GM,** Simuni T (2017) Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Exp. Neurol. 298:202-209.
221. Szeto JYY. **Halliday GM**, Naismith SL, Lewis SJL (2017) Exploring the phenotype in mild cognitive impairment to aid the prediction of those at risk of transitioning to Parkinson's disease and dementia with Lewy bodies. J. Geriatr. Psychiatr. Neurol. 30:196-205.
222. Tan RH, Ke YD, Ittner LM, **Halliday GM** (2017) ALS/FTLD: Experimental models versus reality. Acta Neuropathol. 133:177-196.
223. Tan R, Yang Y, Kim WS, Dobson-Stone C, Kwok JB, Kiernan MC, **Halliday G** (2017) Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathol. Comm. 5:76.
224. Tan RH, Kril JJ, Yang Y, Tom N, Hodges JR, Villemagne VL, Rowe CC, Leyton C, Kwok JBJ, Ittner LM, **Halliday GM** (2017) Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement. 9:10-20.
225. Taskesen E, Mishra A, van der Sluis S, Ferrari R; **International FTD-Genomics Consortium**, Veldink JH, van Es MA, Smit AB, Posthuma D, Pijnenburg Y (2017) Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci. Rep. 7:8899 & 8:7789.
226. Trist BG, Davies KM, Cottam V, Genoud S, Ortega R, Roudeau S, Carmona A, De Silva K, Wasinger V, Lewis SJG, Sachdev P, Smith B, Troakes C, Vance C, Shaw C, AlSarraj S, Ball HJ, **Halliday GM**, Hare DJ, Double KD (2017) Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. Acta Neuropathol. 134:113-127.
227. Van Langenhove T, Piguet O, Burrell JR, Leyton C, Foxe D, Abela M, Bartley L, Kim S, Jary E, Huang Y, Dobson-Stone C, Kwok J, **Halliday GM**, Hodges JR (2017) Predicting development of amyotrophic lateral sclerosis in frontotemporal dementia. J. Alzheimers Dis. 58:163-170.
228. Weissleder C, Kondo M, Yang CH, Fung SJ, Rothmund DA, Wong M, Double KD, **Halliday GM**, Herman MM, Kleinman JE, Webster MJ, Shannon Weickert C (2017) Early life decline in neurogenesis markers and age-related changes of TrkB splice variant expression in the human subependymal zone. Eur. J. Neurosci. 46:1768-78.
229. Yang Y, **Halliday GM**, Hodges JR, Tan RH (2017) von Economo neuron density and thalamus volumes in behavioural deficits in frontotemporal dementia cases with and without a *C9ORF72* repeat expansion. J. Alzheimer Dis. 58:701-709.
230. Yang Y, Shepherd CS, **Halliday GM** (2017) Increased aneuploidy is not a universal feature across α-synucleinopathies. Letter. Mov. Disord. 32:475-476.
231. Ahmed RM, Caga J, Devenney E, Hsieh S, Bartley L, Highton-Williamson E, Ramsey E, Zoing M, **Halliday GM**, Piguet O, Hodges JR, Kiernan MC (2016) Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. J. Neurol. 263:1593-603.
232. Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, Rohrer J, **Halliday GM**, Eisen A, Hodges JR, Kiernan MC (2016) Neuronal network disintegration: common pathways linking neurodegenerative diseases. J. Neurol. Neuropathol. Psychiatry 87:1234-1241.
233. Ahmed RM, Irish M, Piguet O, **Halliday GM**, Ittner LM, Farooqi S, Hodges JR, Kiernan MC (2016) Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behavior and metabolism. Lancet Neurol. 15:332-42.
234. Bleasel JM, **Halliday GM**, Kim WS (2016) Animal modeling an oligodendrogliopathy – multiple system atrophy. Acta Neuropathol. Comm. 4:12.
235. Burrell JR, Forrest S, Bak TH, Hodges JR, **Halliday GM**, Kril JJ (2016) Expanding the phenotypic associations of globular glial tau subtypes. Alzheimers Dement. 4:6-13.
236. Burrell JR, **Halliday GM,** Kril JJ, Ittner LM, Götz J, Kiernan MC, Hodges JR (2016) The frontotemporal dementia–motor neuron disease continuum. Lancet 388:919-31.
237. Chen BJ, Mills JD, Takenaka K, Bliim N, **Halliday GM**, Janitz M (2016) Characterization of circular RNA landscape in multiple system atrophy brain. J. Neurochem. 139:485-496.

238. Coupland KG, Kim WS, **Halliday GM**, Hallup M, Dobson-Stone C, Kwok JBJ (2016) Role of the long non-coding RNA *MAPT*-AS1 in regulation of *Microtubule Associated Protein Tau (MAPT)* expression in Parkinson's disease. PLoS One 11:e0157924.
239. Devenney E, Landin-Romero R, Irish M, Hornberger M, Mioshi E, **Halliday G**, Kiernan MC, Hodges JR (2016) The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. Neuroimage Clin. 13:439-445.
240. Dzamko N, Rowe DB, **Halliday GM** (2016) Increased peripheral inflammation in asymptomatic LRRK2 G2019S mutation carriers. Mov Disord. 31:889-897.
241. Fu YH, Hsiao JHT, Paxinos G, **Halliday GM**, Kim WS (2016) ABCA7 mediates phagocytic clearance of amyloid-β in the brain. J. Alzheimers Dis. 54:569-84.
242. Fu YH, Paxinos G, Watson C, **Halliday GM** (2016) The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. J. Chem. Neuroanat. 76:98-107.
243. Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hemandez DG, Nalls MA, Clark L, Honig L, Marder K, van der Flier W, Holstege H, Louwersheimer E, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, **Halliday GM**, Mann D, Pickering-Brown S, Powell J, Lunnon K, Lupton MK, International Parkinson's Disease Genomics Consortium (IPDGC), Dickson D, Hardy J, Singleton A, Bras J (2016) Genome-wide analysis of genetic correlation in dementia with Lewy Bodies, Alzheimer's and Parkinson's disease. Neurobiol. Aging 38:214.e7-214.e10.
244. **Halliday GM**, Kiernan MC, Kril JJ, Mito R, Masuda-Suzukake M, Hasegawa M, McCann H, Bartley L, Dobson-Stone C, Kwok JBJ, Hornberger M, Hodges JR, Tan RH (2016) TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioural variant frontotemporal dementia. J. Neurol. Sci. 366:197-201.
245. Hu Y-B, Zou Y, Huang Y, Zhang Y-F, Lourenco GF, Chen S-D, **Halliday GM**, Wang G, Ren R-J (2016) ROCK1 is associated with Alzheimer's disease-specific plaques, as well as enhances autophagosome formation but not autophagic Aβ clearance. Front. Cell. Neurosci. 10:253.
246. Kovacs GG, Ferrer I, Grinberg L, Alafuzoff I, Attems J, Budka H, Cairns N, Crary JF, Duyckaerts C, Ghetti B, **Halliday G**, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray M, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzbergere T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril J, Mann D, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüleer A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters H, Weis S, Wharton SB, White CL, Wisniewski T, Woulfe JM, Yamada M, Dickson DW (2016) Age-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 131:87-102.
247. Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf O, **Halliday G**, Kirik D (2016) A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human α-synuclein. Mol. Neurodegen. 11:61.
248. Leyton CE, Britton AK, Hodges JR, **Halliday GM**, Kril JJ (2016) Distinctive pathological mechanisms involved in the primary progressive aphasias. Neurobiol. Aging 38:82-92.
249. Matrone C, Dzamko N, Madsen P, Nyegaard M, Pohlmann R, Sondergaard RV, Lassen LB, Andresen TL, **Halliday GM**, Jensen PH, Nielsen MS (2016) Mannose 6phosphate receptor is reduced in α-synuclein overexpressing models of Parkinson's disease. PLoS One 11:e0160501.
250. McCann H, Cartwright H, **Halliday GM** (2016) Neuropathology of α-synuclein propagation and Braak hypothesis. Mov. Disord. 31:152-160.
251. Mills JD, Ward M, Kim WS, **Halliday GM**, Janitz M (2016) Strand-specific RNAsequencing analysis of multiple system atrophy brain transcriptome. Neuroscience 322:234-50.
252. O'Callaghan C, Hornberger M, Balsters JH, **Halliday GM**, Lewis SJG, Shine JM (2016) Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. Brain 139:845-855.
253. Perera G, Ranola M, Rowe DB, **Halliday GM**, Dzamko N (2016) Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamics biomarker. Sci. Rep. 6:31391.

254. Postuma R, Berg D, Adler C, Bloem B, Chan PB, Deuschl G, Gasser T, Goetz C, **Halliday G**, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M (2016) The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 15:546-548.
255. Postuma R, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, **Halliday G**, Goetz C, Gasser T, Dubois B, Chan PB, Bloem B, Adler C, Deuschl G (2016) Abolishing the 1-year rule: How much evidence will be enough? Mov. Disord. 31:1623-1627.
256. Rusznák Z, Kim WS, Hsiao T, **Halliday GM**, Paxinos G, Fu YH (2016) Early *in vivo* effects of the human mutant amyloid-ß precursor protein (hAβPPSwInd) on the mouse olfactory bulb. J. Alzheimers Dis. 49:443-5.
257. Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, Yong KX, Lehmann M, Taner N, Graff-Radford N, Boeve BF, Murray ME, Qurat ul Ain K, Petersen RC, Dickson DW, Knopman DS, Rabinovici GD, Suarez Gonzalez A, Gil-Néciga E, Snowden JS, Harris J, Pickering-Brown SJ, Louwersheimer E, can der Flier WM, Scheltens P, Pijnenburg YAL, Galasko D, Sarazin M, Dubois B, Magnin E, Galimberti D, Scarpini E, Cappa SF, Hodges JH, **Halliday GM**, Bartley L, Bras JT, Hardy J, Rossor MN, Collinge J, Fox NC, Mead S (2016) Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer Dement. 12:862-71.
258. Shibuya K, Park SB, Geevasinga N, Menon P, Howells J, Simon NG, Huynh W, Noto Y, Götz J, Kril J, Ittner LM, Hodges J, **Halliday G**, Vucic S, Kiernan MC (2016) Motor cortical function determines prognosis in sporadic ALS. Neurology 87:513-20.
259. Tan RH, Kril JJ, McGinley C, Hassani M, Masuda-Suzukake M, Hasegawa M, Mito R, Kiernan MC, **Halliday GM** (2016) Cerebellar neuronal loss in ALS cases with ATXN2 intermediate repeat expansions. Ann. Neurol. 79:295-305.
260. van der Jeugd A, Vermaercke B, **Halliday G**, Staufenbiel M, Götz J (2016) Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. Neurobiol. Learn. Mem. 130:34-43.
261. Wang G, Huang Y, Chen W, Chen S, Wang Y, Xiao Q, Liu J, Fung VSC, **Halliday G**, Chen S (2016) Variants in the *SNCA* gene associate with motor progression while variants in the *MAPT* gene associate with the severity of Parkinson's disease. Parkinsonism Rel. Disord. 24:89-94.
262. Wang G, Huang Y, Wang L-L, Zhang Y-F, Xu J, Zhou Y, Lourenco G, Zhang B, Wang Y, Ren R-J, **Halliday GM**, Chen S-D (2016) MiRNA-146a suppresses ROCK1 allowing hyperhyperphosphorylation of tau in Alzheimer's disease. Sci. Rep. 6:26697.
263. Weissleder C, Fung SJ, Wong MW, Barry G, Double KL, **Halliday GM**, Webster MJ, Weickert CS (2016) Decline in proliferation and immature neuron markers in the human subependymal zone during aging: Relationship to EGF- and FGF-related transcripts. Front. Aging Neurosci 8:274.
264. Abbott SK, Jenner AM, Spiro AS, Batterham M, **Halliday GM**, Garner B (2015) Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson's disease. J. Parkinson Dis. 5:175-185.
265. Ahmed RM, Latheef S, Bartley L, Irish M, **Halliday GM**, Kiernan MC, Hodges JR, Piguet O (2015) Eating behavior in frontotemporal dementia: Peripheral hormones vs hypothalamic pathology. Neurology 85:1310-7.
266. Berg D, Postuma RB, Adler CH, Bloem B, Chan PB, Dubois B, Gasser T, Goetz C, **Halliday GM**, Hardy J, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30:1600-1611.
267. Cairns NJ, Perrin RJ, Franklin EE, Carter D, Vincent B, Xie M, Bateman RJ, Benzinger T, Friedrichsen K, Brooks WS, **Halliday GM**, McLean C, Ghetti B, Morris JC, the Alzheimer Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer Network (2015) Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology 35:390-400.
268. Chen J, Mills JD, **Halliday GM**, Janitz M (2015) The role of transcriptional control in multiple system atrophy. Neurobiol. Aging 36:394-400.
269. Cheshire P, Ayton S, Bertram K, Ling H, Li A, McClean C, **Halliday G**, O'Sullivan SS, Revesz T, Finkelstein DI, Storey E, Williams DR (2015) Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Mov. Disord. 30:796-804.

270. Cordato NJ, **Halliday GM** (2015) Differentiation of progressive supranuclear palsy. Neurodegener. Dis. Manag. 5:385-8.
271. Coupland KG, Kim WS, **Halliday G**, Hallup M, Dobson-Stone C, Kwok JBJ (2015) Effect of *PSEN1* mutations on *MAPT* methylation in early-onset Alzheimer's disease. Curr. Alz. Res. 12:745-51.
272. Devenney E, Bartley L, Hoon C, O'Callaghan C, Kumfor F, Hornberger M, Kiernan MC, **Halliday G**, Piguet O, Hodges JR (2015) Progression in behavioural variant frontotemporal dementia: a longitudinal study. JAMA Neurol. 26:1-9.
273. Dobson-Stone C, Shaw A, Hallup M, Bartley L, McCann H, Brooks WS, Loy CT, Schofield PR, Mather K, Kochan NA, Sachdev PS, **Halliday GM**, Piguet O, Hodges J, Kwok JBJ (2015) Is *CHCHD10* Pro34Ser a disease-causing mutation for frontotemporal dementia and amyotrophic lateral sclerosis? Letter. Brain 138:e385.
274. Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, **Halliday G**, Neumann M, Spillantini MG, Tolnay M, Uchihara T (2015) PART is part of Alzheimer disease. Acta Neuropathol. 129:749-56.
275. Dzamko N, Geczy C, **Halliday GM** (2015) Inflammation is genetically implicated in Parkinson's disease. Neuroscience 302:89-102.
276. Fatima M, Tan, R, **Halliday GM**, Kril JJ (2015) Spread of pathology in amyotrophic lateral sclerosis: Assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol. Commun. 3:47.
277. Forrest SL, Kril JJ, **Halliday GM** (2015) Frontotemporal lobar degeneration with tau inclusions (FTLD-tau): recent developments in pathology and pathogenesis. Aust. Biochem. 46:8-11.
278. Fu YH, Hsiao JHT, Hill AF, Paxinos G, **Halliday GM**, Kim WS (2015) ABCA5 regulates amyloid-beta production and is associated with Alzheimer's disease neuropathology. J. Alzheimers Dis. 43:857-69.
279. Gabery S, **Halliday G**, Kirik D, Englund E, Petersen A (2015) Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. Neuropath. Appl. Neurobiol. 41:843-848.
280. **Halliday G** (2015) Progressive supranuclear palsy finally has a measureable tau abnormality. J. Neurol. Neurosurg. Psychaitry 86:241.
281. **Halliday G** (2015) Re-evaluating the gliocentric view of multiple system atrophy by highlighting the neuronal involvement. Brain 138:2116-2119.
282. **Halliday GM**, Murphy K (2015) Reply; Lysosomal dysfunction in Parkinson's disease. Brain 138:e340.
283. Helmfors L, Boman A, Civitelli L, Nath S, Sandin L, Janefjord C, McCann H, Zetterberg H, Blennow K, **Halliday** G, Brorsson A-C, Kågedal K (2015) Protective properties of lysosome on β-amyloid pathology; Implications for Alzheimer disease. Neurobiol. Dis. 83:122-133.
284. Huang Y, Wang G, Rowe D, Wang Y, Kwok J, Xiao Q, Mastaglia F, Liu J, Chen SD, **Halliday GM** (2015) *SCNA* gene, but not *MAPT,* influences onset age of Parkinson's disease in Chinese and Australians. BioMed Research International 2015:135674.
285. Ittner LM, **Halliday GM,** Kril JJ, Götz J, Hodges JR, Kiernan MC (2015) FTD and ALS - translating mouse studies into clinical trials. Nature Rev. Neurol. 2015;11:360366.
286. Ke YD, van Hummel A, Stevens CH, Gladbach A, Ippati S, Bi M, Lee WS, Krüger S, van der Hoven J, Volkerling A, Bongers A, **Halliday GM**, Haass NK, Kiernan M, Delerue F, Ittner LM (2015) Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 130:661-678.
287. Leshchyns'ka I, Liew HT, Shepherd C, **Halliday GM**, Stevens CH, Ke YD, Ittner LM, Sytnyk V (2015) Amyloid β-dependent reduction of NCAM2-mediated synaptic adhesion in the hippocampus contributes to synapse loss in Alzheimer's disease. Nature Commun. 6:8836.
288. Lewis SJG, Szeto JYY, O'Callaghan C, Shine JM, Walton CC, Naismith SL, **Halliday GM** (2015) The relationships between mild cognitive impairment and phenotype in Parkinson's disease. NPJ Parkinson's Disease 1:15003.
289. Lourenco GF, Janitz M, Huang Y, **Halliday GM** (2015) Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiol. Dis. 82:445-454.
290. McCann H, Fung VSC, Klein C, **Halliday GM** (2015) Unusual α-synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without SGCE mutation. Neuropathol. Appl. Neurobiol. 41:837-42.
291. McCann H, McGeachie AB, Silberstein P, Lewis SJG, **Halliday GM** (2015) Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathol. Appl. Neurobiol. 41:681-5.

292. Mills JD, Chen J, Kim WS, Waters PD, **Halliday GM**, Janitz M (2015) Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in cortical white matter. Neurogenetics 16:201-213.
293. Mills JD, Kavanagh T, Kim WS, Chen BJ, Waters PD, **Halliday GM**, Janitz J (2015) High expression of long intervening non-coding OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. Mol. Brain 10;8:2.
294. Mills JD, Kim WS, **Halliday GM**, Janitz J (2015) Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. Neurogenetics 16:107-22. 216.
295. Murphy KE, Gysbers AM, Abbott SK, Spiro AS, Furuta A, Cooper A, Garner B, Kabuta T, **Halliday GM** (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Mov. Disord. 30:1639-1647.
296. Postuma R, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Hardy J, **Halliday G**, Goetz C, Gasser T, Dubois B, Chan PB, Bloem B, Adler C, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson's disease. *Mov. Disord. 30:1591-1601.*
297. Prusiner SB, Woerman AL, Rampersaud R, Watts JC, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz S, Geschwind DH, Glidden DV, **Halliday G**, Middleton LT, Gentleman SM, Mordes DA, DeArmond SJ, Giles K (2015) Evidence for α-synuclein prions causing multiple system atrophy in humans with Parkinsonism. Proc. Natl. *Acad. Sci. USA 112:E5308-17.*
298. Shine JM, Mills JMZ, Qiu J, O'Callaghan C, Terpenning Z, **Halliday GM**, Naismith SL, Lewis SGL (2015) Validation of the psychosis and hallucinations questionnaire in non-demented patients with Parkinson's disease. Mov. Disord. Clinical Practice 2:175181.
299. Shine JM, Muller A, O'Callaghan C, Hornberger M, **Halliday GM**, Lewis SJG (2015) Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a taskbased fMRI study. NPJ Parkinson's Disease 1:15003.
300. Stoessl AJ, **Halliday GM** (2014) Confidence in using dopamine transporter SPECT to diagnose degeneration of the nigrostriatal system but perhaps not early Parkinson's disease. Mov. Disord. 29:1705-6.
301. Tan RH, Devenney E, Kiernan MC, **Halliday GM**, Hodges JR, Hornberger M (2015) Terra incognita – cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioural variant frontotemporal dementia. Front. Aging Neurosci. 7:121.
302. Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C, Forrest S, Affleck A, Kwok JBK, Hodges JR, Kiernan MC, **Halliday GM** (2015) TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain 138:3110-3122.
303. Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam KE, van de Berg WDJ, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DMA, Imai Y, **Halliday GM**, Li JY, El-Agnaf OMA (2015) Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiol. Dis. 79:81-99.
304. Van Eersel J, Stevens CH, Prybyla M, Gladbach A, Stefanoska K, Xin CCK, Ong, WY, Hodges JR, Sutherland GT, Kril JJ, Abramowski D, Staufenbiel M, **Halliday GM**, Ittner LM (2015) Early-onset axonal pathology in a novel P301S-tau transgenic mouse model of frontotemporal lobar degeneration. Neuropath. Appl. Neurobiol. 41:906925.
305. Yang Y, Shepherd C, **Halliday GM** (2015) Aneuploidy in Lewy body diseases. Neurobiol. Aging 36:1253-60.
306. Abbott SK, Li H, Munoz SS, Knoch B, Batterham M, Murphy K, **Halliday GM**, Garner B (2014) Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Mov. Disord. 29:518-526.
307. Ahmed RM, Macmillan M, Bartley L, **Halliday GM**, Kiernan MC, Hodges JR, Piguet O (2014) Systemic metabolism in frontotemporal dementia. Neurology 83:1812-8.
308. Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O'Brien J, Fox NC, **Halliday GM**, Schott JM (2014) Biomarkers in dementia: clinical utility and new directions. J. Neurol. Neurosurg. Psychiatry 85:1426-34.
309. Berg D, Postuma RB, Bloem B, Chan PB, Dubois B, Gasser T, Goetz C, **Halliday GM**, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, CW Olanow, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 29:454-462.

310. Bleasel JM, Wong J, **Halliday GM**, Kim WS (2014) Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol. Comm. 2:15.
311. Blennerhassett R, Lillo P, **Halliday GM**, Hodges JR, Kril JJ (2014) Distribution of pathology in frontal variant Alzheimer's disease. J. Alzheimers Dis. 39:63-70.
312. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark L, Honig L, Marder K, van der Flier W, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, **Halliday G**, Mann D, Pickering-Brown S, Dickson D, Singleton A, Hardy J (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the eitiology of dementia with Lewy bodies. Hum. Mol. Genet. 23:6139-46.
313. Chare L, Hodges JR, McGinley C, Tan RH, Kril JJ, **Halliday GM** (2014) New criteria for frontotemporal dementia syndromes impact most on language variants. J. Neurol. Neurosurg. Psychiatry 85:865-870.
314. Cheshire P, Bertram K, Ling H, O'Sullivan SS, **Halliday G**, McLean C, Bras J, Flotynie T, Storey E, Williams DR (2014) Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegener. Dis. 13:24-28.
315. Coupland KG, Mellick GD, Silbern PA, Mather K, Armstrong NJ, Sachdev PS, Brodaty H, Huang Y, **Halliday G**, Hallup M, Kim WS, Dobson-Stone C, Kwok JBJ (2014) DNA methylation of MAPT gene in Parkinson's disease cohorts and modulation by vitamin E *in vitro*. Mov. Disord. 29:1606-14.
316. Davies KM, Bohic S, Carmona A, Ortega R, Cottam V, Hare DJ, Finberg JPM, Reyes S, **Halliday GM**, Mercer JFB, Double KL (2014) Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol. Aging 35:858-866.
317. Don AS, Hsiao JHT, Bleasel JM, Couttas TA, **Halliday GM**, Kim WS (2014) Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol. Comm. 2:150.
318. Dzamko N, Zhou J, Huang Y, **Halliday G** (2014) Parkinson's disease-implicated kinases in the brain: insights into disease pathogenesis. Front. Mol. Neurosci. 7:57.
319. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JBJ, DobsonStone C, Brooks WS, Schofield PR, **Halliday GM**, Hodges JR, Piguet O, Bartley L, Thompson E, Haan E, Hernández I, Ruiz A, Boada M, Borroni B, Padovani A, Cruchaga C, Cairns NJ, Benussi L, Binetti G, Ghidoni R, Forloni G, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Clarimón J, Lleó A, Blesa R, Landqvist Waldö M, Nilsson K, Nilsson C, Mackenzie IRA, Hsiung G-YR, Mann DMA, Grafman J, Morris CM, Attems J, Griffiths TD, McKeith IG, Thomas AJ, Pietrini P. Huey ED, Wassermann EM, Baborie A, Jaros E, Pastor P, Razquin C, Ortega-Cubero S, Alonso E, Perneczky R, Diehl-Schmid J, Alexopoulos P, Kurz A, Rainero I, Rubino E, Pinessi L, Rogaeva E, St George-Hyslop P, Rossi G, Tagliavini F, Giaccone G, Rowe JB, Schlachetzki JCM, Uphill J, Collinge J, Mead S, Danek A, Van Deerlin VM, Grossman M, Trojanowski JQ, van der Zee J, Deschamps W, Van Langenhove T, Cruts M, Van Broeckhoven C, The Belgian Neurology Consortium and the European Early-Onset Dementia consortium, Cappa SF, Le Ber I, Hannequin D, Golfier V, Vercelletto M, Brice A, The French research network on FTLD/FTLD-ALS, Nacmias B, Sorbi S, Bagnoli S, Piaceri I, Nielsen JE, Hjermind LH, Riemenschneider M, Mayhaus M, Ibach B, Gasparoni G, Pichler S, Gu W, Rossor MN, Fox NC, Warren JD, Spillantini MG, Morris HR, Rizzu P, Heutink P, Snowden JS, Rollinson S, Richardson A, Gerhard A, Bruni AC, Maletta R, Frangipane F, Cupidi C, Bernardi L, Anfossi M, Gallo M, Conidi ME, Smirne N, Rademakers R, Baker M, Dickson DW, Graff-Radford NR, Petersen RC, Knopman D, Josephs KA, Boeve BF, Parisi JE, Seeley WW, Miller BL, Karydas AM, Rosen H, van Swieten JC, Dopper EGP, Seelaar H, Pijnenburg YAL, Scheltens P, Logroscino G, Capozzo R, Novelli V, Alessandro Puca A, Franceschi M, Postiglione A, Milan G, Sorrentino P, Kristiansen M, Chiang H-H, Graff C, Pasquier F, Rollin A, Deramecourt V, Lebert F, Thumma AR, Kapogiannis D, UK Brain Expression Consortium, North American Brain Expression Consortium, Ferrucci L, Pickering-Brown S, Hardy J, Momeni P, Singleton AB (2014) Frontotemporal dementia and its subtypes: a genome wide association study. Lancet Neurol. 13:686–99.
320. Gallagher MD, Suh E, Grossman, M, Elman L, McCluskey L, Van Swieten JC, AlSarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer J, **Halliday G**, Van Broeckhoven C, Seilhean D, Shaw P, International Collaboration for Frontotemporal Lobar Degeneration, Trojanowski J, Lee VMY, Van Deerlin V, Chen-Plotkin AS (2014) *TMEM106B* is a genetic modifier of frontotemporal lobar degeneration with *C9orf72* hexnucleotide repeat expansion. Acta Neuropathol. 127:407-18.

321. Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, **Halliday GM**, Kirik D (2014) Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain 137:2493-508.
322. **Halliday GM**, Leverenz JB, Schneider JS, Adler CH (2014) The neurobiological basis of cognitive impairment in Parkinson's disease. Mov. Disord. 29:634-650.
323. Howitt J, Gysbers AM, Ayton S, Carew-Jones F, Pulz U, Finkelstein D, **Halliday GM**, Tan S-S (2014) Increased Ndfip1 in the substantia nigra of Parkinsonian brains is associated with elevated iron levels. PLoS One 9:e87119.
324. Kim WS, Kågedal K, **Halliday GM** (2014) α-Synuclein biology in Lewy body diseases. Alzheimer's Research & Therapy 6:73.
325. Kordower J, **Halliday G** (2014) Misfolded proteins in HD fetal grafts: further evidence of cell-to-cell transfer? Ann. Neurol. 76:20-1.
326. Kragh CL, Gysbers AM, Rockenstein E, Murphy K, **Halliday G**, Masliah E, Jensen PH (2014) Prodegenerative I□B□ expression in oligodendroglial α-synuclein models of multiple system atrophy. Neurobiol. Dis. 63C:171-183.
327. Lam BYK, **Halliday GM**, Irish M, Hodges JR, Piguet O (2014) Longitudinal white matter changes in frontotemporal dementia subtypes. Human Brain Mapp. 35;3547– 3557.
328. Mahul-Mellier A-L, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, **Halliday G**, Hantschel O, Lashuel HA (2014) c-Abl phosphorylates α-syn and regulates its degradation, implication for α-syn clearance and contribution to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 23(11):2858-79.
329. McCann H, Stevens CH, Cartwright H, **Halliday GM** (2014) α-Synucleinopathy phenotypes. Parkinson. Rel. Disord. 20 (Suppl. 1):S62-S67.
330. Muller AJ, Shine JM, **Halliday GM**, Lewis SJG (2014) Visual hallucinations in Parkinson's disease: theoretical models. Mov. Disord. 29:1591-8.
331. Murphy KE, Gysbers AM, Abbott S, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, **Halliday GM** (2014) Reduced glucocerebrosidase is related to increased α-synuclein in sporadic Parkinson's disease. Brain 137:834-848.
332. Murphy KE, **Halliday GM** (2014) Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy 10:1350-1351.
333. Po K, Leslie FVC, Gracia N, Bartley L, Kwok JBC, **Halliday GM**, Hodges JR, Burrell JR (2014) Heritabiity in frontotemporal dementia: more missing pieces? J. Neurol. 261:2170-7.
334. Riley BE, Gardai SJ, Emig-Agius D, Bessarabova M, Ivliev A, Schule B, Alexander J, Wallace W, **Halliday GM**, Langston W, Braxton S, Yednock T, Shaler T, Johnston JA (2014) Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. PLoS One 9:e102909.
335. Shine JM, **Halliday GM**, Gilat M, Matar E, Bolitho SJ, Carlos M, Naismith SL, Lewis SJG (2014) The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Human Brain Mapp. 35:2206-2219
336. Shine JM, O'Callaghan C, **Halliday GM**, Lewis SJG (2014) Tricks of the mind: hallucinations as a disorder of attention. Prog. Neurobiol. 116:58-65
337. Tan R, Devenney E, Hodges JR, Kiernan MC, **Halliday GM**, Dobson-Stone C, Kwok JB, Hornberger M (2014) Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One 9:e105632.
338. Tan RH, Wong S, Kril JJ, Piguet O, Hornberger M, Hodges JR, **Halliday GM** (2014) Beyond the temporal pole – Limbic memory circuit integrity in the semantic variant of primary progressive aphasia. Brain 137:2065-2076.
339. Wong JH, **Halliday GM**, Kim WS (2014) Exploring myelin dysfunction in multiple system atrophy. Exp. Neurobiol. 23:337-44.
340. Abbott SK, Jenner AM, Mitchell TW, Brown SHJ, **Halliday GM**, Garner B (2013) An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids 48:307-18.
341. Bleasel JM, Hsiao J-HT, **Halliday GM**, Kim WS (2013) Increased expression of ABCA8 in multiple system atrophy is associated with changes in pathogenic proteins. Journal of Parkinson's Disease 3:331-339.

342. Dang TNT, Dobson-Stone C, Garos E, Kim WS, Hallup M, Bartley L, Piguet O, Hodges JR, **Halliday GM**, Double KL, Schofield PR, Crouch PJ, Kwok JBJ (2013) Endogenous progesterone levels and frontotemporal dementia: modulation of TDP43 and tau levels *in vitro* and treatment of A315T *TARDBP* mouse model. Dis. Model Mech. 6:1198-204.
343. Davies K, Hare DJ, Cottam V, Chen N, Hilgers L, **Halliday G**, Mercer JFB, Double KL (2013) Localisation of copper transporters in the human brain. Metallomics 5:4351.
344. Dobson-Stone C, Luty AA, Thompson EM, Blumbergs P, Brooks WS, Short CL, Field C, Panegyres PJ, Hecker J, Solski JA, Blair I, Fullerton JM, **Halliday GM**, Schofield PR, Kwok JBJ (2013) Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1q12.2: genetic, clinical and neuropathological analysis. Acta Neuropathol. 125:523-33.
345. Dzamko N, Chua G, Ranola M, Rowe D, **Halliday GM** (2013) Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. Journal of Parkinson's Disease 3:145152.
346. Dzamko N, **Halliday G** (2013) Unlocking the secrets of LRRK2 function with specific kinase inhibitors. Future Neurology 8:347-357.
347. Guerreiro PS, Huang Y, Gysbers A, Cheng D, Outeriro TF, **Halliday GM** (2013) Observed interactions between LRRK2 and α-synuclein in Parkinson's disease. J. Mol. Med. (Berl.) 91:513-22.
348. **Halliday G** (2013) Motor deficits associated with changes in β-amyloid in Parkinson's disease. J. Neurol. Neurosurg. Psychaitry 84:475-476.
349. Hsiao J-H, Hill AF, **Halliday GM**, Kim WS (2013) Elevation in shingomyelin synthesis is associated with increases in amyloid-beta peptide generation. PloS One 8:e74016.
350. Huang Y, **Halliday GM** (2013) Can we really diagnose dementia with Lewy bodies yet? Translational Neurodegeneration 2:4.
351. Kavanagh T, Mills JD, Kim WS, **Halliday GM**, Janitz M (2013) Pathway analysis of the human brain transcriptome in disease. J Mol. Neurosci. 51:28-36.
352. Kemp S, Harding AJ, **Halliday GM**, Mahant N, Fung VSC (2013) Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Mov. Disord. 28:1804-1806.
353. Kim WS, Hsio J-HT, Bhatia S, Glaros EN, Don AS, Tsuruoka S, Shannon Weikert C, **Halliday GM** (2013) ABCA8 stimulates sphinomyelin production in oligodendrocyte. Biochem. J. 452:401-10.
354. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, **Halliday GM**, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136:2419-2431.
355. Kragh CL, Fillon G, Hensen HD, Neumann M, Gysbers A, Richter-Landsberg C, Haas C, Zalc B, **Halliday GM**, Lubetzki C, Gai WP, Kahle PJ, Jensen PH (2013) FASdependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One 8:e55243.
356. Mills JD, Kavanagh T, Kim WS, Chen BJ, Kawahara Y, **Halliday GM**, Janitz M (2013) Unique transcriptome patterns of the white and grey matter reveals structural and functional heterogeneity in the human frontal lobe. PLoS One 8:e78480.
357. Murphy KE, Cottle L, Gysbers AA, Cooper AA, **Halliday GM** (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol. Comm. 1:11.
358. Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, Morris CM, Theuns J, Crosiers D, Cras P, Engelborghs S, De Deyn PP, Van Broeckhoven C, Mann DMA Snowden J, Pickering-Brown S, Halliwell N, Davidson Y, Gibbons L, Harris J, Sheerin U, Bras J, Hardy J, Clark L, Marder K, Honig LS, Berg D, Maetzler W, Brockmann K, Gasser T, Novellino F, Quattrone A, Annesi G, De Marco EV, Rogaeva E, Masellis M, Black SE, Bilbao JM, Foroud T, Ghetti B, Nichols WC, Pankratz N, **Halliday G**, Lesage S, Klebe S, Durr A, Duyckaerts C, Brice A, Giasson BI, Trojanowski JQ, Hurtig HI, Tayebi N, Landazabal C, Knight MA, Keller M, Singleton AB, Wolfsberg TY, Sidransky E (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70:727-735.
359. Ravenscroft TA, Baker MC, Rutherford N, Neumann M, Mackenzie IR, Josephs KA, Boeve BF, Petersen R, **Halliday GM**, Kril J, Van Swieten JC, Seeley WW, Dickson DW, Rademakers R (2013) Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiol. Aging 34:2235.e11-3.
360. Reyes S, Cottam V, Kirik D, Double K, **Halliday GM** (2013) Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov. Disord. 28:1351-1359.

361. Reyes S, Fu Y, Double KL, Smoothly V, Thompson LH, Kirik D, Paxinos G, Watson C, Cooper HM, **Halliday GM** (2013) Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiol. Aging 34:873-86.
362. Tan RH, Pok K, Wong S, Brooks D, **Halliday GM**, Kril JJ (2013) The pathogenesis of cingulate atrophy in behavioural variant frontotemporal dementia and Alzheimer's disease. Acta Neuropathol. Comm. 1:30.
363. Tan RH, Shepherd CE, Kril JJ, McCann H, McGeachie A, McGinley C, Affleck A, **Halliday GM** (2013) Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP-43. Acta Neuropathol. Comm. 1:33.
364. Tan R, Wong S, Hodges JR, **Halliday GM**, Hornberger M (2013) Retrosplenial cortex (BA 29) volumes in behavioural variant frontotemporal dementia and Alzheimer's disease. Dement. Geriat. Cog. Disord. 35:177-182.
365. Wang J-H, Gouda-Vossos A, Dzamko N, **Halliday G**, Huang Y (2013) DNA extraction from fresh frozen and formalin-fixed paraffin-embedded human brain tissue. Neurosci. Bull. 29:649-654.
366. Zhou J, Zhang H, Huang Y, He Y, Zheng Y, Anderson JP, Gai W, Liang Z, Ren X, Wang Q, Yang J, Wang X, **Halliday G**, Wang X (2013) Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neurosci. Ther. 19:688-694.
367. Dzamko N, **Halliday G** (2012) An emerging role for LRRK2 in the immune system. Biochem. Soc. Transact. 40:1134-9.
368. Dobson-Stone C, Hallup M, Bartley L, Shepherd CE, **Halliday GM**, Schofield PR, Hodges JR, Kwok JBJ (2012) C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 79:995-1001.
369. Elliott DA, Kim WS, Gorissen S, **Halliday GM**, Kwok JBJ (2012) Leucine-Rich Repeat Kinase 2 and alternative splicing in Parkinson's disease. Mov. Disord. 27:10041011.
370. Fu YH, Yuan Y, **Halliday G**, Rusznak Z, Watson C, Paxinos G (2012) A cyto- and chemo-architectural analysis of the dopamine cell clusters in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct. Funct. 217:591-612.
371. **Halliday G** (2012) An evidence base for noradrenergic deficits in Parkinson's disease. Mov. Disord. 27:1589-1591.
372. **Halliday G**, Bigio EH, Cairns NJ, Neumann M, Mackenzie IRA, Mann DMA (2012) Mechanisms of disease in frontotemporal lobar degeneration: Gain of function versus loss of function effects. Acta Neuropathol. 124:373-382.
373. **Halliday G**, McCann H, Shepherd C (2012) Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev. Neurother. 12:673-686.
374. Hornberger M, Wong S, Tan R, Irish M, Piguet O, Kril J, Hodges JR, **Halliday GM** (2012) *In vivo* and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. Brain 135:3015-3025.
375. Huang Y, Chegini F, Chua G, Murphy K, Gai WP, **Halliday GM** (2012) Macroautophagy in sporadic and the genetic form of Parkinson's disease with A53T α-synuclein mutation. Translational Neurodegeneration 1:2.
376. Huang Y, **Halliday GM** (2012) Aspects of innate immunity and Parkinson's disease. Front. Pharmacol. 3:33.
377. Kim WS, **Halliday GM** (2012) Changes in sphingomyelin level affect α-synuclein and ABCA5 expression. Journal of Parkinson's Disease 2:41-46.
378. Lewis SJG, Shine JM, Duffy S, **Halliday G**, Naismith SL (2012) Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov. Disord. 27:1262-1267.
379. Lim Y-A, Giese M, Shepherd C, **Halliday G**, Kobayashi M, Takamatsu K, Staufenbiel M, Eckert A, Goetz J (2012) Role of hippocalcin in mediating Aβ toxicity. Biochim. Biophys. Acta 1822:1247-1257.
380. Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos P, **Halliday GM** (2012) GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J. Comp. Neurol. 520:2591-2607.
381. Schofield EC, Hodges, JR, Bak TH, Xuerub JH, **Halliday GM** (2012) The relationship between clinical and pathological variables in Richardson's syndrome. J. Neurol. 259:482-90.
382. Schwartz RS, **Halliday GM**, Cordato DJ, Kril JJ (2012) Small-vessel disease in patients with Lewy Body Disease: a clinicopathological study. Mov. Disord. 27:15061512.

383. Sharpe LJ, Wong J, Garner B, **Halliday GM**, Brown AJ (2012) Is seladin-1 really a selective Alzheimer's disease indicator? J. Alzheimers Dis. 30:35-39.
384. Shine JM, **Halliday GH**, Carlos M, Naismith SL, Lewis SJG (2012) Investigating visual misperceptions in Parkinson's disease: a novel behavioural paradigm. Mov. Disord. 27:500-5.
385. Stevens CH, Rowe D, morel-Kopp M-C, Orr C, Russell T, Ranola M, Ward C, **Halliday GM** (2012) Reduced T helper and B lymphocytes in Parkinson's disease. J. Neuroimmunol. 252:95-99.
386. Valenzuela MJ, Matthews FE, Brayne C, Ince P, **Halliday G**, Kril JJ, Dalton MA, Richardson K, Forster G, Sachdev PS, MRC CFAS (2012) Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol. Psychiatry 71:783-91.
387. Wong J, Garner B, **Halliday GM**, Kwok JBJ (2012) Srp20 regultes TrkB premRNA splicing to generate TrkB-Shc transcripts with implication for Alzheimer's disease. J. Neurochem. 123:159-171.
388. Wong J, Higgins M, **Halliday G**, Garner B (2012) Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience 210:363-374.
389. Cheng D, Jenner AM, Guanghou S, Mitchell TW, Nealon JR, Kim WS, McCann H, Wenk WR, **Halliday GM**, Garner B (2011) Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One 6:e17299.
390. Chen-Plotkin AS, Martinez-Lage M, Sleiman PMA, Hu W, Greene R, McCarty Wood E, Bing S, Murray Grossman M, Schellenberg G, Kimmo H, Weiner MF, White CL, Brooks W, **Halliday GM**, Kril JJ, Gearing M, Beach TG, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering-Brown SM, Snowden J, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Lladó A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IRA, Feldman HH, Hamilton RL, Cruts M, Engelborghs S, De Deyn PP, Van Broeckhoven C, Mayeux R, Vonsattel JPG, Bird TD, Cairns NJ, Goate A, Frosch MP, Riederer PF, Bogdanovic N, Lee VMY, Trojanowski JQ, Van Deerlin VM (2011) Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch. Neurol. 68:488-97.
391. Elliott DA, Tsoi K, Holinkova S, Chan SL, Kim WS, **Halliday GM**, Rye K-A, Jans DA, Garner B (2011) Isoform-specific proteolysis of apolioprotein-E in the brain. Neurobiol. Aging 32:257-271.
392. **Halliday GM**, Holton J, Revesz T, Dickson D (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122:187-204.
393. **Halliday G**, Lees A, Stern M (2011) Milestones in Parkinson's disease – Clinical and pathologic features. Mov. Disord. 26:1015-1021.
394. **Halliday GM**, Song YJC, Harding AJ (2011) Striatal □-amyloid in dementia with Lewy bodies but not Parkinson's disease. J. Neural Transm. 118:713-719.
395. **Halliday GM**, Stevens C (2011) Glia: Initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 26:6-17.
396. Huang Y, Chen S, Wenning G, Golbe L, Wang S, Wang Y, Zhao G, Lv P, Song YJC, Lees A, Litvan I, Chen B, **Halliday G** (2011) Atypical parkinsonian disorders. Chin. J. Contemp. Neurol. Neurosurg. 11:7-14.
397. Huang Y, Rowe DB, **Halliday GM** (2011) Interaction between α-synuclein and tau geneotypes and the progression of Parkinson's disease. Journal of Parkinson's Disease 1:271–276.
398. Huang Y, Zheng L, **Halliday G**, Dobson-Stone C, Wang Y, Tang H, Cao L, Deng Y, Wang G, Zhang Y, Wang J, Hallup M, Kwok J, Chen S-D (2011) Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. Curr. Alzheimer Res. 8:765-70.
399. Komadina NC, Terpening Z, Huang Y, **Halliday GM**, Naismith SL, Lewis SJG (2011) The utility and limitations of the Addenbrooke's Cognitive Examination – Revised for detecting mild cognitive impairment in Parkinson's disease. Dement. Geriatr. Cog. Disord. 31:349-357.
400. Kril JJ, **Halliday GM** (2011) Pathological staging of frontotemporal lobar degeneration. J. Mol. Neurosci. 45:379–383.
401. Masters C, Kril K, **Halliday G**, Pamphlett R, Collins S, Hill A, McLean C (2011) Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology 43:93-102.
402. Piguet O, Petersén Å, Lam BYK, Gabery S, Murphy K, Hodges JR, **Halliday GM** (2011) Eating and hypothalamus changes in behavioural-variant frontotemporal dementia. Ann. Neurol. 69:312-319.
403. Piguet O, **Halliday GM**, Reid WGJ, Casey BJ, Carmen R, Huang Y, Hodges JR, Kril JJ (2011) Clinical phenotypes of autopsy-confirmed Pick's disease. Neurology 76:253259.

404. Reid WGJ, Hely MA, Morris JGL, Loy C, **Halliday GM** (2011) Dementia in Parkinson's disease: A 20 year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatry 82:1033-1037.
405. Schofield EC, Hodges J, Macdonald V, Cordato NJ, Kril JJ, **Halliday GM** (2011) Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov. Disord. 26:256-63.
406. Shine JM, **Halliday GM**, Naismith SL, Lewis SJL (2011) Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks? Mov. Disord. 26:2154-2159.
407. Song YJC, Huang Y, **Halliday GM** (2011) Clinical correlates of similar pathologies in parkinsonian syndromes. Mov. Disord. 26:499-506.
408. Zhou J, Broe M, Huang Y, Anderson JP, Gai WP, Milward EA, Porritt M, Howells D, Hughes AJ, Wang X, **Halliday GM** (2011) Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol. 121:695-704.
409. Double KL, **Halliday GM**, Dunkley PR, Dickson PW, Gerlach M, Riederer P (2010) Pigmentation in the human brain and risk of Parkinson's disease. Letter. Ann. Neurol. 67:553-554.
410. Double KL, Reyes S, Werry EL, **Halliday GM** (2010) Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions? Prog. Neurobiol. 92:316-329.
411. Elliott DA, **Halliday GM**, Garner B (2010) Apolipoprotein-E dimers in human frontal cortex and hippocampus. BMC Neuroscience 11:23.
412. Gabery S, Murphy K, Schultz K, Loy C, McCusker E, Kirik D, **Halliday G**, Petersén A (2010) Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol. 120:777-88.
413. **Halliday GM**, McCann H (2010) The progression of pathology in Parkinson's disease. Ann. N.Y. Acad. Sci. 1184:188-195.
414. Kågedal K, Kim WS, Appelqvist H, Chan S, Cheng D, Hellström L, Barnham K, McCann H, **Halliday G**, Garner B (2010) Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim. Biophys. Acta 1801:831-838.
415. Kim WS, Bhatia S, Elliott DA, Hellström L, Kägedal K, McCann H, **Halliday GM**, Barnham KJ, Garner B (2010) Increased ATP-binding casette A1 expression in Alzheimer's disease hippocampal neurons. J. Alzheimers Dis. 21:193-205.
416. Kordower J, **Halliday G,** Obeso JA (2010) Reply to: "Being too inclusive about synuclein inclusions". Nature Med. 16:261.
417. Loy CT, Kril JJ, Trollor J, Kiernan MC, Kwok JBJ, **Halliday GM**, Hodges JR (2010) A 48 year- old woman with bizarre and complex delusions. Case report. Nat. Rev. Neurol. 6:175-179.
418. Loy CT, McCusker E, Kril JJ, Kwok JBJ, Brooks WS, McCann H, Isaacs A, **Halliday GM** (2010) Very early onset FTD with no family history predicts underlying FUS pathology. Letter. Brain 133:e158; author reply e159
419. Luty AA, Kwok JBJ, Dobson-Stone C, Loy C, Karlström H, Sobow T, Tchorzewska J, Maruszak A, Barcikowska M, Panegyres PK, Zekanowski C, Brooks WS, Williams KL, Blair IP, **Halliday GM**, Schofield PR (2010) Sigma nonopoid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann. Neurol. 68:639-649.
420. Ma J-F, Huang Y, Chen S-D, **Halliday GM** (2010) Immunohistochemical evidence for macroautophagy in neurons and endothelial cells in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 36:312-319.
421. Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, **Halliday G**, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJM, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DMA (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119:1-4.
422. Mitew S, Kirkcaldie MTK, **Halliday GM**, Shepherd CE, Vickers JC, Dickson TC (2010) Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol. 119:567-577.
423. Obeso JA, Rodríguez-Oroz MC, Goetz CG, Marin C, Kordower J, Rodríguez M, Hirsch EC, Farrer M, Schapira AH, **Halliday G** (2010) Missing pieces in the Parkinson's disease puzzle. Nature Med. 16:653-661.
424. Schofield EC, **Halliday GM**, Kwok J, Loy C, Hodges JR (2010) Low serum progranulin predicts the presence of mutations: a prospective study. J. Alz. Dis. 22:981-984.

425. Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, Seelaar H, Van Swieten JC, Brown JM, Johannsen P, Nielsen JE, Holm IE, The FReJA Consortium, Dickson DW, Rademakers R, Graff-Radford NR, Parisi JE, Petersen RC, Hatanpaa KJ, White CL, Weiner MF, Geser F, Van Deerlin VM, Trojanowski JQ, Miller BL, Seeley WW, van der Zee J, Kumar-Singh, S, Engelborghs S, De Devn PP, Van Broeckhoven C, Bigio EH, Deng HX, **Halliday GM**, Kril JJ, Munoz DG, Mann DM, Pickering-Brown SM, Doodeman V, Adamson G, Ghazi-Noori S, Fisher EMC, Holton JL, Revesz T, Rossor MN, Collinge J, Mead S, Isaacs AM (2010) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 120:33-41.
426. Van Deerlin VM, Sleiman PMA, Martinez-Lage M, Chen-Plotkin A, Wang L-S, Graff-Radford NR, Dickson D, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DMA, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulum M, al-Sarraj S, Troakes C, Rosenberg RN, White CL, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, de Munain AL, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IRA, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JPG, Troncoso JC, Kril JJ, Kwok JBJ, **Halliday GM**, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tunón MT, Martínez MCC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM-Y (2010) Common variants at 7p21 are associated with frontotemporal degeneration with TDP-43 inclusions. Nat. Genet. 42:234-239.
427. Werry EL, Enjeti S, **Halliday GM**, Sachdev PS, Double KL (2010) Effect of age on proliferation-regulating factors in human adult neurogenesis regions. J. Neurochem. 115:956-64.
428. Brooks D, **Halliday GM** (2009) Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res. Bull. 78:97-104.
429. Davies RR, **Halliday GM**, Xuereb JH, Kril JJ, Hodges JR (2009) The neural basis of semantic memory: evidence from semantic dementia. Neurobiol. Aging 30:20432052.
430. Dickson DW, Braak H, Duda J, Duyckaerts C, Gasser T, **Halliday G**, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8:1150-1157.
431. Double KL, Rowe DB, Carew-Jones F, Hayes M, Chan DKY, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, Riederer P, Gerlach M, **Halliday GM** (2009) Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp. Neurol. 217:297-301.
432. Grünblatt E, Monoranu CM, Apfelbacher M, Keller D, Michel TM, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, McLean C, **Halliday GM,** Harper C, Deckert J, Roggendorf W, Riederer P (2009) Tryptophan is a marker of human postmortem brain tissue quality. J. Neurochem. 110:1400-1408.
433. **Halliday GM** (2009) Thalamic changes in Parkinson's disease. Parkinson. Rel. Dis. 15 Suppl. 3:S152-S155
434. **Halliday G**, Herrero MT, Murphy K, McCann H, Ros-Bernal F, Barcia C, Mori H, Blesa FJ, Obeso J (2009) No Lewy pathology in monkeys with over 10 years of severe MPTP parkinsonism. Mov. Disord. 24:1519-23.
435. Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, **Halliday G**, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJM, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DMA (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 117:15-8.
436. Mehta P, Mellick GD, Rowe DB, **Halliday GM**, Jones MM, Nanwaring N, Vandebona H, Silburn PA, Wang JJ, Mitchell P, Sue CM (2009) Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Mov. Disord. 24:290-292.
437. Mevawalla N, Fung V, Morris JGL, **Halliday GM** (2009) Unilateral rest tremor in vascular parkinsonism associated with a contralateral lesion of the locus coeruleus. Mov. Disord. 24:1242-1244.

438. Monoranu CM, Apfelbacher M, Grünblatt E, Puppe B, Alafuzoff I, Ferrer I, AlSaraj, S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, **Halliday G**, Kril J, Harper C, McLean C, Riederer P, Roggendorf W (2009) pH measurement as quality control on human postmortem brain tissue: A study of the BrainNet Europe Consortium. Neuropathol. Appl. Neurobiol. 35:329-337.
439. Piguet O, Double KL, Kril JJ, Harasty JA, Macdonald V, McRitchie DA, **Halliday GM** (2009) White matter loss in healthy ageing: a postmortem analysis. Neurobiol. Aging 30:1288-1295.
440. Piguet O, **Halliday GM**, Creasey H, Broe GA, Kril JJ (2009) Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. Int. Psychogeriatr. 21:688-695.
441. Shepherd C, McCann H, **Halliday G** (2009) Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol. 118:37-52.
442. Sokolova A, Hill MD, Rahimi F, Warden LA, **Halliday GM**, Shepherd CE (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 19:392-398.
443. Song YJC, **Halliday GM**, Holton JL, Lashley T, O'Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz TR (2009) Degeneration in different parkinsonian syndromes relates directly to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 68:1073-83.
444. Sutherland GT, **Halliday GM**, Silburn PA, Mastaglia FL, Rowe DB, Boyle RS, O'Sullivan JD, Ly T, Wilton SD, Mellick GD (2009) Do polymorphisms in the familial parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov. Disord. 24:833-838.
445. Truong L, Brooks D, Amaral F, Henderson JM, **Halliday GM** (2009) Relative preservation of thalamic centromedian nucleus in Parkinsonian patients with dystonia. Mov. Disord. 24:2128-2135.
446. Van Eersel J, Bi M, Ke YD, Hodges JR, Xureb JH, Gregory GC, **Halliday GM**, Götz J, Kril JJ, Ittner LM (2009) Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J. Neural Transm. 116:1243-51
447. Woodhouse A, Shepherd CE, Sokolova A, Carroll VL, King AE, **Halliday GM**, Dickson TC, Vickers JC (2009) Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease. Acta Neuropathol. 117:19-29.
448. Double KL, Dedov VN, Fedorow H, Kettle E, **Halliday GM**, Garner B, Brunk U (2008) The comparative biology of neuromelanin and lipofuscin in the human brain. Cell. Mol. Life Sci. 65:1669-1682.
449. **Halliday GM** (2008) Clarifying the pathological progression of Parkinson's disease. Editorial. Acta Neuropathol. 115:377-378.
450. **Halliday G**, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally-followed patients with Parkinson's disease. Acta Neuropathol. 115:409415.
451. **Halliday GM**, McCann H (2008) Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms. Exp. Neurol. 209:12-21.
452. Hely MA, Reid WGJ, Adena MA, **Halliday GM**, Morris JGL (2008) The Sydney Multicentre Study of Parkinson's disease: The inevitability of dementia at 20 years. Mov. Disord. 23:837-844.
453. Huang Y, **Halliday G**, Chen S-D, Hodges J (2008) Frontotemporal lobe degeneration. Chin. J. Neurol. 41:851-855.
454. Huang Y, Song YJC, Murphy K, Revesz, T, Holton JL, Lashley T, Gai WP, **Halliday GM** (2008) LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol. 116:639-46.
455. Karlstrom H, Brooks WS, Kwok JBJ, Broe GA, Kril JJ, McCann H, **Halliday GM**, Schofield PR (2008) Variable phenotype of Alzheimer's disease with spastic paraparesis. J. Neurochem. 104:573-583.
456. Luty AA, Kwok JBJ, Thompson EM, Blumbergs P, Brooks WS, Loy CT, DobsonStone C, Panegyres PK, Hecker J, Nickolson GA, **Halliday GM**, Schofield PR (2008) Pedigree with frontotemporal lobar degeneration – motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurology 8:32.
457. Murphy K, Karaconji T, Hardman C, **Halliday G** (2008) Excessive dopamine neuron loss in progressive supranuclear palsy. Mov. Disord. 23:607-610.
458. Sutherland G, Mellick G, Newman J, Double KL, Stevens J, Lee L, Rowe D, Silburn P, **Halliday GM** (2008) Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. Am. J. Genet. B 147B:495-499.
459. Young V, **Halliday GM**, Kril JJ (2008) Neuropathologic correlates of white matter hyperintensities. Neurology 71:804-811.

460. Behnke S, Double KL, Duma S, Broe GA, Guenther V, Becker G, **Halliday GM** (2007) Substantia nigra echomorphology in a healthy very old population: correlation with motor slowing. Neuroimage 34:1054-1059.
461. Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Lee VMY, Hatanpaa KJ, White CL, Schneider JA, Grinberg LT, **Halliday G**, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DMA (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114:5-22.
462. Dedov VN, Griffiths FM, Garner B, **Halliday GM**, Double KL (2007) Lipid content determines aggregation of neuromelanin granules *in vitro*. J. Neural Transm. Suppl. 72:35-38.
463. **Halliday G** (2007) Clinicopathological aspects of motor parkinsonism. Parkinsonism Relat. Disord. 13:S208-S210.
464. Huang Y, **Halliday GM**, Vandebona H, Mellick GD, Mastaglia F, Stevens J, Kwok J, Garlepp M, Silburn P, Horne MK, Kotschet K, Venn A, Rowe DB, Rubio JP, Sue CM (2007) Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov. Disord. 22:982-989.
465. Kipps CM, Davies RR, Mitchell J, Kril JJ, **Halliday GM**, Hodges JR (2007) Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dementia Geriatr. Cog. Disord. 23:334-342.
466. Litvan I, **Halliday G**, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet M-F, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, Jenner P, Melamed E, Myers RH, Parker D, Price DL (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol. 66:251-257.
467. Litvan I, Chesselet M-F, Gasser T, Di Monte DA, Parker D, Hagg T, Hardy J, Jenner P, Myers RH, Price DL, Hallett M, Langston WJ, Lang AE, **Halliday G**, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J. Neuropathol. Exp. Neurol. 66:329-336.
468. Qi BC, Huang Y, Rowe D, **Halliday G** (2007) VISA – a pass to innate immunity. Int. J. Biochem. Cell Biol. 39:287-291.
469. Shepherd CE, Grace E, Mann DMA, **Halliday GM** (2007) Relationship between neuronal cell loss and 'inflammatory plaques' in early-onset Alzheimer's disease. Neuropath. Appl. Neurobiol. 33:328-333.
470. Song YJC, Lundvig DMS, Huang Y, Gai WP, Blumbergs PC, Højrup P, Otzen D, **Halliday GM**, Jensen PH (2007) P25α relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am. J. Pathol. 171:1291-1303.
471. Sutherland G, Mellick G, Sue C, Chan DKY, Lee L, Rowe D, Silburn P, **Halliday G** (2007) A functional polymorphism in the parkin gene promotor affects the age of onset of Parkinson's disease. Neurosci. Lett. 414:170-173.
472. Sutherland GT, Nowk G, **Halliday GM**, Kril JJ (2007) Tau isoform expression in frontotemporal dementia without tau deposition. J. Clin. Neurosci. 14:1182-1185.
473. Taylor JM, Song YJC, Huang Y, Farrer MJ, Delatycki M, **Halliday GM**, Lockhart PJ (2007) PArkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases. Neurobiol. Dis. 27:238-247.
474. Baker K, Huang Y, McCann H, Gai WP, Jensen PH, **Halliday GM** (2006) P25α immunoreactive but α-synuclein immunonegative neuronal inclusions in multiple system atrophy. Letter. Acta Neuropathol. 111:193-195.
475. Bennett HP, Piguet O, Grayson DA, Creasey H, Waite LM, Lye T, Corbett AJ, Hayes M, Broe GA, **Halliday GM** (2006) Cognitive, extrapyramidal and MRI predictors of functional impairment in non-demented older community dwellers: the Sydney Older Person Study. J. Am. Geriatr. Soc. 54:3-10.
476. Cordato NJ, **Halliday GM**, Caine D, Morris JGL (2006) Comparison of motor, cognitive and behavioural features in progressive supranuclear palsy and Parkinson's disease. Mov. Disord. 21:632-638.
477. David D, Ittner LM, Gehrig P, Nergenau D, Shepherd C, **Halliday G**, Götz J (2006) β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 6:65666577.

478. Davies RR, Kipps CM, Mitchell J, Kril JJ, **Halliday GM**, Hodges JR (2006) Progression in frontotemporal dementia: identifying a benign behavioural variant by magnetic resonance imaging. Arch. Neurol. 63:1627-1631.
479. de Silva R, Lashley T, Strand C, Shiarli A-M, Shi J, Tian JZ, Bailey KL, Davies P, Bigio EH, Arima K, Iseki E, Murayama S, Kretzchmar H, Neumann M, Lippa C, **Halliday G**, MacKenzie J, Ravid R, Dickson D, Wszolek Z, Iwatsubo T, Pickering-Brown SM, Holton J, Lees A, Revesz T, Mann DMA (2006) An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol. 111:329-340.
480. Double KL, **Halliday GM** (2006) New face of neuromelanin. J. Neural Transm. Suppl. 70:119-123.
481. Fedorow H, Garner B, Pickford R, Hook JM, Kettle E, Cartwright M, **Halliday GM**, Gerlach M, Riederer P, Double KL (2006) Investigations of the lipid component of neuromelanin. J. Neural Transm. 113:735-739.
482. Fedorow H, **Halliday GM**, Rickert C, Gerlach M, Riederer P, Double KL (2006) Evidence for specific phases in the development of human neuromelanin. Neurobiol. Aging 27:506-12.
483. Gregory GC, Macdonald V, Schofield PR, Kril JJ, **Halliday GM** (2006) Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol. Aging 27:387-93.
484. **Halliday GM**, Del Tredici K, Braak H (2006) Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J. Neural Transm. Suppl. 70:99-103.
485. **Halliday GM**, Fedorow H, Rickert CH, Gerlach M, Riederer R, Double KL (2006) Evidence for specific phases in the development of human neuromelanin. J. Neural Transm. 113:721-728.
486. **Halliday GM**, Song YJ, Creasey H, Morris JG, Brooks WS, Kril JJ (2006) Neuropathology in the S305S tau gene mutation. Letter. Brain 129:e40.
487. Huang Y, Hayes M, Harding AJ, Brooks WS, Fung VSC, Rowe D, Joffe R, Crimmins D**,** Hely M, **Halliday GM** (2006) Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. Parkinsonism & Related Disorders 12:309-313.
488. Kersaitis C, **Halliday GM**, Xeureb JH, Pamphlett RS, Hodges JR, Kril JJ (2006) Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neuron disease identifies a group with mainly early pathology. Neuropathol. Appl. Neurobiol. 32:83-91.
489. Pickering-Brown SM, Baker M, Gass J, Boeve B, Dickson D, Loy CT, Brooks WS, Martins RN, Kwok JBJ, **Halliday GM**, Kril J, Schofield PR, Mann DMA, Hutton M (2006) Mutations in progranulin explain atypical phenotypes with associated with variants in MAPT. Letter. Brain 129:3124-3126.
490. Piguet O, Bennett HP, Waite LM, Kril JJ, Creasey H, Grayson DA, Broe GA, **Halliday GM** (2006) Preserved cognition and functional independence after a large right posterior cerebral artery infarct: longitudinal clinical and neuropathological findings. Neurocase 12:81-90.
491. Rahimi F, Shepherd CE, **Halliday GM**, Geczy CL, Raftery MJ (2006) Antigenepitope retrieval to facilitate proteomic analysis of formalin-fixed archival brain tissue. Anal. Chem. 78:7216-7221.
492. Shepherd CE, Goyette J, Utter V, Yang Z, Geczy CL, **Halliday GM** (2006) Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. Neurobiol. Aging 27:1554-1563.
493. Shiarli AM, Jennings R, Shi J, Bailey K, Davidson Y, Tian J, Bigio EH, Ghetti B, Murrell JR, Delisle MB, Mirra S, Crain B, Zolo P, Arima K, Iseki E, Murayama S, Kretzschmar H, Neumann M, Lippa C, **Halliday G**, MacKenzie J, Khan N, Ravid R, Dickson D, Wszolek Z, Iwatsubo T, Pickering-Brown SM, Mann DMA (2006) Comparison of the extent of tau pathology in patients with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathol. Appl. Neurobiol. 32:374-387.
494. Broe M, Shepherd CE, Mann DMA, Milward EA, Gai WP, Thiel E, **Halliday GM** (2005) Insoluble α-synuclein in Alzheimer's disease without Lewy body formation. Neurotox. Res. 7:69-76.
495. Cordato NJ, Duggins AJ, **Halliday GM**, Morris JGL, Pantelis C (2005) Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain 128:1259-1266.
496. Davies RR, Hodges JR, Kril JJ, Patterson K, **Halliday GM**, Xuereb JH (2005) The pathological basis of semantic dementia. Brain 128:1984-1995.

497. Fedorow H, Pickford R, Hook JM, Double KL, **Halliday GM**, Gerlach M, Riederer P, Garner B (2005) Dolichol is the major lipid component of human substantia nigra neuromelanin. J. Neurochem. 92:990-995.
498. Fedorow H, Tribl F, **Halliday G**, Gerlach M, Riederer P, Double KL (2005) Neuromelanin in human dopaminergic neurons: Comparative biology with peripheral melanins and relevance to Parkinson's disease. Prog. Neurobiol. 75:109-124.
499. Graham A, Davies R, Xuereb J, **Halliday G**, Kril J, Creasey H, Graham K, Hodges J (2005) Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 128:597-605.
500. Gregory GC, **Halliday GM** (2005) What is the dominant A species in human brain tissue? A review. Neurotox. Res. 7:29-41.
501. **Halliday G** (2005) The emergence of proto-objects in complex visual hallucinations. Commentary. Behavioral Brain Sciences 28:767-768.
502. **Halliday GM** (2005) Clarifying Lewy body parkinsonism with visual hallucinations. Editorial. Lancet Neurol. 45:588-589.
503. **Halliday GM**, Macdonald V, Henderson JM (2005) A comparison of degeneration in the motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 128:2272-2280.
504. **Halliday GM,** Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL (2005) α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128:2654-2664.
505. **Halliday GM**, Song YJC, Lepar G, Brooks WS, Kwok JB, Kersaitis C, Gregory G, Shepherd CE, Rahimi F, Schofield PR, Kril JJ (2005) Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann. Neurol. 57:139-143.
506. Huang Y, Garrick R, Cook R, O'Sullivan D, Morris J, **Halliday GM** (2005) Pallidal stimulation reduces treatment-induced dyskinesias in "minimal-change" multiple system atrophy. Mov. Disord. 20:1042-1047.
507. Kril JJ, Macdonald V, Patel S, Png F, **Halliday GM** (2005) Distribution of brain atrophy in behavioural variant frontotemporal dementia. J. Neurol. Sci. 232:83-90. 429. Kwok JBJ, Hallupp M, Loy C, Chan DKY, Woo J, Mellick GD, Buchanan DD, Silburn PA, **Halliday GM**, Schofield PR (2005) GSK3ß polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 58:829-839.
508. Lepar G, Harding AJ, Kwok JBJ, **Halliday GM** (2005) Inheritance of dementia with Lewy bodies: comment and review of the literature. Curr. Trends Neurol. 1:5166.
509. Li J, Scheller C, Koutsilieri E, Griffiths F, Beart P, Mercer L, **Halliday G**, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL (2005) Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J. Neurochem. 95:599-608.
510. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda J, Lippa C, Perry EK, Aarsland D, Arai H, Ballard GC, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, **Halliday G**, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, for the Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863-1872.
511. Orr CF, Rowe DB, Mizuno Y, Mori H, **Halliday GM** (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128:2665-2674.
512. Osborne PB, **Halliday GM**, Cooper HM, Keast JR (2005) Localization of immunoreactivity for deleted in colorectal cancer (DCC), for the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience 131:671-681.
513. Raftery M, Campbell R, Glaros E, Rye, K-A, **Halliday GM**, Jessup W, Garner B (2005) Phosphorylation of apolipoprotein-E at an atypical CK2 PSD/E site *in vitro*. Biochemistry 44:7346-7353.
514. Schofield EC, Caine D, Kril JJ, Cordato NJ, **Halliday GM** (2005) Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Mov. Disord. 20:34-39.
515. Shepherd CE, Gregory GC, Vickers JC, **Halliday GM** (2005) Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. Neuropathol. Appl. Neurobiol. 31:503-511.

516. Aarsland D, Ballard C, **Halliday G** (2004) Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J. Geriatr. Psychiatr. Neurol. 17:137145.
517. Broe M, Kril J, **Halliday GM** (2004) Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 127:2214-2220.
518. Brooks WS, Kwok JBJ, **Halliday GM**, Godbolt A, Rossor MN, Creasey H, Jones AO, Schofield PR (2004) Hemorrhage is uncommon in a new Alzheimer family with the Flemish amyloid precursor protein mutation. Neurology 63:1613-1617.
519. Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, **Halliday GM** (2004) Identification of families with cortical Lewy body disease. Am. J. Med. Genet. 128B:118-122.
520. Henderson J, Rodriguez M, O'Sullivan D, Pell M, Fung V, Benabid AL, **Halliday G** (2004) Partial lesion of the thalamic ventral intermediate nucleus after chronic high frequency stimulation. Mov. Disord. 19:709-711.
521. Hodges JR, Davies R, Xuereb J, Casey B, Broe M, Bak T, Kril J, **Halliday GM** (2004) Clinicopathological correlates in frontotemporal dementia. Ann. Neurol. 56:399-406.
522. Huang Y, Cheung L, Rowe DB, **Halliday GM** (2004) Genetic contributions to Parkinson's disease. Brain Res. Rev. 46:44-70.
523. Kersaitis C, **Halliday GM**, Kril JJ (2004) Regional and cellular pathology in frontotemporal dementia: Relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol. 108:515-523.
524. Kril JJ, **Halliday GM** (2004) Clinicopathological staging of frontotemporal dementia severity: correlation with regional atrophy. Dement. Geriatr. Cog. Disord. 17:311-315.
525. Kril JJ, Hodges J, **Halliday G** (2004) Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. Neurosci. Lett. 361:9-12.
526. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda J, Feldman H, Gauthier S, **Halliday G**, Lawlor B, Lippa C, Lopez O, Machado J, O'Brien J, Payfer J, Reid W (2004) Dementia with Lewy bodies. Lancet Neurol. 3:19-28.
527. Meredith GE, **Halliday GM**, Totterdell S (2004) A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: New insights into Lewy body formation. Parkinsonism & Related Disorders 10:191-202.
528. Piguet O, Brooks WS, **Halliday GM**, Schofield PR, Stanford PM, Kwok JBJ, Spillantini MG, Yankopoulou D, Nestor PJ, Broe GA, Hodges JR (2004) Similar early clinical presentations in familial and non-familial frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 75:1743-1745.
529. Shepherd CS, Gregory GC, Vickers JC, Brooks WS, Kwok JBJ, Schofield PR, Kril JJ, **Halliday GM** (2004) Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol. Dis. 15:115-119.
530. Stanford PM, Brooks WS, Teber ET, Hallup M, McLean C, **Halliday GM**, Martins RN, Kwok JBJ, Schofield PR (2004) Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J. Neurol. 251:1098-1104.
531. Bennett HP, Piguet O, Grayson DA, Creasey H, Waite LM, Broe GA, **Halliday GM** (2003) A 6-year study of cognition and spatial function in the demented and nondemented elderly: the Sydney Older Persons Study. Dement. Geriatr. Cog. Disord. 16:181-186.
532. Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, **Halliday GM** (2003) Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 60:1005-1011.
533. Caramins M, **Halliday G**, McCusker E, Trent RJ (2003) Genetically confirmed clinical Huntington's disease with no observable cell loss. J. Neurol. Neurosurg. Psychiatry 74:968-970.
534. Double KL, Rowe DB, Hayes M, Chan DKY, Blackie J, Corbett A, Fung V, Morris J, **Halliday GM** (2003) Identifying the pattern of olfactory deficits in Parkinson's disease using the Brief Smell Identification Test. Arch. Neurol. 60:545-549.
535. Double KL, **Halliday GM**, Henderson J, Griffiths FM, Heinemann T, Riederer P, Gerlach M (2003) The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp. Neurol. 184:530-535.
536. **Halliday GM**, Double KL, Macdonald V, Kril JJ (2003) Identifying severely atrophic cortical subregions in Alzheimer's disease. Neurobiol. Aging 24:797-806.
537. Harasty J, Seldon HL, Chan P, **Halliday G**, Harding A (2003) The left human speech-processing cortex is thinner but longer than the right. Laterality 8:247-260. 460.

538. Henderson JM, Watson S, **Halliday GM**, Heinemann T, Gerlach M (2003) Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav. Brain Res. 139:105-113.
539. Henderson JM, Lu Y, Wang S, Cartwright H, **Halliday GM** (2003) Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J. Neurol. Neurosurg. Psychiatry 74:956-958.
540. Hodges JR, Davies R, Xuereb J, Kril J, **Halliday G** (2003) Survival in frontotemporal dementia. Neurology 61:349-354.
541. Kwok JBJ, **Halliday GM**, Brooks WS, Dolios G, Laudon H, Murayama O, Hallup M, Badenhop RF, Vickers J, Wang R, Naslund J, Gandy SE, Takashima A, Schofield PR (2003) Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J. Biol. Chem. 278:67486754.
542. Schofield E, Kersaitis C, Shepherd CE, Kril JJ, **Halliday GM** (2003) Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain 126:827-840.
543. Stanford PM, Shepherd CE, **Halliday GM**, Brooks WS, Schofield P, Brodaty H, Martins RN, Kwok JBJ, Schofield PR (2003) Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain 126:814-826.
544. Cordato NJ, Pantelis C, **Halliday GM**, Velakoulis D, Wood SJ, Currie J, Soo M, Olivieri G, Broe GA, Morris JGL (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125:789-800.
545. **Halliday G**, Ng T, Rodriguez M, Harding A, Blumbergs P, Evans W, Fabian V, Fryer J, Gonzales M, Harper C, Kalnins R, Masters CL, McLean C, Milder DG, Pamphlett R, Scott G, Tannenberg A, Kril J (2002) Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathol. 104:72-78.
546. Harding AJ, Lakay B, **Halliday GM** (2002) Selective hippocampal neuron loss in dementia with Lewy bodies. Ann. Neurol. 51:125-128.
547. Harding AJ, Broe GA, **Halliday GM** (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125:391-403.
548. Harding AJ, Stimson E, Henderson JM, **Halliday GM** (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125:2431-2445.
549. Hardman CD, Henderson J, Finkelstein DI, Paxinos G, Horne MK, **Halliday GM** (2002) Comparison of the basal ganglia in rats, marmosets, macaques, baboons and humans: volume and neuronal number for the output, internal relay and striatal modulating nuclei. J. Comp. Neurol. 445:238-255.
550. Henderson JM, Pell M, O'Sullivan DJ, McCusker EA, Fung, V, Hedges P, **Halliday GM** (2002) Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov. Disord. 17:133-137.
551. Kril JJ, Patel S, Harding AJ, **Halliday GM** (2002) Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol. 103:370-376.
552. Kril JJ, Patel S, Harding AJ, **Halliday GM** (2002) Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. J. Neurol. Neurosurg. Psychiatry 72:747-751.
553. Macdonald V, **Halliday GM** (2002) Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov. Disord. 17:1166-1173.
554. Macdonald V, **Halliday G** (2002) Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol. Dis. 10:378-386.
555. Münch G, Shepherd C, McCann H, Brooks WS, Kwok JBJ, Arendt T, Hallupp M, Schofield P, Martins R, **Halliday GM** (2002) Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. Neuroreport 13:601-604.
556. Orr CF, Rowe DB, **Halliday GM** (2002) An inflammatory review of Parkinson's disease. Prog. Neurobiol. 68:325-340.
557. Shepherd CE, Thiel E, McCann H, **Halliday GM** (2002) Neurofilamentimmunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol. Dis. 9:249-257.
558. Broe M, Shepherd CE, Milward EA, **Halliday GM** (2001) Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 101:616-624.

559. Caine D, Patterson K, Hodges JR, Heard R, **Halliday G** (2001) Severe anterograde amnesia with extensive hippocampal degeneration in a case of rapidly progressive frontotemporal dementia. Neurocase 7:57-64.
560. Cordato NJ, **Halliday GM**, McCann H, Davies L, Williamson P, Fulham M, Morris JGL (2001) Corticobasal syndrome with tau pathology. Mov. Disord. 16:656-667.
561. **Halliday GM** (2001) A review of the neuropathology of schizophrenia. Clin. Exp. Pharm. Physiol. 28:64-65.
562. **Halliday G**, Kril J (2001) Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease-In reply. Letter. Arch. Neurol. 58:518519.
563. **Halliday G**, Shepherd C (2001) Cortical inflammation in dementia with Lewy bodies-In reply. Letter. Arch. Neurol. 58:519-520.
564. Harasty JA, **Halliday GM**, Xuereb J, Croot K, Bennett H, Hodges JR (2001) Cortical degeneration associated with phonologic and semantic language impairments in AD. Neurology 56:944-950.
565. Harding AJ, **Halliday GM** (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 102:355-363.
566. Henderson JM, Gai WP, Hely MA, Reid WGJ, Walker G, **Halliday GM** (2001) Parkinson's disease with late Pick's dementia. Mov. Disord. 16:311-319.
567. Henderson JM, O'Sullivan DJ, Pell M, Fung VSC, Hely MA, Morris JGL, **Halliday GM** (2001) Lesion of thalamic centromedian-parafascicular complex after chronic deep brain stimulation. Neurology 56:1576-1579.
568. Kril JJ, **Halliday GM** (2001) Alzheimer's disease: its diagnosis and pathogenesis. Int. Rev. Neurobiol. 48:167-217.
569. Shepherd CE, Thiel E, McCann H, **Halliday GM** (2001) Neurofilamentimmunoreactive neurons are not selectively vulnerable in Alzheimer's disease. Neurobiol. Dis. 8:136-146.
570. Spira PJ, Sharpe DM, **Halliday G**, Cavanagh J, Nicholson GA (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann. Neurol. 49:313-9.
571. Stanford PM, **Halliday GM**, Brooks WS, Kwok JBJ, Schofield P (2001) Progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17 and familial tauopathies. Letter. Brain 124:1666-1670.
572. Broe GA, Grayson DA, Creasey H, Waite LM, Casey B, Bennett HP, Brooks WS, **Halliday GM** (2000) Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol. 57:1586-91.
573. Cordato NJ, **Halliday GM**, Harding AJ, Hely MA, Morris JGL (2000) Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann. Neurol. 47:718-728.
574. Eyles DW, Pond SM, Van der Schyf CJ, **Halliday GM** (2000) Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. Life Sci. 66:1345-1350.
575. **Halliday G**, Robinson S, Shepherd C, Kril J (2000) Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharm. Physiol. 27:1-8.
576. **Halliday GM**, Hardman CD, Cordato N, Hely M, Morris JGL (2000) A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain 123:724-732.
577. **Halliday GM**, Shepherd CE, McCann H, Reid WGJ, Grayson DA, Broe GA, Kril JJ (2000) Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch. Neurol. 57:831-836.
578. Harding A, **Halliday G**, Caine D, Kril J (2000) Degeneration of the anterior thalamic nuclei differentiates alcoholics with the amnesia. Brain 123:141-154.
579. Harding AJ, Kril JJ, **Halliday GM** (2000) Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathol. 99:199208.
580. Henderson JM, Carpenter K, Cartwright H, **Halliday GM** (2000) Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann. Neurol. 47:345-352.
581. Henderson JM, Carpenter K, Cartwright H, **Halliday GM** (2000) Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123:1410-1421.
582. Opeskin K, Kalins RM, **Halliday G**, Cartwright H, Berkovic SF (2000) Idiopathic generalised epilepsy: lack of significant microdysgenesis. Neurology 55:1101-1106.

583. Shepherd CE, Thiel E, McCann H, Harding AJ, **Halliday GM** (2000) Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch. Neurol. 57:817-822.
584. Stanford PM, **Halliday GM**, Brooks WS, Kwok JBJ, Storey CE, Creasey H, Morris JGL, Fulham M, Schofield P (2000) Progressive supranuclear palsy pathology caused by a novel silent mutation, S305S, in exon 10 of the *tau* gene: expansion of the disease phenotype caused by *tau* gene mutations. Brain 123:880-893.
585. Baker KG, Harding AJ, **Halliday GM**, Kril JJ, Harper CG (1999) Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke's encephalopathy. Neuroscience 91:429-438.
586. **Halliday GM**, Pond SM, Cartwright H, McRitchie DA, Castagnoli N, Van der Schyf CJ (1999) Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp. Neurol 158:155-163.
587. Harasty JA, **Halliday GM**, Kril JJ, Code C (1999) Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. Brain 122:675-686.
588. Hardman CD, **Halliday GM** (1999) The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. Mov. Disord. 14: 626-633.
589. Hardman CD, **Halliday GM** (1999) The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease. Exp. Neurol. 158:135-142.
590. Kril JJ, **Halliday GM** (1999) Brain shrinkage in alcoholics: a decade on and what have we learned? Prog. Neurobiol. 58:381-387.
591. McRitchie DA, Reid WGJ, **Halliday GM**, Hely M, Morris JGL (1999) Neuropathology of three clinical cases prospectively diagnosed with dementia with Lewy bodies. J. Clin. Neurosci. 6:149-154.
592. Cullen KM, **Halliday GM** (1998) Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. Neurobiol. Aging 19:297-306.
593. **Halliday GM**, McRitchie DA, Macdonald V, Double KL, Trent R, McCusker E (1998) Regional specificity of brain atrophy in Huntington's disease. Exp. Neurol. 154:663-672.
594. Harding AJ, **Halliday GM** (1998) Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 24:195-201.
595. Harding AJ, **Halliday GM**, Kril JJ (1998) Variation in hippocampal neuron number with age and brain volume. Cerebral Cortex 8:710-718.
596. McRitchie DA, Cartwright H, Pond SM, van der Schyf CJ, Castagnoli N, van der Nest DG, **Halliday GM** (1998) The midbrain dopaminergic cell groups in the baboon *Papio ursinus*. Brain Res. Bull. 47:611-623.
597. Taddei K, Kwok JBJ, Kril JJ, **Halliday GM**, Creasey H, Hallupp M, Fisher C, Brooks WS, Chung C, Andrews C, Masters C, Schofield PR, Martins RN (1998) Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. Neuroreport 9:3335-3339.
598. Caine D, **Halliday GM**, Kril JJ, Harper CG (1997) Operational criteria for the classification of chronic alcoholics: Identification of Wernicke's encephalopathy. J. Neurol. Neurosurg. Psychiatry 62:51-60. Abstracted in Alcohol Research 2:113-114.
599. Cullen KM, **Halliday GM**, Caine D, Kril JJ (1997) The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: Reduced cell number in both amnesic and non-amnesic patients. J. Neurol. Neurosurg. Psychiatry 63:315-320.
600. Cullen KM, **Halliday GM**, Double KL, Brooks WS, Creasey H, Broe GA (1997) Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience 78:641-652.
601. **Halliday G**, Brooks W, Arthur H, Creasey H, Broe GA (1997) Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neurosci. Lett. 227:49-52.
602. Harasty J, Double KL, **Halliday GM**, Kril JJ, McRitchie DA (1997) Language associated cortical regions are proportionally larger in the female brain. Arch. Neurol. 54:171-176.
603. Harding A, Wong A, Svoboda M, Kril JJ, **Halliday GM** (1997) Chronic alcohol consumption does not cause hippocampal neuron loss in humans. Hippocampus 7:78-87.
604. Hardman CD, **Halliday GM**, McRitchie DA, Cartwright HR, Morris JGL (1997) Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp. Neurol. 144:183-192.
605. Hardman CD, **Halliday GM**, McRitchie DA, Morris JGL (1997) The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 56:132-142.

606. Hickie I, Lloyd A, Dixon G, **Halliday G**, McRitchie D, Scott E, Mitchell P, Wakefield D (1997) Utilising molecular biological and histopathological techniques to study the dopaminergic system in patients with melancholia. Aust. N.Z. J. Psychiat. 31:27-35.
607. Kril JJ, **Halliday GM**, Svoboda MD, Cartwright H (1997) The cerebral cortex is damaged in chronic alcoholics. Neuroscience 79:983-998.
608. Macdonald V, **Halliday GM**, Trent R, McCusker EM (1997) Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropath. Appl. Neurobiol. 23:492-495.
609. McRitchie DA, Cartwright HR, **Halliday GM** (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol. 144:202-213.
610. Baker KG, **Halliday GM**, Kril JJ, Harper CG (1996) Chronic alcoholics without Wernicke-Korsakoff syndrome or cirrhosis do not lose serotonergic neurons in the dorsal raphe nucleus. Alcohol. Clin. Exp. Res. 20:61-66.
611. Baker KG, **Halliday GM**, Kril JJ, Harper CG (1996) Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. Met. Brain Dis. 11:217-227.
612. Cullen KM, **Halliday GM**, Cartwright H, Kril JJ (1996) Improved specificity and sensitivity in the visualization of neurofibrillary tangles, senile plaques and neuropil threads. Neurodegeneration 5:177-187.
613. Double KL, **Halliday GM**, Kril JJ, Harasty JA, Cullen K, Brooks WS, Creasey H, Broe GA (1996) Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiol. Aging 17:513-521.
614. Double KL, **Halliday GM**, McRitchie DA, Reid WGJ, Hely MA, Morris JGL (1996) Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease. Dementia 7:304-313.
615. Flowers D, Harasty J, **Halliday G**, Kril J (1996) Microwave modification of the methenamine silver technique for the demonstration of Alzheimer-type pathology. J. Histotechnol. 19:33-38.
616. **Halliday GM**, Baker KG (1996) Noradrenergic locus coeruleus neurons. Letter. Alcohol. Clin. Exp. Res. 20:191-192.
617. **Halliday GM**, Cullen KM, Kril JJ, Harding AJ, Harasty J (1996) Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: A quantitative study using different antisera. Neurosci. Lett. 209:29-32.
618. **Halliday GM**, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JGL (1996) Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J. Clin. Neurosci. 3:52-60.
619. Harasty JA, **Halliday GM**, Code C, Brooks WS (1996) Quantification of cortical atrophy in a case of progressive fluent aphasia. Brain 119:181-190.
620. Harasty J, **Halliday GM**, Kril JJ (1996) Reproducible sampling regimen for specific cortical regions: Application to speech-associated areas. J. Neurosci. Meth. 67:43-51.
621. Harding AJ, **Halliday GM**, Ng JLF, Harper CG, Kril JJ (1996) Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Neuroscience 72:699-708.
622. Hardman CD, McRitchie DA, **Halliday GM**, Cartwright HR, Morris JGL (1996) Substantia nigra pars reticulata neurons in Parkinson's disease. Neurodegeneration 5:49-55.
623. Hely MA, Reid WGJ, **Halliday GM**, McRitchie DA, Leicester J, Joffe R, Brooks W, Broe GA, Morris JGL (1996) Diffuse Lewy body disease: Clinical features in nine cases without coexistent Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 60:531-538.
624. Johnson SM, Trussell DC, McRitchie DA, **Halliday GM**, Hardman CD (1996) Anatomical and immunohistochemical identification of catecholaminergic neurones in brain slice preparations used in electrophysiology. J. Neurosci. Meth. 64:83-93.
625. McRitchie DA, **Halliday GM**, Pamphlett R (1996) Diagnostic evaluation of the substantia nigra. Neuropath. Appl. Neurobiol. 22:228-232.
626. McRitchie DA, Hardman CD, **Halliday GM** (1996) Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364:121-150.
627. Cullen KM, **Halliday GM** (1995) Mechanisms of cell death in the cholinergic basal forebrain neurons in chronic alcoholics. Met. Brain Dis. 10:81-91.
628. Cullen KM, **Halliday GM** (1995) Neurofibrillary tangles in chronic alcoholics. Neuropath. Appl. Neurobiol. 21:312-318.

629. **Halliday G**, Baker K, Harper C (1995) Serotonin and alcohol related brain damage. Met. Brain Dis. 10:25-30.
630. **Halliday GM**, Davies L, McRitchie DA, Cartwright H, Pamphlett R, Morris JGL (1995) Ubiquitin-positive achromatic neurons in corticobasal degeneration. Acta Neuropathol. 90:68-75.
631. Harding AJ, Ng JLF, **Halliday GM**, Oliver J (1995) Comparison of the number of vasopressin-producing hypothalamic neurons in rats and humans. J. Neuroendocrinol. 7:629-636.
632. Lamont P, Murray N, **Halliday G**, Hilton J, Pamphlett R (1995) Brain-stem nuclei in sudden infant death syndrome (SIDS): Volumes, neuronal numbers and positions. Neuropath. Appl. Neurobiol. 21:262-268.
633. McRitchie DA, **Halliday GM** (1995) Calbindin D28k -containing neurons are restricted to the medial substantia nigra in humans. Neuroscience 65:87-91.
634. McRitchie DA, **Halliday GM**, Cartwright H (1995) Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience 68:539-551.
635. Robinson SR, Noone DF, Kril JJ, **Halliday GM** (1995) Diffuse and mature amyloid plaques contain ferritin-rich cells. Alzheimer's Research 1:191-196.
636. Setiawan Y, **Halliday GM**, Harding AJ, Moore DE, Allen BJ (1995) Effect of L-B10-P-boronophenylalanine-fructose and the boron neutron capture reaction on mouse brain dopaminergic neurons. Cancer Res. 55:874-877.
637. Baker KG, **Halliday GM**, Harper CG (1994) Effect of chronic alcohol consumption on the human locus coeruleus. Alcohol. Clin. Exp. Res. 18:1491-1496.
638. Cullen K, **Halliday GM** (1994) Chronic alcoholics have substantial glial pathology in the forebrain and diencephalon. Alcohol Alcohol. Suppl. 2:255-259.
639. **Halliday GM**, Cullen K, Harding AJ (1994) Neuropathological correlates of memory dysfunction in the Wernicke-Korsakoff syndrome. Alcohol Alcohol. Suppl. 2:247-253.
640. **Halliday G**, Flowers D, Baum L (1994) Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathol. 87:174-186.
641. Harding AJ, **Halliday GM**, Cullen K (1994) Practical considerations for the use of the optical disector in estimating neuronal number. J. Neurosci. Meth. 51:83-89.
642. Byrne C, **Halliday G**, Ellis J, Harper C (1993) Thalamic vacuolation in acute Wernicke's encephalopathy. Met. Brain Dis. 8:107-114.
643. Cox M, **Halliday GM** (1993) Parvalbumin as an anatomical marker for discrete subregions of the ambiguus complex in the rat. Neurosci. Lett., 160:101-105.
644. **Halliday GM**, Cullen K, Cairns MJ (1993) Quantitation and three dimensional reconstruction of the Ch4 nucleus in the human basal forebrain. Synapse 15:1-16.
645. **Halliday G**, Ellis J, Heard R, Caine D, Harper C (1993) Brainstem serotonergic neurons in chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. J. Neuropathol. Exp. Neurol. 52:567-579.
646. Ellis J, **Halliday G** (1992) A comparative study of avidin-biotin-peroxidase complexes for the immunohistochemical detection of antigens in neural tissue. Biotech. Histochem. 67:367-371.
647. **Halliday G**, Ellis J, Harper C (1992) The locus coeruleus and memory: a study of chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. Brain Res. 598:33-37.
648. **Halliday GM**, McCann HL, Cotton RGH, Creasey H, McCusker EM, Broe GA, Harper CG (1992) Brainstem serotonin-synthesizing neurons in Alzheimer's disease – A clinicopathological correlation. Acta Neuropathol. 84:638-650.
649. Huang XF, Paxinos G, **Halliday GM**, Törk I (1992) The dorsal, posterodorsal and ventral tegmental nuclei: a cytoarchitectonic and chemoarchitectonic study in the human. J. Comp. Neurol. 318:117-137.
650. Konrat G, **Halliday G**, Sullivan C, Harper C (1992) Preliminary pathological evidence of delayed development in the hypoglossal and vagal nuclei of SIDS infants: a necropsy study. J. Child Neurol. 7:44-49.
651. Polson JW, **Halliday G**, McAllen RM, Coleman MJ, Dampney RAL (1992) Cell subgroups in the subretrofacial vasomotor nucleus in the rostral ventrolateral medulla: a correlative morphological, immunohistochemical and functional study. J. Auton. Nerv. Sys. 38:117-138.
652. Törk I, **Halliday GM**, Cotton RGH (1992) Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. J. Chem. Anat. 5:311-313.

653. Baker KG, **Halliday GM**, Halasz P, Hornung JP, Geffen LB, Cotton RGH, Törk I (1991) Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. Synapse 7:301-320.
654. Baker KG, **Halliday GM**, Hornung JP, Geffen LB, Cotton RGH, Törk I (1991) Distribution, morphology and number of monoamine-synthesizing and peptidecontaining neurons in the human dorsal raphe nucleus. Neuroscience 42:757-775.
655. Gai WP, **Halliday GM**, Blumbergs PC, Geffen LB, Blessing WW (1991) Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 114:2253-2267.
656. **Halliday GM**, McLachlan EM (1991) A comparative analysis of neurons containing catecholamine-synthesizing enzymes and neuropeptide-Y in the ventrolateral medulla of rats, guinea pigs and cats. Neuroscience 43:531-550.
657. **Halliday GM**, McLachlan EM (1991) Four groups of tyrosine hydroxylaseimmunoreactive neurons in the ventrolateral medulla of rats, guinea pigs and cats identified on the basis of chemistry, topography and morphology. Neuroscience 43:551-568.
658. Baker KG, **Halliday GM**, Törk I (1990) Cytoarchitecture of the human dorsal raphe nucleus. J. Comp. Neurol. 301:147-161.
659. **Halliday GM**, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 510:104-107.
660. **Halliday GM**, Gai WP, Blessing WW, Geffen LB (1990) Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience 39:81-96.
661. **Halliday GM**, Li YW, Blumbergs PC, Joh TH, Cotton RGH, Howe PRC, Blessing WW, Geffen LB (1990) Neuropathology of immunohistochemically-identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27:373-385.
662. **Halliday GM**, Törk I (1989) Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. Brain Res. Bull. 22:725-735.
663. **Halliday GM**, Törk I (1988) Substance P-like immunoreactive fibres in the ventromedial mesencephalic tegmentum of rat. Brain Res. Bull. 21:659-670.
664. **Halliday GM**, Li YW, Joh TH, Cotton RGH, Howe PRC, Geffen LB, Blessing WW (1988) Distribution of monoamine-synthesizing neurons in the human medulla oblongata. J. Comp. Neurol. 273:301-317.
665. **Halliday GM**, Li YW, Joh TH, Cotton RGH, Howe PRC, Geffen LB, Blessing WW (1988) The distribution of substance P-like immunoreactive neurons in the human medulla oblongata, colocalization with monoamine-synthesizing neurons. Synapse 2:353-370.
666. **Halliday GM**, Li YW, Oliver JR, Joh TH, Cotton RGH, Howe PRC, Geffen LB, Blessing WW (1988) The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata. Neuroscience 26:179-191.
667. Li YW, **Halliday GM**, Joh TH, Geffen LB, Blessing WW (1988) Tyrosine hydroxylase-containing neurons in the supraoptic and paraventricular nuclei of the adult human. Brain Res. 461:75-88.
668. Oades RD, **Halliday GM** (1987) Ventral tegmental (A10) systems: Neurobiology: 1.Anatomy and connectivity. Brain Res. Rev. 12:117-165.
669. **Halliday GM**, Törk I (1986) Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. J. Comp. Neurol. 252:423-445.
670. **Halliday GM**, Törk I (1984) Electron-microscopic analysis of the mesencephalic ventromedial tegmentum in the cat. J. Comp. Neurol. 230:393-412.

Book chapters

671. Jezewski RC, **Halliday GM**, Shepherd CE (2021) The ageing brain and brain banking. In Martin CR, Preedy VR, Rajendrim R (eds.): Assessments, treatments and modelling in aging and neurological disease. The Neuroscience of Aging. London: Academic Press. pp. 103-115.
672. Ahmed RM, **Halliday GM**, Hodges JR (2021) Hypothalamic symptoms of frontotemporal dementia disorders. In Swaab DF, Buijs R, Kreier F, Lucassen PJ, Salehi A (eds): The human hypothalamus: Neuropsychiatric Disorders. Amsterdam: Elsevier. Handbook of Clinical Neurology, Series 3, Vol. 182 pp.269-280.
673. Kumfor F, **Halliday GM**, Piguet O (2017) Clinical aspects of Alzheimer's disease. In Beart P, Robinson M, Rattray M, Maragakis N (eds.): Neurodegenerative diseases: pathology, mechanisms, and potential therapeutic targets. New York: Springer. Adv. Neurobiol. Vol. 15: pp.31-53.

674. **Halliday G**, Lewis SJG, Ince PG (2017) The pathology of dementia with Lewy bodies. In Ames D, Burns A, O'Brien J (eds.): Dementia, 5th edition. Boca Raton: Taylor & Francis Group. pp.714-729.
675. Revesz T, Clark B, Holton JL, Houlden HH, Ince PG, **Halliday GM** (2015) Extrapyramidal diseases of movement. In Love S, Perry A, Ironside J, Budka H (eds.): Greenfield's Neuropathology. 9th edition. Boca Raton: CRC Press. pp.740-798.
676. Lewis SJG, Shine JM, Brooks D, **Halliday GM** (2015) Hallocinogenic mechanisms: pathological and pharmacological insights. In Collerton D, Mosimann, UP, Perry E (eds.): The Neuroscience of Visual Hallucinations. Wiley-Blackwell. pp.121-149.
677. Stevens CH, **Halliday GM** (2014) The role of astrocytes in Parkinson's disease. In Thomas M (ed.): Inflammation in Parkinson's Disease: Scientific and Clinical Aspects. New York: Springer. pp.127-144.
678. Kragh CL, Romero-Ramos M, **Halliday GM,** Jensen PH (2014) α-Synuclein in Parkinson's disease. In Segura-Aguilar J (ed.): Handbook of Neurotoxicity – Dopamine Neurotoxicity & Parkinson's Disease. Säo Paulo, Brazil: Springer Brazil. pp.691-726.
679. **Halliday G**, Tan R, Cartwright H (2013) Neuropathology for the Movement Disorder Specialist. In Burn D (eds.): Oxford Textbook of Movement Disorders. Oxford: Oxford University Press. pp.11-20.
680. **Halliday G**, Murphy K, Cartwright H (2013) Pathology of Parkinson's disease. In Wolters E, Baumann C (eds.): Parkinson Disease and Other Movement Disorders. Amsterdam: Vu University Press. pp.303-320.
681. **Halliday G**, Reyes S, Double K (2012) Substantia nigra, ventral tegmental area and retrorubral field. In Mai JK, Paxinos G (eds.): The human nervous system. 3rd Ed. London: Academic Press. pp.439-455.
682. Michell AW, Barker R, **Halliday G** (2011) Lesions associated with eye movements. In **Halliday G**, Barker R, Rowe D (eds.): Non-dopamine lesions in Parkinson's disease. New York: Oxford University Press. pp.50-64.
683. Ince PG, **Halliday G** (2011) The pathology of dementia with Lewy bodies. In Ames D, Burns A, O'Brien J (eds.): Dementia, 4th edition. London: Hodder Arnold. pp.608-618.
684. Hartmann A, **Halliday G** (2011) Lesions associated with pain and sensory abnormalities. In **Halliday G**, Barker R, Rowe D (eds.): Non-dopamine lesions in Parkinson's disease. New York: Oxford University Press. pp.141-166.
685. Fahn S, **Halliday G** (2011) Lesions associated with the classic triad of parkinsonian motor features. In **Halliday G**, Barker R, Rowe D (eds.): Non-dopamine lesions in Parkinson's disease. New York: Oxford University Press. pp.3-17.
686. **Halliday G**, Murphy K (2010) Pathology of Parkinson's disease. In Fahn S, Lang A, Shapira A (eds.): Movement Disorders 4. Philadelphia: Elsevier. pp.132-154.
687. Huang Y, Chan P, **Halliday G** (2007) Genetics of Parkinson's disease. In Qureshi GA, Parvez SH (eds.): Oxidative Stress and Neurological Disorders. Holland: Elsevier. pp. 663-688.
688. **Halliday GM**, Gandevia SC (2007) Pyramidal and extrapyramidal system. In Schapira AHV (ed.): Neurology and clinical neuroscience. Philadelphia: Mosby Elsevier. pp.396401.
689. **Halliday GM** (2006) The status of α-synuclein in Alzheimer cases with and without Lewy bodies. In Iqbal K, Winblad B, Avila J (eds.): Alzheimer's disease: New advances. Bologna: Medimond. pp.267-273.
690. Gregory GC, Shepherd CS, **Halliday GM** (2006) Physiological and neurotoxic properties of A peptides. In Barrow CJ, Small DH (eds.): A peptide and Alzheimer's disease. London: Springer-Verlag. pp.179-197.
691. Karlstrom H, Brooks WS, Kwok JBJ, Kril JJ, **Halliday GM**, Schofield PR (2005) Variable phenotype of Alzheimer's disease with spastic paraparesis. In Foundation Ipsen Conference Proceedings (Cummings J, Hardy J, Poncet M, Christen Y eds.): Genotypeprotéotype-phenotype relationships in neurodegenerative disorders. Berlin: SpringerVerlag. pp.73-92.
692. Henderson JM, Macdonald V, **Halliday GM** (2005) Thalamic and cortical changes in parkinsonian disorders. In Bolom JP, Ingham CA, Magill PJ (eds.): Basal ganglia VIII. New York: Springer Science. pp.415-424.
693. Hodges JR, Davies R, Xuereb J, Kril J, **Halliday G** (2004) Survival in frontotemporal dementia. In Vellas B, Fitten LJ, Feldman H, Giacobini E, Grundman M, Winblad B (eds.): Research and practice in Alzheimer's disease and other dementias.Vol. 8 Paris: Serdi. pp.15-19.
694. Harding AJ, Paxinos G, **Halliday GM** (2004) Serotonin and tachykinin systems. In Paxinos G (ed.): The rat nervous system. 3rd. Ed. Sydney: Academic Press, pp.12031254.

695. Kril JJ, Patel S, Harding AJ, **Halliday GM** (2003) Hippocampal neuron loss in vascular dementia and Alzheimer's disease. In Vellas B, Fitten LJ, Feldman H, Giacobini E, Grundman M, Winblad B (eds.): Research and practice in Alzheimer's disease. Vol. 7 Paris: Serdi. pp.199-203.
696. Morris JGL, Hely MA, **Halliday GM** (2003) Parkinsonism and ageing. In Sachdev P (ed.): The ageing brain: The neurobiology and neuropsychology of ageing. New York: Plenum. pp.265-282.
697. Koutcherov Y, Huang X-F, **Halliday G**, Paxinos G (2003) Organisation of human brainstem nuclei. In Paxinos G, Mai JK (eds.): The human nervous system. 2nd Ed. San Diego: Academic Press. pp.267-320.
698. **Halliday G** (2003) Substantia nigra and locus coeruleus. In Paxinos G, Mai JK (eds.): The human nervous system. 2nd Ed. San Diego: Academic Press. pp. 449-463.
699. Henderson JM, **Halliday GM**, O'Sullivan DJ, Pell M, Fung V, McCusker EA, Hely M, Morris J, Annett LE, Dunnett SB, Ghika J, Favre J (2002) Which basal ganglia surgical targets ameliorate parkinsonian symptoms? Observations regarding the thalamus and subthalamus. In Faull R (ed.): Basal ganglia VII. New York: Plenum. pp.533-542.
700. Harper CG, Sheedy D, **Halliday GM**, Double KL, Dodd PR, Lowehl JM, Kril JJ (1998) Neuropathological studies: the relationship between alcohol and ageing. In: Lisansky Gomberg ES, Hegedus AM, Zucker RA (eds) NIAAA research monograph 33: Alcohol Problems and Aging. pp.117-134.
701. McRitchie DA, **Halliday GM**, Cartwright H, Hely MA, Morris JGL (1996) Pattern of midbrain pathology in different Parkinsonian syndromes. In Ohye C, Kimura M, McKensie J (eds.): The basal ganglia V. New York: Plenum. pp.441-444.
702. McRitchie D, **Halliday G** (1995) Calcium binding proteins differentiate midbrain dopaminergic systems in humans. In Hanin I, Yoshida M, Fisher A (eds.): Alzheimer's and Parkinson's disease. Recent developments. Advances in Behavioural Biology, Vol. 44, New York: Plenum. pp.303-306.
703. McRitchie D, **Halliday G** (1995) Cytoarchitecture and chemistry of midbrain dopaminergic cell groups in the human brain. In Tracey D, Paxinos G, Stone J (eds.): Neurotransmitters in the human brain. New York: Plenum. pp.115-127.
704. **Halliday GM**, Harding AJ, Paxinos G (1995) Serotonin and tachykinin systems. In Paxinos G (ed.): The rat nervous system. 2nd. Ed. Sydney: Academic Press, pp.929974.
705. **Halliday G**, Cullen K (1995) Neurotransmitter changes in Alzheimer's disease. In Tracey D, Paxinos G, Stone J (eds.): Neurotransmitters in the human brain. New York: Plenum. pp.199-219.
706. Cullen K, **Halliday G** (1995) Cytoarchitecture and chemistry of ascending cholinergic systems in the human brain. In Tracey D, Paxinos G, Stone J (eds.): Neurotransmitters in the human brain. New York: Plenum. pp.129-153.
707. Baker K, **Halliday G** (1995) Ascending noradrenergic and serotonergic systems in the human brain. In Tracey D, Paxinos G, Stone J (eds.): Neurotransmitters in the human brain. New York: Plenum. pp.155-171.
708. Brooks W, **Halliday G**, Harper C, Broe G, Creasey H (1993) Neuropathological correlates of population-based studies of neurodegenerative diseases. In Beregi E, Gergely IA, Rajczi J (eds.): Recent advances in aging science. Bologna: Monduzzi Editore. pp.667-671.
709. **Halliday GM**, Cotton RGH, Törk I, Blumbergs PC, Blessing WW, Geffen LB (1991) Serotonergic neurons in Parkinson's disease using antibody PH8 to phenylalanine hydroxylase. In Blau N, Curtius HC, Levine RA, Cotton RGH (eds.): Pteridines and related biogenic amines. Berlin: Walter de Gruyter & Co. pp.283-290.
710. Pearson J, **Halliday GM**, Sakamoto N, Michel JP (1990) Human catecholaminergic neurons. In Paxinos G (ed.): The human nervous system. San Diego: Academic Press. pp.1023-1050.
711. Paxinos G, Törk I, **Halliday GM**, Mehler RW (1990) Human homologues to brainstem nuclei identified in other animals as revealed by AChE distribution. In Paxinos G (ed.): The human nervous system. San Diego: Academic Press. pp.149-202.
712. **Halliday GM**, Li YW, Joh TH, Cotton RGH, Geffen LB, Blessing WW (1988) Topography of monoamine and substance P containing neurons in the human pons and midbrain. In Sandler M, Dahlstrom A, Belmaker RH (ed.): Progress in catecholamine research. Part B: Central aspects. Neurology and Neurobiology, Vol. 42B. New York: Alan R. Liss. pp.179-185.

713. Törk I, **Halliday G**, Scheibner T, Turner S (1984) The organization and connections of the mesencephalic ventromedial tegmentum (VMT) in the cat. In Bandler R (ed.): Modulation of sensorimotor activity during alterations in behavioural states. New York: Alan R. Liss. pp.39-73.

Books

714. Paxinos G, **Halliday G**, Watson C, Koutcherov Y (2020) Atlas of the developing mouse brain E17.5, P0 and P6. 2nd Ed. Amsterdam: Elsevier.
715. **Halliday G,** Barker R, Rowe D (eds.) (2011) Non-dopamine lesions in Parkinson's disease. New York: Oxford University Press.
716. Paxinos G, **Halliday G**, Watson C, Koutcherov Y, Wang HQ (2006) Atlas of the developing mouse brain E17.5, P0 and P6. Amsterdam: Elsevier.

Governance, Leadership and Engagement

SOMS Roles Committees

- Level 3 supervisor in Neuroscience Theme – *provide academic leadership and career development within the Neuroscience theme, fortnightly meetings with Neuroscience leadership, development of theme meetings, performance reviews for ~10 academics in 2021*
- Adhoc HDR progress review committees – *assist with reviewing PhD students in the school*
- Academic supervisor for SoMS 3G and 3K laboratories at the BMC – *supervisor and manager of the SOMS laboratories in 3G and 3K of the BMC responsible for WHS issues and reporting*

USYD Roles and Committees

- Head BMC ForeFront Research Team – *head of the ForeFront research team~100 researchers at the BMC working on neurodegenerative diseases – see website (https://www.forefrontresearch.org)*
- Chair BMC Research Advisory Committee - *provide strategic academic leadership and advice regarding BMC research to ensure the delivery of high-quality, multidisciplinary research*
- Member BMC Executive Leadership Group – *implement the BMC strategic plan and provide strategic guidance and leadership to the executive directors of the BMC*
- Member University Leadership Group – *strategic guidance and leadership to the executive*
- Member Sydney Analytical Academic Advisory Committee - *provide strategic guidance and leadership to the director of the Sydney Analytical*
- Member Adhoc Academic Appointments Committees – *sit on professorial academic appointment committees*

Clinical Responsibilities

- Research neuropathologist Sydney Brain Bank
- Honorary Visiting Scientist Westmead Hospital Anatomical Pathology
- CIA DINAD (diagnosing non-Alzheimer neurodegenerative diseases) research program
- CIA Frontier (frontotemporal dementia syndromes) Biomarker and Brain Donor Programs
- CIA Motor Neuron Disease Brain Donor Program
- CIB NSW Movement Disorder Brain Donor Program

Mentoring (*School, Faculty, External mentoring activities*)

- Mentor for the ForeFront research team – *provide career and funding advice and mentoring to the academic researchers in the group*
- Level 3 supervisor in Neuroscience Theme – *provide career development and mentoring within the Neuroscience theme, performance reviews for ~10 academics in 2021*
- Australian Academy for Health and Medical research mentor program – *mentor to researchers wanting to join the academy*

External Roles

- Chair, Sectional Committee Physiology and Neuroscience, Australian Academy of Science – *chair the procedures to assess potential new members*
- Co-Chair MRFF Australian Parkinson's Mission Research Committee – *oversee $30million MRFF research program to develop disease modifying therapies for Parkinson's disease*
- Co-Chair NINDS Parkinson's Disease CDE Neuropathology Subgroup – *coordinate the NIH data commons required for neuropathology research for all funded NIH grants on Parkinson's disease*

- Member NHMRC Research Committee – *advises NHMRC Council on research policies and funding from the MREA*
- Member Viertel Medical Advisory Board – *review for the senior Viertel fellowships and for clinical postdoctoral fellowships*
- Member QMIR Appointments and Promotions Committee – *yearly appointments and promotions committee member*
- Member Basic Science Committee, International Parkinson & Movement Disorder Society – *one of 12 basic scientists organizing scientific symposia for the society*
- Member MDS Criteria for Parkinson's Disease Project, International Parkinson & Movement Disorder Society – *developing new diagnostic criteria for prodromal and clinical Parkinson's disease*
- Member Task Force on Parkinson's Disease Subtypes, International Parkinson & Movement Disorder Society – *developing criteria for subtyping Parkinson's disease for precision medicine*
- Member Task Force on the Definition of Multiple System Atrophy, International Parkinson & Movement Disorder Society – *developing new diagnostic criteria for multiple system atrophy*
- Member Defeat MSA DownUnder Scientific Research Advisory Board– *on the scientific research advisory board that develops and oversees funding strategies for the research program*
- Previous Member Executive Committee of the International Society for Frontotemporal Dementia (2017-2020) – *executive member of the international society for research on frtontotemporal dementia*
- Previous Executive Committee Member Australian Brain Alliance (2018-2021) – *on the executive of the Academy of Science's Australian Brain Alliance to coordinate neuroscience research and data in Australia*
- Previous Member Scientific Advisory Board, Danish Research Institute of Translational Neuroscience (2013-2020) – *member of the scientific advisory board for the Danish EMBO institute of ~50 researchers*
- Previous Member Research Committee Motor Neuron Disease Australia (2018-2022) – *on the research committee that develops and oversees funding strategies for the research program*
- Previous Member US MSA Coalition Scientific Advisory Board (2016-2022) – *on the scientific advisory board that develops and oversees funding strategies for the research program*
- Previous Chair Scientific Conference Committee, International Society for Frontotemporal Dementia (2013-2020) – *oversee the scientific program for the international conferences of the society*
- Previous Chair Scientific Program Committee, NHMRC National Institute for Dementia Research (2018) - *oversee the scientific program for the national conferences of the institute*

Reviewing Activities

- Member, Editorial Board, Sciences Advances
- Member, Editorial Board, IBRO Reports
- Member, Editorial Board, Journal of Gerontology and Biological Sciences
- Member, Editorial Board, Neurobiology of Disease
- Member, Editorial Board, Neuropathology and Applied Neurobiology
- Member, Editorial Board, Translational Neurodegeneration
- Member, Editorial Board, Journal of Parkinson's Disease
- Member, Editorial Board, Journal of Neural Transmission
- Member, Editorial Board, Acta Neuropathologica
- Member, MRFF BioMedTech Incubator Grant Assessment Committee (2023)
- Previous Chair NHMRC Fellowship Review Panel (2018)
- Previous Chair NHMRC Project Grant Review Panel (2017)
- Previous Member NHMRC Ideas Grant Review Panel (2023)
- Previous Member NHMRC Investigator Grant Review Panel (2020, 2022)
- Previous Member NHMRC Targeted Research Panel (2020)
- Previous Member NHMRC Synergy Grant Review Panel (2019)